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Abstract 
Background 
Over the last decade, several new treatments for type 2 diabetes have launched for 
routine care in the United Kingdom (UK). Little was known however about how 
general practitioners (GPs) prescribed these drugs, why GPs chose each therapy, or 
how they compared in terms of effectiveness.  
Methods  
This thesis describes prescribing trends and comparative effectiveness of type 2 
diabetes drugs, using routine UK clinical care data and observational study designs.  
Results 
All analyses used a cohort of 280,241 individuals treated in UK primary care 
between 2000 and 2017. First, I show rapid changes in prescribing practice for type 2 
diabetes drugs. After metformin monotherapy, GPs have increasingly added new 
drug classes, in particular the Dipeptidyl peptidase 4 inhibitors (DPP4is) and sodium 
glucose cotransporter-2 inhibitors (SGLT2is). From their launch in 2007 and 2012, 
by 2017 prescriptions for DPP4is and SGLT2is grew to 42% (95% CI: 38, 47) and 
22% (95% CI: 17, 27) of therapy intensifications. 
To describe patient characteristics associated with treatment intensification with a 
sulfonylurea (SU), a DPP4i or a SGLT2i, I applied multinomial regression analysis. I 
found inequalities by socioeconomic status and ethnicity. People of South Asian 
ethnicity had lower odds of receiving SGLT2is compared to SUs, odds ratio: 0.6 
(95% CI: 0.4, 0.9). 
5
   
 
Finally, I used a new-user propensity score matched design to contrast intensification 
with SUs, DPP4is and SGLT2is and reveal differences in clinical variables. People 
prescribed SGLT2is had the greatest falls in glycated haemoglobin (HbA1c) at 60 
weeks, of 16.1 mmol/mol (95% CI: 18.7, 13.5), compared to SUs and DPP4is (13.8 
mmol/mol (95% CI: 15.4, 12.2) and 9.8 mmol/mol (95% CI: 11.6, 7.9) respectively). 
Conclusions 
Electronic health records offer important clinical information for clinicians, and 
answer questions not investigated by randomised controlled studies. This work 
addresses methodological challenges in drug research using electronic health 
records.
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1 Chapter 1: Background information and rationale for thesis 
 
Chapter summary 
• Type 2 diabetes is a common and increasing global public health burden, 
characterised by raised blood glucose. 
• People with type 2 diabetes are at greater long-term risk for cardiovascular 
and kidney disease, and mortality. 
• Drugs to treat type 2 diabetes show good evidence of reducing blood 
glucose levels, but evidence is limited for whether drugs reduce long term 
diabetes-related outcomes. 
• Evidence comparing the drugs used to treat diabetes is principally based 
on clinical trials. However, these studies are restricted in scope and may 
not be generalisable to primary care settings. 
• In this thesis I describe the application of pharmacoepidemiological 
methods to electronic health records to assess the real-world use of new 
type 2 diabetes drugs and the comparative effect of these drugs on clinical 
variables which complements data from clinical trials. 
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1.1 Type 2 diabetes and long term outcomes 
Diabetes is a group of metabolic diseases, characterised by dysregulation and chronic 
elevation of blood glucose, with a number of subtypes. Type 1 diabetes is an 
autoimmune disease that results in loss of the insulin-producing β-cell in the pancreas 
and is predominantly diagnosed in children and young people. Type 2 diabetes is more 
common, accounting for 75-85% of people with diabetes. Affected individuals show 
decreased sensitivity to insulin (insulin resistance) and/or decreased secretion of insulin 
resulting in high blood glucose levels.(2, 3) The pathogenesis of type 2 diabetes is 
complex and not completely understood, but is likely caused by both environmental, 
lifestyle and genetic factors.(4)  
Prevalence of diabetes in 2015 (encompassing all types of diabetes) was estimated to be 
8.8% of the global population, but this is expected to rise to 10.4% by 2040.(5) By 2030, 
global prevalence of type 2 diabetes is expected to be over 500 million.(6)  
People living with type 2 diabetes carry an increased burden of risk for many health 
problems, including cardiovascular disease, blindness, kidney disease, and nerve 
damage.(7) They have double the risk of mortality from cardiovascular disease than 
people without diabetes.(8) Cardiovascular disease is the leading cause of death among 
people with type 2 diabetes, around 50% of people with type 2 diabetes die from 
cardiovascular causes.(9, 10) In the UK, diabetic retinopathy is the main cause of 
blindness and around 30% of people with type 2 diabetes have diabetic retinopathy.(11) 
Up to 30% of people with diabetes have chronic kidney disease (CKD), compared to 6-
14
   
 
9% in the general population.(12) Global deaths due to type 2 diabetes related kidney 
disease were estimated to account for 349,000 deaths in 2017.(13) 
1.2  Treatment for type 2 diabetes 
The aim of type 2 diabetes treatment is to reduce blood glucose and associated adverse 
health events.(4) Table 1.1 summarizes the drug classes approved for type 2 diabetes in 
the UK with their actions, risks and benefits. New drugs must have proven efficacy to 
lower blood glucose before regulatory agencies will grant a marketing authorisation.(14, 
15) However, clinicians are keen to prescribe their patients drugs that provide 
advantages beyond controlling blood glucose. They want to decrease risks for 
comorbidities associated with type 2 diabetes such as cardiovascular disease. Blood 
glucose levels may predict long-term microvascular outcomes such as kidney disease or 
blindness.(16) Evidence of cardiovascular benefit is less clear.
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1.2.1 Biguanides  
The biguanides include metformin, phenformin and buformin. Metformin and 
phenformin have been used to treat diabetes in the UK since the 1950s. Phenformin and 
buformin were shown to cause lactic acidosis and are no longer used.(21) Since 2002, 
the National Institute for Health and Care Excellence (NICE) has recommended 
metformin as the first line treatment for type 2 diabetes. This was a move away from 
sulfonylureas as studies indicated that metformin was as effectiveness for reducing 
blood glucose, and did not lead to weight gains associated with sulfonylureas.(22) 
Metformin is an insulin-sensitizing agent and works by reducing gluconeogenesis in the 
liver, a process that is often upregulated among people with type 2 diabetes. It also 
increases insulin sensitivity in peripheral tissues.(23)  
1.2.2 Sulfonylureas 
Sulfonylureas have the longest history for the treatment of type 2 diabetes.(24) The class 
includes older agents (tolbutamide, chlorpropamide, tolazamide and acetohexamide) and 
newer agents that are more effective (gliclazide, glimepiride, glipizide, glibenclamide, 
and gliquidone).(25) They were the first class of oral antidiabetic drugs used in clinical 
practice. Now they are more often used to intensify treatment following the failure of 
metformin monotherapy. Sulfonylureas lower blood glucose by stimulating insulin 
secretion in the pancreas. Due to this direct effect on insulin secretion, sulfonylureas are 
associated with higher risks of hypoglycaemic episodes.(26) 
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1.2.3 Thiazolidinediones 
Thiazolidinediones (TZD) are a class of insulin sensitizers that decrease blood glucose 
by activating the peroxisome proliferator-activated receptors (PPARs).(27) However, 
the PPARs have wide-ranging effects on the body and TZDs have a history of adverse 
effects. The first agent, troglitazone was introduced to the UK in 1997, but then 
withdrawn following reports of liver toxicity.(28) Rosiglitazone was granted approval in 
2000 and prescribed widely, however, in 2010 the European Medicine Agency (EMA) 
and the United States (US) Food and Drug Administration (FDA) halted marketing 
authorisation after researchers showed that rosiglitazone was associated with adverse 
cardiovascular effects.(29, 30) The only TZD available in the UK without restriction is 
pioglitazone. Yet, the UK Medicines and Healthcare products Regulatory Agency 
(MHRA) has warned of an association with increased bladder cancer risk, and France 
recently suspended authorisation for pioglitazone.(31, 32) In 2008, partly in response to 
the problems with rosiglitazone, the FDA issued new guidance. They now require drug 
manufacturers to investigate the cardiovascular risk profiles for type 2 diabetes drugs in 
phase IV post-marketing studies.(33) 
1.2.4 Glucagon-like peptide-1 receptor agonists 
In 2005, another class of agents was introduced with a different molecular target, the 
Glucagon-like peptide-1 receptor agonists (GLP1s). These are delivered subcutaneously 
and bind with the GLP-1 receptors in the β-cells of the pancreas to increase insulin 
secretion.(34) This class includes the following agents: exenatide, liraglutude, 
lixisenatide, albiglutide and dulaglutide.(35) The first agent approved in Europe was 
exenatide in 2006.(36) 
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1.2.5 Dipeptidyl peptidase 4 inhibitors 
Following the success of the GLP-1s, drug companies developed another class of drugs 
with a similar molecular target, the Dipeptidyl peptidase 4 inhibitors (DPP4is). The 
DPP4is also exert their action on GLP-1, but instead of acting directly on the receptor, 
they inhibit the enzyme dipeptidyl peptidase (DPP-4) which cleaves GLP-1.(37) The 
first agent approved by the European Medicines Agency was sitigliptin in March 2007, 
followed by vildagliptin later in the same year.(38) The GLP-1s and DPP4is are 
collectively referred to as the ‘incretin mimetics’. 
1.2.6 Sodium-glucose cotransporter-2 inhibitors  
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the newest class of 
antidiabetic drugs, introduced at the end of 2013. This class inhibits glucose resorption 
from urine in the kidneys by inhibiting the SGLT2 protein, thus reducing blood glucose 
levels. The SGLT2i class includes many agents, including: dapagliflozin, empagliflozin, 
canagliflozin and ertugliflozin.(39) 
1.2.7 Other drug classes 
General practitioners (GPs) can prescribe other drugs to treat type 2 diabetes, including 
insulin, alpha-glucosidase inhibitors, and meglinitides. Whilst insulin is an important 
and widely used medicine for type 2 diabetes, NICE predominantly recommends it for 
later in therapy. As I focus on early stages of treatment, insulin is out of scope for this 
thesis. Though NICE-approved, GPs rarely give alpha-glucosidase inhibitors and 
meglinitides in the UK.(18, 19) 
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1.3 Treatment guidance 
NICE is the body in the UK responsible for reviewing and creating evidence-based 
guidelines for National Health Service (NHS) providers. At the end of 2015, NICE 
published an updated set of type 2 diabetes guidelines, which provided a clear 
prescribing pathway for GPs and included new drug classes. According to these most 
recent recommendations, before medication, GPs should advise on diet and exercise to 
help people reduce body weight.(40) Where this is unsuccessful, NICE recommends 
pharmacotherapy.(40) First-line therapy is metformin unless there are contraindications 
such as chronic kidney disease.(19, 40) If metformin monotherapy does not adequately 
control blood glucose, further drugs are added. With the introduction of DPP4is and 
SGLT2is as treatment options, clinicians in the UK had a wider array of therapies to 
choose from when prescribing at the first stage of treatment intensification, Figure 1.1. 
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According to the 2015 NICE recommendations, clinicians should choose from four drug 
classes to combine with metformin at the first stage of intensification; DPP4is, SUs, 
TZDs and SGLT2is.(40) Other international bodies produce guidance for the treatment 
of diabetes, including the American Diabetes Association (ADA), the European 
Association for the Study of Diabetes (EASD), and the Scottish Intercollegiate 
Guidelines Network (SIGN).  
A joint position statement from the ADA and EASD recommend a wider choice of 
second line intensification agents, and include insulin and GLP-1 receptor agonists as 
possible additions in metformin therapy in their treatment algorithm.(2, 41) Whereas the 
Scottish guidelines recommend the same first-stage intensification therapies as the NICE 
guidance.(42) 
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1.4 Evidence for new oral drugs:  
I embarked on this PhD in late 2015 and formed the plan for the work at the start of 2016. 
Over the course of my studies, a lot of evidence has emerged about the new oral type 2 
diabetes drugs. Some of the most recent evidence is pertinent to the evaluation of the final 
analysis of this thesis. Therefore, I have provided a brief summary of the evidence to provide 
context. 
1.4.1 Randomised controlled trials (RCTs) 
Prior to 2008, the FDA regulatory frameworks for introducing new diabetes treatments 
required drug companies to show non-inferiority of new agents against placebo and active 
comparators for reducing blood glucose. These studies were, in the main, of short duration and 
so did not address long-term changes in outcomes that are important for people with diabetes, 
such as cardiovascular and kidney disease.(43) 
Analysis of the UK Prospective Diabetes Study (UKPDS) data demonstrated that lower 
glycated haemaglobin (HbA1c) led to decreased risks of mortality and microvascular disease: 
a 1% decrease in HbA1c was associated with 21% reduced risk of death, 37% reduced risk of 
microvascular disease and 14% reduction of risk for myocardial infarction.(44) However, the 
benefits of lowering HbA1c on risk for macrovascular complications remains unclear. 
Subsequent studies that compared standard to intensive blood glucose control, including 
ADVANCE, ACCORD, VADT, and a meta-analysis found heterogeity in the effect of 
intensive glucose reductions on cardiovascular outcomes.(9, 45-47) These studies indicated 
that intensive glucose lowering did not lead to benefits in cardiovascular mortality, and may 
23
   
 
be associated with poorer cardiovascular outcomes for some individuals.(48, 49) These studies 
did not make comparisons between drugs, but between HbA1c targets, and used a range of 
drugs to achieve HbA1c control including metformin, TZDs and SUs. 
Post-marketing studies of cardiovascular outcomes 
In 2008, the FDA issued guidance, to require drug companies to investigate cardiovascular 
outcomes for type 2 diabetes drugs once licensed.(33) As a result, a number of cardiovascular 
outcome studies were initiated, summarised in Table 1.2. 
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Some studies, including CANVAS, EMPA-REG, DECLARE-TIMI and CREDENCE 
have demonstrated cardiovascular benefits for the SGLT2i class of agents, and are 
shaping guidance.(43) The most recent 2018 ADA-EASD position statement now 
recommends prescribing of SGLT2is or GLP-1s to people with increased cardiovascular 
disease risk at treatment intensification following metformin monotherapy.(41)  
The trials also identified SGLT2is as potential modifiers of renal outcomes. The 
CREDENCE study investigated the SGLT2i canagliflozin in people with kidney 
disease, and found that, compared to placebo, the canagliflozin treated group had a 34% 
(95% confidence interval [CI]: 19, 47) reduced risk for a renal-specific composite 
endpoint (end-stage kidney disease, doubling of creatinine, or death from renal 
cause).(57) Evidence is growing that the SGLT2i class may be a promising treatment for 
Diabetic Kidney Disease. Two trials, the ongoing DAPA-CKD and EMPA-KIDNEY 
will investigate the possible protective characteristics of dapagliflozin and empagliflozin 
on the kidney.(59) 
Three large placebo-controlled studies, TECOS, SAVOR and CARMELINA have 
investigated the DPP4i class (sitagliptin, saxagliptin and linagliptin respectively). These 
studies were also completed in limited populations; all recruited people with high risk 
for, or existing cardiovascular disease. The CARMELINA trial also included people 
with kidney disease. This class however has not shown the cardiovascular outcome 
benefits apparent in the SGLT2i class.(60) 
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The clinical trial evidence is rapidly evolving. Many studies were released over the 
period of this PhD, and a number of studies are expected to release results in the coming 
year, such as VERTIS-CV.(61) 
However, there are some limitations of the clinical trial evidence and their relevance to 
type 2 diabetes treatment in routine care:  
1. The cardiovascular outcome trials were restricted to people with an increased risk of, 
or already diagnosed, cardiovascular disease. Therefore, the generalisability of these 
findings to the population being treated in primary care may be limited.  
2. The studies are only of monotherapy treatment regimes, or with a range of 
background therapies, which is not reflective of the current recommendations for their 
use. Current NICE recommendations advise their use only in combination with 
metformin and after metformin alone has failed.  
3. Current studies are also predominately placebo-controlled and so the benefits of the 
active agents compared to other drugs are not yet established. 
1.4.2 Comparative evidence for SUs, DPP4is and SGLT2is 
For the period investigated, NICE directed clinicians to choose from SUs, TZDs, 
DPP4is or SGLT2is to add to metformin monotherapy. At the commencement of this 
work, in 2016, a systematic review summarised the comparative effectiveness evidence 
for antidiabetic treatments. In their evidence synthesis, they included 204 studies, 165 
RCTs and 39 observational studies.(62) Most of the studies found were short-term, with 
a low number of outcomes reported for the major endpoints.(62) Evidence was limited 
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for the SGLT2i and DPP4is. They did find that SGLT2is with metformin resulted in a 
weight loss when compared to combination therapy of metformin with DPP4is.(62) 
Since this review, and over the course of my studies further comparative studies have 
been published, summarised below. 
1.4.3 Comparative RCTs 
A clinical trial, the CANTATA-SU study, compared an SGLT2i to an SU for kidney 
outcomes. CANTATA-SU found that those randomised to canagliflozin had lower risks 
for the outcome (30% decline in estimated Glomerular Filtration Rates (eGFR) at 104 
weeks), though the confidence interval was wide and did not exclude one (Hazard ratio: 
0.66, 95% CI: 0.42, 1.04).(63) Two clinical trials, CAROLINA and GRADE are in 
progress. CAROLINA is assessing linagliptin against the SU glimepiride for 
cardiovascular outcomes.(61) GRADE is a pragmatic clinical trial comparing metformin 
combined with SUs, DPP4is, GLP-1s and insulin for cardiovascular outcomes.(64)  
In 2019, a meta-analysis of 14 placebo-controlled studies (including five SGLT2i and 
four DPP4i comparisons to placebo) showed that SGLT2is reduced incidence of 
cardiovascular disease, all-cause mortality and renal events compared to DPP4is or 
GLP1s.(65) Another 2019 network meta-analysis included 91 studies and made pair-
wise contrasts across antidiabetic medications. It showed SGLT2is decreased risks for 
heart failure relative to DPP4is (OR: 0.68, 95% CI: 0.59, 0.78), but the evidence was 
weaker for comparisons with SUs (OR: 0.70, 95% CI: 0.44, 1.11).(66) 
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1.4.4 Comparative observational evidence 
A review published in 2018 summarised the evidence for SGLT2is and cardiovascular 
outcomes from nine observational studies.(67) The nine studies made a range of 
comparisons. Four compared SGLT2i users to non-users.(68-71) Two of the studies 
compared SGLT2i agents to the DPP4i class (72, 73), one compared an SGLT2i agent 
to insulin (74) and another two compared specific SGLT2i agents, dapagliflozin and 
canagliflozin, to users of other agents.(75, 76) The findings strongly favoured SGLT2is 
for death and cardiovascular outcomes. All-cause mortality was up to 50% lower for 
SGLT2is than comparator groups. 
This review and an editorial from Suissa in 2018 highlighted that these investigations 
were likely to be limited by flaws in study design and showed significant potential for 
estimates being biased.(67, 77) The sources of bias highlighted were: i) channelling of 
new drugs (SGLT2is) to healthier populations, ii) introduction of ‘immortal-time’ bias, 
and, iii) a bias referred to by the authors as ‘time-lag bias’, where studies compared 
drugs prescribed at different stages of drug intensification.(67, 77) The impact of these 
sources of bias could lead to overestimations of the clinical benefit of SGLT2is 
compared to other drugs used in clinical practice. 
Further observational studies have made direct comparisons between the second-line 
therapies SUs, DPP4is and SGLT2is.(78, 79) One used a new-user cohort after 
metformin monotherapy, and measured changes in HbA1c and weight. They compared 
people intensifying metformin monotherapy with SGLT2is to DPP4is, SUs and other 
drugs.(78) However, they did not adjust for important differences between drug cohorts 
at baseline which may be associated with the outcome. For example, the people 
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intensified using SGLT2i were younger (55 yrs., standard deviation [SD]: 10.14) than 
those intensified on DPP4is (60.8 yrs., SD: 12.34) and SUs (61.5 yrs., SD: 12.97).(78)  
An observational study of new-users of SUs, DPP4is and TZDs after metformin therapy 
was published in 2018. The study combined data from multiple cohorts from eight sites 
and compared rates at which people met HbA1c targets, with secondary outcomes 
including kidney disorders. This study did not find differences in HbA1c or kidney 
outcomes between SUs and DPP4i, yet noted distinct heterogeneity in the estimates 
from the multiple sites included in the analysis.(80) 
Whilst the comparative evidence has gained pace over the course of my PhD research, it 
is still lacking in the following areas: 
1. Few head-to-head comparisons of the three drugs currently used in clinical practice to 
intensify metformin monotherapy (SGLT2is, SU and DPP4is). 
2. Improper methodological design or lack of adjustment for baseline characteristics in 
non-randomised studies.  
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1.5 Pharmacoepidemiology 
Pharmacoepidemiology is a specialism of epidemiology combining the study of 
clinical epidemiology and pharmacology. Pharmacoepidemiology is becoming 
increasingly important to the pharmaceutical industry and regulatory agencies.(81) 
Regulatory bodies regard RCTs as the ‘gold standard’ for drug studies, where 
randomisation minimises bias in causal effect estimates. Results from clinical trials 
form the basis for drug approvals for many international organisations.(33, 81)  
However, RCTs have limitations:  
i) Can under-represent parts of the target population, for example, people from 
minority ethnicity groups or individuals of older age. 
ii) Are often expensive to conduct and need large sample sizes with long follow-up 
to determine differences in relevant outcomes.(82) 
Developing epidemiological methods, growing availability of routinely collected 
longitudinal health data, and high costs for clinical trials mean that 
pharmacoepidemiological research has become more prominent in the regulatory 
drug world.(81) Such studies offer evidence from routinely collected health records 
to show the effects of medicines used in clinical practice over the long-term. They 
can generate evidence for drugs on the market, in broad populations, and for rare 
outcomes.(83) However, observational studies are susceptible to bias if treated 
individuals differ systematically to untreated people, detailed in Section 1.4.(77, 84, 
85) 
For antidiabetic therapy, trials undertaken to demonstrate efficacy for reducing 
HbA1c can be short and include modest numbers of participants to fulfil initial 
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regulatory requirements. The new requirement to examine cardiovascular outcomes 
means that studies need many more people, with longer follow-up, and with 
inclusion criteria restricted to people with high-risks for adverse events to find 
clinically important differences.  
Observational research may fill gaps in the current evidence, by looking at long-term 
changes in diabetes-related outcomes, whilst making head-to-head comparisons of 
the drug options. This thesis uses routinely collected data and 
pharmacoepidemiological methods to complement the growing body of evidence for 
first-stage intensification antidiabetic treatments. 
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1.6  Rationale, aims and objectives for project 
1.6.1 Aim 
The aim of this thesis is to use observational data from UK primary care health 
records to investigate changing prescribing of oral antidiabetic drugs at the first stage 
of treatment intensification, and to develop methods to compare these drugs for 
important clinical outcomes.  
1.6.2 Thesis rationale 
The results generated from this thesis should help to inform clinical prescribing 
decisions in UK primary care. It will show the potential of the use of electronic 
health records to contribute to the comparative effectiveness evidence of type 2 
diabetes treatments. 
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1.6.3 Objectives 
The specific objectives of this research are: 
• Complete a systematic review of the literature for the comparative evidence 
for type 2 diabetes drug recommended at the first stage of treatment 
intensification, with the specific aim of comparing kidney outcomes. 
 
• Determine the frequency and proportions of agents prescribed in UK primary 
care, and how this changed since 2000 by focusing on the drugs used at both 
treatment initiation and at initial intensification following metformin 
monotherapy,.  
 
• Investigate associations between patient characteristics or other attributes and 
the prescribing practice of primary care physicians.  
 
• Develop methods to contrast multiple treatments using electronic health 
records and compare type 2 diabetes clinical variables for commonly used 
oral antidiabetic drugs. 
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1.7  Thesis arrangement 
This thesis is arranged in a research paper style format. I have drafted four 
manuscripts based on this work, three of which are published in peer-reviewed 
journals. The final paper is under review. Below summarises each chapter: 
Chapter 2: A published systematic literature review of observational and 
interventional research that compares the effect of oral type 2 diabetes drug regimens 
on kidney outcomes. 
Chapter 3: Describes the methods applied throughout the thesis for data analysis. 
This section outlines the data sources used, and how treatments were defined using 
electronic health records.  
Chapter 4: Includes a published paper with the results of the first analysis that 
shows prescribing trends for antidiabetic therapies in the UK. This work presents 
trends at the first stages of treatment and in the context of contraindications, 
specifically reduced kidney function. 
Chapter 5: Comprises another paper published with Clinical Epidemiology, that 
describes the patient-level factors associated with prescriptions of first-stage 
intensification drugs in the routine clinical care of patients with type 2 diabetes.  
Chapter 6: Consists of a manuscript that applies propensity score matching to 
compare changes in clinical variables between the commonly prescribed drugs. This 
is under review at the British Medical Journal (BMJ). 
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Chapter 7: First summarises the findings from this work and discusses the strengths 
and limitations. Then addresses implications for future research using electronic 
health records for the study of diabetes drug prescribing. 
37
   
 
2 Chapter 2: A systematic review comparing the evidence for 
kidney function outcomes between oral antidiabetic drugs for 
type 2 diabetes (Paper 1) 
 
 
Chapter summary 
• Kidney outcomes are an important consideration for clinicians treating 
people with type 2 diabetes as approximately 40% of people with diabetes 
develop kidney disease.(1) 
• Widely cited clinical trials did not address the comparative effect of 
diabetes drugs for kidney outcomes.  
• The aim of this chapter is to review and collate data from published studies 
that compares type 2 diabetes drugs, over the long term, for kidney-related 
outcomes. 
• The paper identified just 15 eligible studies that made comparisons 
between oral antidiabetic drugs for renal outcomes. With most of the 
comparisons made between metformin and thiazolidinediones or 
metformin and sulfonylureas. 
• The work confirmed that little evidence existed for comparative effects of 
oral type 2 diabetes drugs on renal outcomes. 
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2.1  Introduction to Paper 1 
 
Much of the published RCTs for type 2 diabetes drugs are placebo-controlled short-
term studies that demonstrate efficacy for reducing HbA1c. However, the ultimate 
goal of treatment is to reduce the long-term complications of diabetes. Clinicians 
must make many decisions when treating individuals, such as the best HbA1c target 
or optimal drug, and they must balance the risks and benefits of each choice.  
The aim of this chapter is to focus on the medium to long-term effects of therapy and 
on comparisons of drugs against other available treatments. The paper extends a 
systematic review published in 2016 that covered a range of diabetes-associated 
outcomes including effectiveness, cardiovascular disease, and mortality.(62) The 
2016 review noted that evidence for microvascular outcomes was limited.(62) The 
previous review did not address kidney events specifically, which are an important 
consideration for clinicians treating individuals with type 2 diabetes since around 
40% will develop kidney disease.(1) Recent RCTs including EMPA-REG, 
CANVAS, CANTATA-SU and CREDENCE have shown that SGLT2is slow renal 
function decline.(55, 57, 86) Though EMPA-REG, CANVAS and CANTATA-SU 
did not investigate kidney disease as a primary endpoint. Since publishing this 
review, the CREDENCE trial showed that the canagliflozin group had a 34% 
reduction in risk for a composite renal outcome in people with type 2 diabetes and 
chronic kidney disease.(57) CREDENCE, EMPA-REG and CANVAS were all 
placebo-controlled studies and so did not compare the potential benefits of the 
SGLT2is against SUs or DPP4is. 
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We published the paper in Wellcome Open Research. It provides a systematic review 
of the comparative research that examined outcomes related to renal function, among 
people taking different type 2 diabetes drugs. Drug classes of interest were oral 
agents including metformin, sulfonylureas, DPP4is, SGLT2is and 
thiazolidinediones, as these are recommended by NICE at the first stages of 
treatment. To reflect the decisions faced by clinicians in choosing drugs, we 
excluded placebo-controlled studies and only included head-to-head comparisons. 
After an extensive search, I selected fifteen studies (seven RCTs and eight 
observational studies). Large amounts of heterogeneity were apparent in the 
reporting of kidney function. Many studies have made comparisons between drugs 
used at different stages of drug intensification, predominantly between metformin, a 
first-line agent, and second-line drugs (SU, DPP4i or SGLT2is). There is a paucity 
of evidence in the literature examining comparative kidney outcomes for the newest 
drug classes, SGLT2is and DPP4is, that GPs commonly prescribe in the UK.  
The supplementary files, including the PRISMA reporting checklist, search terms, 
additional information from studies, and study quality criteria referenced in the 
article and the approved Prospero protocol are in Appendix 2.  
With a lack of data available for the comparative effects of kidney outcomes, 
widening the scope of the review would have been beneficial. In addition to kidney 
outcomes, other microvascular events are important to people with diabetes 
including neuropathy, retinopathy and amputations. As the recent clinical trial work 
has shown reduced renal outcomes, understanding the potential for the benefits on 
other microvascular outcomes would also be important.(55, 57, 86)   
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Introduction
Type 2 diabetes mellitus (DM) increases an individual’s risk for 
health problems including cardiovascular disease, blindness, 
chronic kidney disease (CKD), and nerve damage1–4. The devel-
opment of kidney disease is associated with other complica-
tions of type 2 diabetes and with poorer outcomes1,3,5. Therefore, 
slowing the development of, or preventing kidney disease is one 
aim of therapy2. Type 2 diabetes drugs are thought to play a 
major role in protecting the kidneys by controlling blood sugar 
levels and may confer additional protective effects according to 
specific drug profiles3. However, as kidney function declines, 
type 2 diabetes drug options become limited due to prescribing 
restrictions2,3,5–7. This presents a challenge for treating type 2 
diabetes in patients with non-diabetic related kidney disease, as 
well as those with renal diabetic complications.
Treatment choice reflects a complex balancing of expected 
risks and benefits. A recent systematic review focused on 
vascular outcomes, glyclated hemoglobin (HbA1c), body weight, 
hypoglycaemia and common adverse events8. Here we focus on 
kidney-related outcomes as another important aspect of clinical 
care that clinicians must consider when prescribing drugs for 
type 2 DM. Our aim was to provide a summary of the current 
evidence of long term kidney outcomes, from comparative, 
long terms studies of oral antidiabetic drugs. We included the 
following outcomes: change in kidney function (estimated 
glomerular filtration rate), progression or development of 
proteinuria, development of end-stage renal disease (ESRD) and 
composite outcomes compared between different oral drugs for 
the treatment of type 2 DM.
Methods
The protocol for this systematic review was submitted, reviewed 
and approved by PROSPERO (International prospective register 
of systematic reviews, ref. 2016: CRD42016036646). The study 
was conducted and is reported in accordance with the PRISMA 
protocol (Supplementary File 1)9.
Data sources and searches
We searched the databases; Medline, Embase and Web of 
Science for articles published between 1st January 1980 and 
15th May 2018. The search comprised keywords and MESH 
terms relating to three broad themes: kidney function, type 2 
diabetes drugs and clinical studies. We limited the search to 
English-language studies, and studies in humans. The search 
strategies are in Supplementary Table 1 and Supplementary 
Table 2 (Supplementary File 2). The reference lists of relevant 
reviews identified through the search were also screened.
Study selection
One reviewer (SW) screened all citations identified in the 
searches. Titles and abstracts for all studies were compared to 
the selection criteria. Then the full-text of selected studies were 
reviewed against the inclusion and exclusion criteria. Reviewer 
two (MI) was blinded to the articles selected by reviewer one and 
screened a 20% sample of the articles selected by reviewer one 
after the title screen. The studies chosen by the two reviewers 
were compared.
We defined the search and screening strategies before complet-
ing the searches. Studies were eligible for inclusion if they were 
clinical studies that (i) compared two or more classes of oral 
therapy for type 2 DM; (ii) reported kidney outcomes as primary 
or secondary outcomes; (iii) included more than 100 participants, 
and (iv) followed participants for 48 weeks or more. We restricted 
the review to oral antidiabetic drugs recommended at the 
initiation and first intensification of treatment6.
We did not include studies that reported only placebo- 
controlled comparisons as we were interested in the difference in 
effects between active therapy regimes to reflect therapy choices 
made in routine clinical care; placebo-controlled studies would 
not estimate this difference. Our definition of a kidney outcome 
was broad to identify as many studies as possible. We accepted 
any kidney-related outcome, including the incidence of chronic 
kidney disease, reduced estimated Glomerular Filtration Rate 
(eGFR), increased creatinine, ‘micro’ and ‘macro’ albuminuria, 
proteinuria, end stage renal disease (ESRD) and compos-
ite kidney outcomes. We did not include composite microv-
ascular outcomes that combined kidney outcomes with other 
microvascular outcomes such as retinopathy or neuropathy.
Data extraction and quality assessment
After study selection, using a predefined data collection tool, we 
extracted data for the following items: number of participants, 
study design, calendar years covered by the study, length of 
follow-up, drug comparison, mean age of study population, 
exclusion criteria for study, kidney measurements taken at 
baseline, mean duration of diabetes, mean HbA1c at baseline, 
primary outcome for the study, kidney outcomes reported and 
results for kidney outcomes reported. Reviewer one (SW) 
assessed each study for quality, using the GRACE 201410 items 
for observational comparative effectiveness research and the 
Cochrane Collaboration tool for assessing risk of bias in 
randomised trials11 for RCTs.
Results
Figure 1 details the study selection process through which we 
found 9,086 potentially eligible studies. The first reviewer (SW) 
completed the initial title screen and selected 1,896 articles. 
The second reviewer (MI) was blinded and reviewed a 20% 
random sample of these articles. The agreement between 
reviewers was good, reviewer two selected an additional paper 
that was rejected after discussion. After subsequent discussions 
(SW, MI and LT), we selected 15 studies.
We identified 15 eligible studies, seven of which were randomised 
controlled trials (RCTs)12–18 and eight were observational 
studies19–26. Across the 15 studies, three RCTs16–18 and one 
observational study22, reported changes in eGFR as an outcome. 
All seven RCTs12–18 and two observational studies22,25 investi-
gated albumin-creatinine ratio (ACR) as an outcome. Six obser-
vational studies reported kidney endpoints, including kidney 
failure, nephropathy, acute dialysis and composite endpoints with 
eGFR19–21,23,24,26. Comparisons made, and outcomes studied are 
summarised graphically in Figure 2. Given the range of the kid-
ney function outcomes reported and the drug class comparisons 
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Figure 1. Flow diagram of study selection. Ovid was used to search the Embase and Medline databases.
made we did not complete a meta-analysis of the results, instead we 
provide a narrative summary of studies. Selected studies and 
their findings are summarised in Table 1 and Table 2.
In total, we identified 32 direct comparisons between oral 
drugs for the treatment of type 2 DM: 22 comparisons between 
monotherapies, three comparisons between dual therapy 
combinations, and seven comparisons between dual therapies and 
monotherapies, outlined in Table 3. One study compared many 
combination therapy options to metformin; we did not 
include the triple therapy combinations from this study in our 
results, details of the comparisons are in Supplementary Table 3 
(Supplementary File 2)23.
Monotherapy comparisons
Metformin monotherapy vs. thiazolidinedione monotherapy. 
The most common drug comparison was metformin monotherapy 
vs. thiazolidinedione monotherapy (five studies made seven 
comparisons)14,16,19,22,23. Two RCTs found that thiazolidinedi-
ones were associated with improved kidney outcomes (reduced 
proteinuria or improved eGFR) compared to metformin14,16 
while two observational studies found no differences between 
the two drug classes19,22. One observational cohort study showed 
that thiazolidinediones were associated with a higher risk for 
development of kidney failure (a composite of kidney dialysis, 
kidney transplant and CKD stage five) compared to metformin23.
Metformin monotherapy vs. sulfonylurea monotherapy. Six 
observational studies19–23,26 compared metformin monotherapy 
to sulfonylurea monotherapy. Though two of these studies 
(19 and 20) reported similar findings from the same source 
population, we have therefore only reported one of the results, 
making six comparisons. Four comparisons favoured metformin. 
One study found the risk of eGFR falling to below 60 mL/min/
1.73m2 was greater in the sulfonylurea group compared to the 
metformin group22. Three found higher risks of kidney failure 
outcomes (various composites of codes for nephropathy, dialysis, 
renal transplant, ESRD, and reductions in eGFR) for sulfonylu-
rea compared to metformin20,21,23. One study, using proteinuria 
as an outcome, found no difference between drug classes22. One 
further study reported higher rates of acute dialysis for people 
initiating metformin compared to sulfonylureas26.
Sulfonylurea monotherapy vs. thiazolidinedione monotherapy. 
Findings from two RCTs showed differences in ACR that were 
not statistically significant12,16. However, one of these studies also 
showed an increase in mean eGFR among patients treated with a 
TZD, but a fall in the SU group16.
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Figure 2. Graphical representation of drug comparisons and findings. Connecting lines indicate where studies have made comparisons 
between drugs. Lines connect drug names and are labelled with the authors that made the comparison. Dashed line indicates randomised 
studies, single line indicates non-interventional studies. Findings are indicated by the colour of the line: where one drug appears to be 
protective, the line is the colour of the protective drug. Grey lines indicate no significant difference. E.g. Blue lines connecting metformin to 
sulfonylurea indicate that metformin appeared to be protective of kidney function. Arrow heads point towards the drug that appeared to be 
protective. One further comparison not included here. Hung et al. 2012, as two studies by Hung et al. reported similar comparison using 
similar data* Also includes dipstick and urine protein tests, † metformin group largely metformin, but some taking TZD or SU. Abbreviations: 
MTF: metformin, SU: sulfonylurea, TZD: Thiazolidinedione, DPP4i: Dipeptidyl peptidase-4 inhibitor, ACA: acarbose, SGLT: Sodium-glucose 
Cotransporter 2 inhibitors, GLP1: Glucagon-like peptide-1 receptor agonist, eGFR: estimated Glomerular Filtration Rate, ACR: Albumin 
creatinine ratio, ARF: Acute renal failure.
Sulfonylurea monotherapy vs. SGLT2i monotherapy. One 
RCT showed canagliflozin slowed kidney function decline, and 
reduced albuminuria, compared to glimepiride17.
Combination therapy comparisons
Only three studies compared combination therapies.
Metformin plus sulfonylurea vs. metformin plus thiazolidinedi-
one. One RCT compared metformin plus sulfonylurea to metformin 
plus a thiazolidinedione15. They reported that ACR decreased in 
the metformin plus thiazolidinedione group and increased in the 
metformin plus sulfonylurea group15.
Sulfonylurea plus metformin vs. sulfonylurea plus thiazolid-
inedione. One RCT compared sulfonylurea plus metformin to 
sulfonylurea plus thiazolidinedione13. The study found that the 
ACR increased in the sulfonylurea plus metformin group, and 
decreased in the sulfonylurea plus thiazolidinedione group13.
Metformin plus sulfonylurea vs. metformin plus gliptin (DPP4i). 
One observational study compared metformin plus sulfonylu-
rea combination therapy to metformin plus sitagliptin25. The 
results showed weak evidence that metformin plus sitagliptin 
improved the likelihood of reductions in ACR, with an odds ratio 
of 1.20 (95% CI: 0.99–1.47, P = 0.063)25.
Dual therapy vs. monotherapy
Three observational studies made seven comparisons between 
monotherapy options and combination therapy20,21,23. One 
study indicated that people taking metformin were at a lower 
risk of renal failure compared to people taking metformin plus 
sulfonylurea21. Another study found the opposite, people taking 
metformin plus sulfonylurea were at lower risk of kidney failure 
compared to metformin23. The same study found no differences 
in the risk of kidney failure compared to metformin in people 
prescribed; i) metformin plus thiazolidinedione, and ii) metformin 
plus gliptin. They also reported that people prescribed sulfo-
nylurea plus thiazolidinedione, and a sulfonylurea plus DPP4i 
were at higher risk for kidney failure compared to metformin23.
Another observational study found no difference in eGFR 
outcomes between sulfonylurea monotherapy and metformin plus 
sulfonylurea combination therapy20.
Study quality
We assessed each study for quality, using the GRACE 201410 
items for observational comparative effectiveness research 
and the Cochrane Collaboration risk of bias tool for RCTs11 
Supplementary Table 5 and Supplementary Table 6 (Supplemen-
tary File 2) detail the results. For the RCTs, we assessed study 
quality as good, though few studies reported details of randomi-
sation techniques. Of the observational studies, reporting was 
reasonable, according to the GRACE criteria. However, many 
of the studies made comparisons between drugs used at differ-
ent stages of drug intensification, or between monotherapy and 
combination therapy. For example, two observational studies21,23 
used metformin monotherapy as the baseline in comparisons 
with combination therapy. As metformin monotherapy is the 
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Table 3. Results summary.
RCTs Observational
Number Results Number Results
ACR
Monotherapy
MTF     vs     ACA 1 Favours ACA 0
MTF     vs     SU 0 1 No difference
MTF     vs     TZD 2 Both favour TZD 1 No difference
SU     vs    SGLT 1 Favours SGLT 0
SU     vs    TZD 2 Both no difference 0
Dual therapy
MTF+SU    vs     MTF+DPP4i 0 1 No difference
MTF+TZD     vs     MTF+SU 1 Favours MTF+TZD 0
SU+TZD     vs     SU+MTF 1 Favours SU+TZD 0
eGFR
Monotherapy
MTF     vs     ACA 1 No difference 0
MTF     vs     SU 0 1 Favours MTF
MTF     vs     TZD 1 Favours TZD 1 No difference
SU     vs     SGLT 1 Favours SGLT 0
SU     vs     TZD 1 Favours TZD 0
KIDNEY 
OUTCOMES
Monotherapy
MTF     vs     DPP4i 0 1 Favours MTF
MTF     vs     SU 0 4 3 favour MTF, 1 favours SU
MTF     vs     TZD 0 2 1 no difference, 1 favours MTF
SU     vs     DPP4i 0 1 No difference
Mono vs. dual therapy
MTF     vs     MTF+DPP4i 0 1 No difference
MTF     vs     MTF+SU 0 2 1 favours MTF, 1 favours MTF+SU
MTF     vs      MTF+TZD 0 1 No difference
MTF     vs     SU+DPP4i 0 1 Favours MTF
MTF     vs     SU+TZD 0 1 Favours MTF
SU     vs     MTF+SU 0 1 No difference
Abbreviations: ACR: Albumin: Creatinine Ratio, eGFR: estimated glomerular filtration rate, MTF: metformin, SU: sulfonylurea, TZD: 
Thiazolidinedione, DPP4i: Dipeptidyl peptidase-4 inhibitor, ACA: acarbose, , EXE: Exenatide. SGLT: SGLT2i, GLP1: Glucagon-like 
peptide-1 receptor anonist, IPW: Inverse Probability Weight, FU: Follow-up, SD: Standard deviation, ARF: Acute Renal Failure, CKD: 
Chronic Kidney Disease, IQR: Inter Quartile Range, p-yr: person-years, NR: Not reported, DB: Database, KDIGO: Kidney Disease: 
Improving Global Outcomes. One further comparison not included here. Hung et al. 2012, as two studies by Hung et al. reported 
similar comparison using similar data
most common drug for initiating treatment, and the addition 
of other drugs to metformin is likely to be associated with pro-
gression or poor control of type 2 DM, comparing metformin to 
drug prescribed at the first stage of intensification is problematic, 
particularly for renal outcomes. Those people receiving treatment 
intensification will tend to be sicker, and distinguishing between the 
effects of treatment and the effects of the underlying disease may 
not always be possible.
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Conclusion
Key findings
Overall, we have found a lack of consistent evidence of long-
term differences in kidney outcomes between T2DM drugs. In 
comparisons of treatments for type 2 DM, for thiazolidinediones 
vs metformin, there is some evidence of reduced proteinuria - of 
four comparisons with ACR as an outcome (in combination or 
monotherapy), three favoured TZD and one showed no differ-
ence. Most evidence from observational research also suggested 
that metformin is associated with better kidney outcomes than 
sulfonylureas.
Despite frequent use of combination therapies for the treatment 
of diabetes, we found few studies that compared commonly used 
dual therapies that investigated renal outcomes.
Previous work
The finding that thiazolidinediones may reduce proteinuria 
compared with metformin is aligned with observations of other 
authors and supported by animal studies27,28. Though previous 
evidence is limited, other work suggests that TZDs could exert 
reno-protective effects via a number of pathways, including 
reducing blood pressure28. TZDs may also act directly in the 
kidneys via proliferator-activated receptor gamma (PPARg), 
found in the kidney (and in other tissue)27,28. However, changes 
in estimated GFR may reflect changes in fluid status rather than 
true changes in renal function, which was not measured directly in 
any study29.
Strengths
To our knowledge, this is the first systematic review of the 
comparative research literature that investigated the effects of 
type 2 diabetes drug regimens on renal function. We have 
conducted an extensive and detailed search, with broad defini-
tions of renal function.
Limitations
We have focused on renal outcomes only but recognize this is 
just one of many safety and effectiveness factors to be considered 
when deciding treatment options. Despite the importance of care-
ful monitoring and maintenance of kidney function for people with 
diabetes, we identified just 15 long-term studies reporting 
renal outcomes. Renal complications of type 2 diabetes take 
many years to develop after the onset of diabetes and studies may 
not be adequately powered or have sufficient length of follow-
up to detect differences. Therefore, many studies have used the 
surrogate marker of changes in proteinuria as a marker of 
clinical renal outcomes. Further, initial changes in kidney 
function may be misleading. One included study indicates benefits 
of canagliflozin over glimipiride for kidney function decline 
at 104 weeks: however these benefits were not apparent until 
52 weeks17,30. This and the EMPA-REG study31 have indicated 
initial acute falls in eGFR with better outcomes compared to 
placebo only observed over the longer term so this would not be 
apparent in short-term studies.
Our review included both randomised and non-interventional 
studies. Whilst the unique inferential advantages of randomization 
are clear, our review highlights a large overall difference in 
population size depending on study type: randomised trials 
generally included hundreds of patients, whilst non-interven-
tional studies often had tens of thousands of participants. Rarer 
outcomes such as ESRD are therefore more likely to be detected 
in non-interventional settings. This highlights their important 
role, but the evidence generated from them needs to be evaluated 
cautiously due to the potential for bias and confounding.
The available evidence does not reflect drugs currently prescribed 
in routine care. In our review, 69% (22/32) of the comparisons, 
contrasted different monotherapies, with just three comparisons 
between dual therapy combinations. In clinical practice, 
metformin is the most common first-line therapy, and GPs now 
rarely prescribe thiazolidinediones (EU marketing authorization 
for Rosiglitazone was suspended in 201032, following concern 
regarding increased heart failure risk)33.
In the UK, NICE guidance recommends the addition of 
sulfonylureas, Dipeptidyl peptidase-4 inhibitors (DPP4is) 
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2is), or TZDs 
to metformin, yet, just one study compared these combinations 
(MTF+SU vs MTF+DPP4i)25,33–35. Recent studies that have 
shown potentially exciting improvements in renal outcomes for 
patients treated with SGLT2is were conducted against placebo 
and so were not eligible for this study36,37.
We found that definitions of kidney outcomes were not consistent 
across studies. Definitions of renal decline in the observa-
tional studies relied upon either codes for kidney disease 
(e.g. diabetic nephropathy, acute renal failure), surrogate markers 
(e.g. eGFR or proteinuria) or a combination of codes and tests, sum-
marised in Supplementary Table 4 (Supplementary File 2). For the 
albuminuria data, which has a skewed distribution, most studies 
used logarithmic transformation to approximate normal, yet 
not all studies applied this method18. Such differences between 
outcomes will limit future opportunities for pooling effect 
estimates in meta-analyses. Different approaches to study design 
may also limit the validity of findings. We found two observa-
tional studies that made the same comparisons yet found different 
effects. Both examined renal failure, using UK primary care data, 
(QResearch23 and Clinical Practice Research Datalink21). They 
found comparable effect sizes when comparing the use of 
sulfonylurea monotherapy to metformin monotherapy, for renal 
failure (2.63, 95% CI: 2.25, 3.0623 and 2.63, 95% CI: 2.19, 
3.1521). However, when comparing sulfonylurea plus metformin 
dual therapy to metformin monotherapy, estimates of the risk of 
kidney failure were in opposite directions (0.76, 95% CI: 0.62, 
0.9223 and 1.39, 95% CI: 1.12, 1.7221). Difficulties in adjusting for 
levels of diabetic control or change in renal function that led to 
these treatment choices (confounding by indication), may explain 
these conflicting results.
In the randomised controlled studies, we found that eligibility 
criteria were strict. Many studies excluded people most at risk of 
kidney outcomes e.g. those with reduced kidney function or 
cardiovascular disease12,13,15–18. These restrictions limit the gen-
eralisability of study findings to routine clinical settings where 
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people presenting with diabetes have complex comorbidities38. 
Further, as most individuals with type 2 diabetes will receive 
treatment for other comorbid conditions, prescribers need to 
know how diabetic therapies interact with concomitant drugs, yet 
this is not addressed by the studies identified in this review.
Clinical relevance
In clinical practice, kidney function is one of many considera-
tions for treatment choice in type 2 DM. Some of the differences 
we found for albuminuria and eGFR between people taking 
different oral therapies for type 2 diabetes were statistically 
significant, but the clinical importance of these findings may be 
limited. Some surrogate outcomes such as a doubling of cre-
atinine or 30% decline in eGFR are closely associated with 
risk of future ESRD39,40 while ACR is not39,41,42. Outcomes that 
are clinically relevant need to be assessed in future studies. 
Ideally, these should include hard outcomes such as hospital 
admission with acute kidney injury or the development of ESRD. 
Therefore, large, well-designed studies with long follow up, 
including individuals that represent the typical type 2 diabetes 
population, will be required. However, the incidence of kidney 
outcomes is likely to be low in most randomised trials and 
therefore high-quality observational studies will also be needed.
Our review highlights a lack of rigorous studies comparing 
the effects of oral type 2 diabetes drugs on kidney outcomes, in 
particular, for the newer drug intensification options where 
prescribing is rapidly increasing.
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3 Chapter 3: Methods 
 
Chapter summary 
• This chapter describes the data sources used for each study detailed in 
Chapters 4-6: the UK Clinical Practice Research Datalink GOLD dataset, 
and mortality and Index of Multiple Deprivation (IMD) data from the 
Office of National Statistics. 
• It covers how data is generated in clinical practice and then processed into 
a research database.  
• This is followed by the methods applied to identify eligible people, 
covariates, outcomes, and the steps taken to reduce bias in the studies. 
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3.1  Source of Data   
3.1.1 Overview of the UK Clinical Practice Research Datalink 
The primary source of data for this thesis is the UK Clinical Practice Research 
Datalink (CPRD GOLD). CPRD GOLD is a database of electronic medical records 
collected in routine clinical practice from select GP practices in the UK (England, 
Scotland, Wales and Northern Ireland). As of July 2017, there were 17,148,866 
patients, sourced from 718 practices in the UK that have contributed data since 1987,  
of these, the CPRD central processing team deemed 14,942,430 to be ‘up-to-
standard’. Approximately 2.3 million patients are registered at practices contributing 
data.(87) CPRD GOLD covers around 7% of the UK population and is used 
extensively for a range of pharmacoepidemiological studies.(88) 
In the UK, NHS primary care provides the ‘gateway’ into NHS specialist care for 
most patients, apart from those attending emergency services, some sexual health 
clinics and some private care. About 99% of the population are registered with a GP 
practice.(92) Care through the NHS is free at the point-of-care, paid for via tax 
contributions. Outpatients pay a flat fee for prescriptions in England (£9 as of April 
2019), which is waived for people with exempt status.(89) Around 90% of 
prescriptions provided by the NHS are free of charge. People can gain exemption 
from charges if they are over 60 or under 16, pregnant or recently pregnant, or have 
long-term medical conditions which includes people with diabetes.(90) In Scotland, 
Wales and Northern Ireland, all prescriptions are free.  
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Primary care data recording  
Healthcare providers in GP practices use computer software to record details of 
consultations, medical history and treatment. GPs act as the entry point into the 
NHS, they generally know of major health events in a person’s life as hospital staff 
update GPs with diagnoses and treatments provided. GPs hold records for their 
patients covering many years, which is valuable to researchers investigating long-
term exposures and clinical outcomes.  
Use of electronic health records in UK primary care became widespread in the late 
1980s. The department of health encouraged practices to adopt electronic record 
keeping with subsidisation and by requiring electronic records for payments-by-
performance incentives. There are several systems available to practices, including 
Egton Medical Information Systems (EMIS), Vision and SystmOne.(91) Several 
systems are translated into anonymous, research ready databases. CPRD GOLD uses 
records from Vision practices, and others collect data from practices using Vision 
(The Health Improvement Network [THIN] database), EMIS (CPRD Aurum), or 
SystmOne (ResearchOne). However, practices must actively provide data to each 
database, and so coverage of each database relies upon participation. Further, 
practices can change their computer system provider, meaning that patients can 
appear in multiple databases.(91)  
Though not collected for research, data quality is important for clinicians. These 
records are the primary means to record patient interactions within the practice and 
for maintaining a history of an individual’s health status. In addition, the Department 
of Health uses the information to audit clinical standards and to administer the 
Quality Outcomes Framework (QOF). The Department of Health introduced QOF in 
2004 to incentivise GPs to provide health interventions that improve health 
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outcomes. These incentives apply to a range of important health domains, including 
diabetes, and help to standardise both care provision and health status recording 
across a number of diseases.(92, 93)  
Data quality 
The CPRD ensures that data submitted by practices meet quality standards.(88) In 
the CPRD GOLD database, individuals with records of adequate quality are labelled 
‘acceptable’. Records must include sufficient follow-up, a registration status (not 
temporarily registered), age and gender information. Practices must also meet ‘up to 
standard’ requirements ensuring that data collection is consistent and that mortality 
rates are similar over time.(88, 94) 
Data structure 
The CPRD database holds data in a series of data files: Therapy, Clinical, Patient, 
Immunisation, Referral, Test, Additional and Consultation files. Each file provides 
data for different aspects of patient care, detailed in Table 3.1. Each CPRD table are 
linkable using either patient identification numbers, consultation identification 
number, or a code that links additional information to test or clinical records. 
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Data table Data contained within the file Records per patient 
Patient Includes gender, year of birth, marital 
status, ethnicity information, dates included 
in CPRD data, and death dates. 
Contains one record for 
each subject identified in 
the data extract. 
Therapy Records of prescriptions given to patients 
by primary care prescribers. Includes 
product name, prescription duration, date of 
prescription and dosage information. 
Can have multiple or no 
records for each patient 
in extract. 
Clinical Diagnoses, signs and symptoms coded with 
Read codes 
Multiple or no records 
for each patient. 
Immunisation Records of immunisations. Multiple or no records 
for each patient. 
Referral Referrals to a hospital or other care 
settings, and urgency. 
Multiple or no records 
for each patient. 
Test Details of tests or measures taken in 
primary care, and results. 
Multiple or no records 
for each patient. 
Consultation Details of the clinical staff member that the 
patient consulted with.  
Multiple or no records 
for each patient. 
Additional Details that can be linked to test or clinical 
files. Includes a wide variety of items such 
as test results (e.g. serum creatinine) and 
lifestyle choices (e.g. smoking status) and 
symptoms. 
Multiple or no records 
for each patient. 
Table 3.1 Description of the CPRD GOLD data structure, and data available 
within each table 
To extract study populations from CPRD GOLD, researchers use diagnostic, 
medical, procedure or drug prescribing codes, to find eligible individuals. They code 
medical diagnoses, symptoms, procedures and history using the Read code system, 
developed by James Read in the early 1980s and first introduced to the NHS in 
1985.(95, 96) Read codes provide a structured way for researchers to identify clinical 
characteristics. Vision software prompts GPs to provide a Read code before they can 
enter clinical information. Therefore, the Read code system should enable 
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researchers to identify most clinical events in an individual’s history, apart from 
those in free-text as detailed in Section 3.2.  
For exposure status, this project relies upon drug prescribing. Vision software codes 
drug prescriptions with product and British National Formulary (BNF) codes. To 
provide a drug to a patient, the GP must generate a prescription using the software, 
which automatically populates various prescription details. For this reason, 
prescriptions in the therapy file are essentially complete, apart from drugs that are 
given over-the-counter.(97) In studies that compared therapy records in CPRD to 
national prescription data or other sources of primary care data, prescribing rates 
were similar.(98-101) 
The CPRD can also provide linkage of records to other sources of health data, whilst 
maintaining the anonymity of the patient record. NHS Digital act as the data 
custodian and processes linkages to maintain anonymity, methods for linking data 
sources are published.(94) 
3.1.2 ONS 
The completeness of mortality data in the CPRD can be limited, as reporting of 
deaths to GP practices is not legally required. It is an important concern for practices 
to record mortality, for example, to avoid causing distress to relatives by attempting 
to contact deceased people.(102) Completeness and accuracy of mortality 
information may differ according to how patients presented to the healthcare system. 
Data held by the UK Office of National Statistics (ONS) is the most accurate source 
of mortality information, as all deaths in England and Wales must be reported to the 
local authority within 5 days, and the law mandates this.(103) CPRD researchers 
therefore commonly request linkages to information from the UK ONS to access 
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more complete mortality information.(88) Gallagher et al. investigated the estimates 
of mortality after Venous Thromboembolism (VTE) in CPRD and linked datasets. 
Their work indicated that some deaths following VTE were missing from primary 
care records; estimates increased from 169.9/1000 person-years in HES-linked 
CPRD data to 173.2/1000 person-years when these individuals were linked to UK 
ONS mortality records.(103)  
3.1.3 Index of Multiple Deprivation and Hospital Episode Statistic data 
The ONS also provides estimates of socio-economic status, in the form of the index 
of multiple deprivation (IMD), for around 75% of practices that consent to 
linkage.(88) The IMD is a composite of multiple facets of an individual’s life and 
opportunities: housing, income, employment status, education, health, disability, and 
crime.(104) This data is available for patient or practice postcodes and linked to 
Lower Layer Super Output Area (LSOA)-level deprivation measures.(104) For this 
thesis I used the latest LSOA-level deprivation measures available, created in 2015. 
Other data linkages available from CPRD include the Hospital Episodes Statistics 
Database (HES). HES data is a source of administrative health data, for hospital 
admissions in England. CPRD can provide linkage to HES data, however, HES is 
only available for around 75% of CPRD practices and this would limit the study size 
and generalisability.(88) As GPs could only prescribe newer drug options recently, 
maintaining a maximum number of eligible patients was a priority. Therefore, HES 
linkage was not sought for this project. 
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3.2  Strengths and limitations of CPRD data 
As previously stated, CPRD offers a population-based representative sample of 
electronic medical records for the UK population. However, some important 
information is missing from the records that is important to acknowledge.  
GPs use Read codes to classify inputs into the electronic health record, as detailed 
above. However, once a GP starts a record, they can enter clinical information as 
free-text. This free-text entry is not available to researchers as this field may contain 
personal information that could identify patients. As researchers are unaware of 
information recorded in the free-text field, they may miss clinical information not 
recorded in a structured way. This could lead to an underestimation of outcome rates, 
or prevalence of baseline covariates.(105)  
Some facets of a patient’s health status are not available in CPRD GOLD. For 
example, frailty is a measure of vulnerability to health outcomes linked to age. 
Frailty that may be apparent to a GP, and thus inform their prescribing practice, has 
not to date been recorded in the electronic record.(106) Where frailty is linked to 
both prescribing and outcomes, this could introduce confounding.  
Vision software automatically includes information about prescriptions, as outlined 
in Section 3.1.1. However, adherence of patients to GP instructions and whether the 
individual collects the prescription is not available.  
People may exhibit a range of behaviours with drugs whilst collecting prescriptions, 
from strict adherence to only taking the medicines rarely. The veracity with which an 
individual follows a drug prescription extends to other drugs on their prescription. 
An individual that takes their diabetes drugs in a variable way will also likely take 
their antihypertensive medications inconsistently.(107) Misclassification of 
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exposures will bias estimates.  If this is not differential between drugs, effect 
estimates will be biased towards the null. If some patient characteristics associated 
with adherence also affect the choice of prescription, bias could be introduced via 
more complex mechanisms in unpredictable directions.  
People do not tolerate some drugs, leading them to stop taking it as prescribed and 
changing drugs. Using an intention-to-treat design would estimate effects of the drug 
in clinical practice but would not reflect the ‘as-treated’ experience. Therefore, when 
selecting people for each drug cohort I sought to minimise this source of exposure 
misclassification by selecting patients that received more than one prescription, and 
censored patients when they received prescriptions for other drugs indicating 
switching of treatment, Section 1.1. 
Primary care data is a good source of information given that most people with type 2 
diabetes receive most of their care in the community. However, some patient data 
may be incomplete or not recorded. This is a particular problem for variables such as 
body mass index (BMI), blood pressure, renal function, lifestyle factors, and 
ethnicity. Missingness of these items can often be associated with engagement in 
care and future outcomes.(108-110) For example, BMI information could be missing 
due to an individual not engaging with health seeking behaviours, or their GP. These 
people would have fewer BMI measures over time in their GP record, contribute less 
data to the analyses and have worse outcomes. If GPs are more willing to prescribe 
newer drugs to those more invested in health-seeking behaviours, then newer drugs 
will be associated with fewer outcomes and effect estimates biased.  
In 2004, the QOF began incentivising GPs to meet a range of targets when treating 
diabetes, including annual checks for BMI and renal function. Since QOF, an 
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increasing proportion of people with diabetes had a serum creatinine recorded 
between 1997 and 2010.(93) For the years that BMI recording was incentivised by 
QOF 2004-2013, annual BMI recording rates were above 90%, up from 
approximately 80% in 1998.(111, 112) Incentivisation of BMI ceased in 2013, and 
recording of BMI fell to 83% in 2017.(108, 112)  
3.3 Data management 
I processed, managed and analysed data using Stata MP (Version 14.2). For some 
tables and graphics I used R (Version 3.5.0) and RStudio. 
3.3.1 Data protection  
Though CPRD data is pseudonymised, European and UK data protection laws 
demand that use of CPRD GOLD data is approved by an ethics and scientific 
committee before starting work. I stored all patient-level data on university 
approved, secured and regularly backed-up servers and only used the data for the 
purposes of the approved work.
3.4  Creation of diabetes drug code list 
To identify treatment cohorts for this thesis, I used GP prescribing records for type 2 
diabetes drugs. Therefore, an important first step in data processing was to create an 
up-to-date list of type 2 diabetes drugs. I achieved this with the following steps: 
1. Identify initial list of products and British National Formulary (BNF) headers, or 
header codes from a literature search. The BNF is a source of prescribing, 
pharmacology and safety information for drugs approved for use in UK clinical 
practice. 
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2. Search CPRD CodeBrowser tool using the search terms related to type 2 diabetes
drugs, detailed in appendix 3.1. 
3. Manually assign drug class to each item in the list, full drug code list provided in
appendix 3.2. 
3.4.1 Creation of covariate definitions 
Identifying individuals in CPRD, and extracting data on their clinical history 
requires code lists that reflect the information of interest. This section provides an 
overview of the steps taken to identify covariates for each analysis. First, I used 
published disease code lists from departmental colleagues, CALIBER or 
ClinicalCodes.org. CALIBER is a research collaboration with a focus on 
cardiovascular disease that share code lists and Stata do. files which they have used 
in research. Clinicalcodes.org is a resource that collates published clinical codes and 
accompanying papers. As new clinical codes and new drug products are introduced 
over time, I updated and checked code lists. To update code lists, I took the 
following steps: i) search the medical code dictionary provided by CPRD, using 
inclusion and exclusion terms based on literature searches, ii) compare the identified 
records to the source code list, iii) reviewed possible new codes with clinicians 
(Laurie Tomlinson and Liam Smeeth). Figure 3.1 illustrates the generic process.  
Figure 3.1 Step-wise generic process for creating diagnostic code lists using and 
updating existing code lists 
1. Identification of existing 
code list
Using the following resources:
• Departmental code list
• CALIBER
• Clinicalcodes.org
2. Add search terms based 
on existing code list
Create a small list of terms to
ensure that the original list is up-to-
date. Search most recent CPRD
medical code list 
3. Remove newly
identified irrelevant codes
Check new read-terms identified to 
ensure relevance, remove codes 
that are not appropriate.
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Code lists for each manuscript are published online at the LSHTM Data Compass: 
http://datacompass.lshtm.ac.uk/. 
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3.5 Exposure classification 
Each analysis presented in this thesis relies upon creating cohorts of individuals 
taking specific medications that are at the same stage of treatment, which requires 
interpretation of prescribing patterns from patient records. In addition to the 
commonly recognised sources of selection and information bias, ‘time-related’ 
biases are an important consideration for pharmacoepidemiological studies.(113, 
114)  
Two common sources of time-related bias in cohort studies include: 
1. Misclassification of person-time as exposed but where the individual cannot have 
an outcome (e.g. death) due to the exposure status being defined by an event which 
occurred later (e.g. a repeat prescription).(113) Known as Immortal time bias  
2. Comparing treatments used at different stages of disease, sometimes referred to as 
time-lag bias.  
Authors have criticised recent observational studies of SGLT2is for making 
comparisons between drugs used at different stages of treatment intensification: For 
example, SGLT2is vs. insulins. People at earlier stages of treatment are expected to 
survive longer with fewer morbidities compared to those at later stages of treatment 
who have had the disease for longer.(77)  
An important foundation for this thesis is identifying treatment cohorts that are 
similar in terms of disease status, treatment stage and prior treatment.  
3.5.1 Identifying people at the first stage of treatment intensification  
Central to this research project was an investigation of the drugs prescribed at the 
first stage of type 2 diabetes treatment intensification. The first stage treatment 
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intensification cohort was used across three studies (Papers 2, 3 and 4). Exposure 
classification in each manuscript relied upon prescribing patterns, with minor 
differences in inclusion criteria according to the aims of each study. The inclusion 
criteria shared by all papers are provided in Table 3.2, and described below. 
 
Inclusion criteria Exclusion criteria 
• Labelled ‘acceptable’ by CPRD 
with age and gender  
• Aged 18 years and over 
• 12 months of follow-up in health 
record before initial type 2 diabetes 
prescription  
• Record of any type 2 diabetes 
therapy between January 2000 and 
July 2017 
• The first type 2 diabetes 
prescription in therapy records 
must be metformin monotherapy. 
• Intensified treatment with oral 
antidiabetic drugs  
• Initiated treatment for type 
2 diabetes with 
combination therapy. i.e. if 
prescribed metformin on 
the same day as another 
antidiabetic drug 
• Evidence of pregnancy in 
the 12 months before or 
after drug intensification. 
Table 3.2 Inclusion and exclusion criteria for all first-stage intensification 
cohorts included in this thesis 
Labelled ‘acceptable’ by CPRD with age and gender: First, to ensure data quality 
would be of a sufficient standard we only extracted data for individuals labelled as 
‘up-to-standard’ by the CPRD processing team.  
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Aged 18 years and over: Only adults were eligible for the study as NICE treatment 
guidance is different for children with type 2 diabetes. I wanted to ensure that all 
individuals included were subject to the same set of treatment recommendations. 
12 months of follow-up in health record before initial type 2 diabetes 
prescription: This ensured that all individuals were new-users of type 2 diabetes 
drugs. Ensuring that all individuals had 12 months of no treatment before their first 
type 2 diabetes drug minimises the misclassification of prevalent users as incident 
users.(113, 115) 
Record of any type 2 diabetes therapy between January 2000 and July 2017: 
Over these years, treatment guidelines have changed. The first paper in the series 
describes changes in prescribing practice over this period. In subsequent papers, I 
limited the period of interest by only include people intensifying treatment in more 
recent years to ensure that they were subject to the same treatment recommendations 
and so were comparable. 
The first type 2 diabetes prescription in therapy records must be metformin 
monotherapy: This criterion was chosen for two reasons. i) NICE clinical guidance 
recommends the use of metformin monotherapy as first-line treatment, unless 
contraindicated. People starting treatment with drugs other than metformin, may not 
be eligible for metformin for medical reasons, such as low kidney function.(18) In 
2013, 91% of people in the UK started treatment with metformin.(19) Though this 
limits generalisability, metformin was the most common first line treatment used in 
the UK. This also ensured that the vast majority of people in the study have type 2 
diabetes, though misclassification of people with late onset type 1 diabetes may still 
have occurred. 
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Intensified treatment with oral antidiabetic drugs: To ensure that individuals are 
intensifying, rather than switching treatment we checked for further prescribing of 
metformin after the second line drug was prescribed. By requiring that GPs 
prescribed metformin following the first stage of intensification, I reduce the number 
of people that have switched from metformin therapy to another monotherapy 
option, and therefore not treated according to NICE guidance for treatment 
intensification.  
In addition, as NICE only recommends treatment with oral antidiabetic drugs at the 
first stage of treatment intensification, I focussed on these individuals. Though 
Paper 2 provides counts of all drugs, including insulin and GLP-1s that are 
delivered subcutaneously, following metformin monotherapy. This helps to ensure 
that people were comparable in their disease severity and thus reduces time-related 
bias. This criterion also reduces misclassification of people with type 1 diabetes as 
being type 2. Approximately 13% of people aged 30-50 years, with a new diagnosis 
have type 1 diabetes, and require insulin.(116) Research suggest that GPs sometimes 
incorrectly treat these individuals for type 2 diabetes.(117, 118) These people 
incorrectly treated with metformin can become unwell and are then changed to 
insulin monotherapy.(118) Therefore, even though these individuals may have been 
included in the initiation cohort I have excluded them in the first stage intensification 
cohort.  
Excluded if initiated treatment for type 2 diabetes with combination therapy. 
I.e. If GPs prescribed metformin on the same day as another antidiabetic drug. 
As metformin monotherapy is the only recommended course of treatment at 
treatment initiation, people initiated with combination therapy were also excluded. 
These people were treated outside of the guidelines and may have had very high 
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blood glucose or other complicating factors. This would make them inappropriate 
comparisons for people starting treatment with metformin alone.  
Excluded if there was evidence of pregnancy in the 12 months before or after 
drug intensification: Amongst people receiving type 2 diabetes treatments, some 
may be pregnant or breastfeeding.(119) In this situation NICE recommends the use 
of insulin or metformin only, and recommend that GPs stop other antidiabetic 
drugs.(120) To account for this, I excluded individuals with a pregnancy code at the 
time, or within 12 months, of intensification. Of those with a record of pregnancy 
close to the point of treatment intensification, 96% had received intensification with 
insulin, which was expected given NICE prescribing recommendations.
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3.5.2 Interpretation of prescribing patterns 
Across the three studies, the first stage intensification cohort requires a specific 
temporal prescribing pattern to ensure that individuals are treated on a common 
pathway and that they are at the same stage of treatment.  
All individuals must have received a single metformin monotherapy prescription, 
followed by a prescription for another antidiabetic drug class, followed by, or 
coinciding with, a further metformin prescription, Figure 3.2.  
Figure 3.2 Typical pattern of prescriptions for inclusion in study. Each 
individual shows a period of no diabetes prescriptions, then metformin 
monotherapy indicating initiation of treatment, followed by prescriptions for 
further drugs alongside metformin. 
Typical timeline of prescriptions for inclusion
metformin monotherapy
new drug 
prescription
Where:
= Metformin= Index drug,
No diabetes treatment first stage of treatment intensification
74
  
 
There are three analyses presented in this thesis 
1. A study of prescribing trends for oral antidiabetic therapies in the UK (Paper 2, 
Chapter 4) 
2. A drug utilisation study showing patient level factors associated with prescribing 
(Paper 3, Chapter 5) 
3. Comparative cohort study of the effects of the drugs on eGFR, BMI, systolic 
blood pressure (BP) and HbA1c (Paper 4, Chapter 6) 
Each has differing aims, which led to minor differences when using therapy records 
to define inclusion. Table 3.3 details the differences in the aims of each paper, and 
interpretations of treatment patterns, further illustrated in Figure 3.3.  
 
75
  
  P
ap
er
 
A
im
 o
f s
tu
dy
  
C
on
si
de
ra
tio
ns
 fo
r 
tr
ea
tm
en
t d
ef
in
iti
on
 
T
re
at
m
en
t p
at
te
rn
  
2:
 S
tu
dy
 o
f t
re
nd
s 
in
 u
sa
ge
 
D
es
cr
ib
e 
pr
es
cr
ib
in
g 
nu
m
be
rs
 a
t 
in
iti
at
io
n 
of
 tr
ea
tm
en
t a
nd
 a
t 
tre
at
m
en
t i
nt
en
si
fic
at
io
n 
ov
er
 y
ea
rs
 
D
is
tin
gu
is
h 
tre
at
m
en
t i
nt
en
si
fic
at
io
n 
fr
om
 
tre
at
m
en
t s
w
itc
hi
ng
 to
 a
pp
ro
pr
ia
te
ly
 d
es
cr
ib
e 
pr
es
cr
ib
in
g 
pr
ac
tic
es
  
C
he
ck
 th
e 
60
-d
ay
 p
er
io
d,
 a
fte
r 
th
e 
fir
st
 st
ag
e 
of
 in
te
ns
ifi
ca
tio
n,
 
fo
r f
ur
th
er
 m
et
fo
rm
in
 
pr
es
cr
ip
tio
ns
 to
 e
ns
ur
e 
th
at
 th
ey
 
ar
e 
in
te
ns
ify
in
g 
ra
th
er
 th
an
 
sw
itc
hi
ng
 tr
ea
tm
en
t 
3:
 D
ru
g 
ut
ili
sa
tio
n 
U
nd
er
st
an
d 
w
ha
t p
at
ie
nt
 
ch
ar
ac
te
ris
tic
s, 
ap
pa
re
nt
 to
 th
e 
G
P 
at
 
th
e 
tim
e 
of
 p
re
sc
rib
in
g,
 in
flu
en
ce
 
tre
at
m
en
t c
ho
ic
e 
D
is
tin
gu
is
h 
tre
at
m
en
t i
nt
en
si
fic
at
io
n 
fr
om
 
tre
at
m
en
t s
w
itc
hi
ng
 to
 e
ns
ur
e 
co
m
pa
ris
on
s m
ad
e 
be
tw
ee
n 
tre
at
m
en
t g
ro
up
s a
re
 a
pp
ro
pr
ia
te
 
4:
 C
oh
or
t s
tu
dy
 
U
nd
er
st
an
d 
ho
w
 tr
ea
tm
en
t i
s 
as
so
ci
at
ed
 w
ith
 su
bs
eq
ue
nt
 o
ut
co
m
es
 
D
is
tin
gu
is
h 
tre
at
m
en
t s
w
itc
hi
ng
 fr
om
 
in
te
ns
ifi
ca
tio
n 
to
 e
ns
ur
e 
ap
pr
op
ria
te
 c
om
pa
ris
on
s 
A
N
D
 
En
su
re
 th
at
 in
cl
ud
ed
 in
di
vi
du
al
s h
av
e 
a 
su
ff
ic
ie
nt
 w
in
do
w
 o
f e
xp
os
ur
e 
to
 in
te
ns
ifi
ca
tio
n 
tre
at
m
en
t 
C
he
ck
 fo
r f
ur
th
er
 m
et
fo
rm
in
 
w
ith
in
 se
le
ct
ed
 p
er
io
d 
 
A
N
D
 
R
eq
ui
re
 a
 se
co
nd
 p
re
sc
rip
tio
n 
fo
r t
he
 in
de
x 
dr
ug
 w
ith
in
 a
 
re
as
on
ab
le
* 
tim
e 
pe
rio
d 
af
te
r 
in
iti
al
 d
ru
g 
pr
es
cr
ip
tio
n 
T
ab
le
 3
.3
 S
im
ila
ri
tie
s a
nd
 d
iff
er
en
ce
s i
n 
th
e 
as
se
ss
m
en
t o
f t
re
at
m
en
t p
at
te
rn
s f
or
 e
ac
h 
st
ud
y 
*D
ef
in
ed
 in
 S
ec
tio
n 
3.
5.
3.
 
76
  
 
 
Figure 3.3 Illustration of differences in definition of treatment 
according to prescribing patterns in therapy records.  
Timeline a shows simple inclusion criteria for Papers 2 and 3, and timeline 
b shows additional requirements implemented for Paper 4. 
3.5.3 Interpretation of prescribing for cohort study (Paper 4) 
Inclusion criteria are more complex for the cohort study presented in paper 
4, to ensure that individuals have received more than a single prescription 
for the intensification drug. I developed a method where each person has a 
personalised check period where I expected to find further prescriptions. 
If the duration of the initial prescription was short, I expected to find further 
drug prescriptions within a short period to interpret the prescriptions as a 
metformin monotherapy
new drug 
prescription
Where:
= Metformin= Index drug,
further metformin 
prescription indicates 
intensification 
prescription duration        + 60 days metformin monotherapy
further prescription for 
intensification drug 
within check period 
indicates sufficient 
exposure time  
more metformin between 
first and second drug 
prescription indicates 
intensification rather than 
switching
1st 2nd
a check period
new drug 
prescription
b
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course of treatment, and when the prescription duration was long, I allowed 
for longer check periods. The aim was to interpret prescribing patterns more 
accurately than using a generic 60-day check period for all patients. This 
was important as early analyses showed wide variation in the length of the 
initial drug prescription that was associated with the drug prescribed at 
intensification. I found that GPs prescribed initial insulin treatment for a 
mean of 6 days (SD: 5), compared to 40 days (SD: 17) for SUs. This GP 
decision may have been influenced by the complexity of drug delivery or 
likelihood of adverse reactions.  
To implement this dynamic inclusion criterion, with a different check period 
for each individual, the steps were: 
1. Identify the date of drug intensification (index prescription). 
2. Calculate the duration of the prescription. 
3. Determine the period from the first index prescription and the end of 
that prescription, add 60 days; this is the ‘check period’. 
4. Examine the ‘check period’ for further index drug prescriptions.  
5. Identify the date of the further index drug prescription (if any, within 
the check period). 
6. Check for metformin prescriptions between the first and second index 
drug.
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This method assigns people to three groups for each index drug:  
(i) Dual therapy users,  
(ii) Monotherapy users, and 
(iii) An excluded group.  
Follow-up starts when the individual received the first prescription for an 
intensification drug.  
3.5.4 Sensitivity analyses of cohort definition  
Using temporal prescribing patterns for cohort assignment has meant that 
‘information from the future’ informs treatment assignment. For Papers 3 and 4, 
follow-up starts (or individuals are described) at the first prescription for an 
intensification drug. This means that I use future data to inform treatment cohort. An 
individual might die or leave the practice during the check period, resulting in that 
person being incorrectly excluded as someone that switched treatment when the GP 
intention was actually intensification. As people need to survive long enough to 
receive further prescriptions the effect would be that the most unwell people are 
dropped and do not contribute data. So individuals that do make it into the study are 
‘immortal’ during the two prescriptions. 
To investigate the potential impact of this we included a sensitivity analysis in Paper 
3 (Patient level factors associated with prescribing). I included all people that 
were censored or died in the 60 days after prescription of the first line treatment 
intensification drug. The results and further details of this are presented in Section 
5.2. 
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For Paper 4 (Comparative study of drugs on continuous variables), I started 
follow-up on the date of the first intensification prescription. This approach was 
favoured over the alternative of starting follow-up only when the GP prescribed a 
second intensification drug, as I would miss early changes in clinical measures in the 
analysis of outcomes. For example, if HbA1c quickly reduced in the month after 
treatment intensification, starting follow-up only at the point that a second drug was 
prescribed would miss clinically important changes in HbA1c.  
3.5.5 Missing duration information 
 
The check period required a valid duration for each prescription. CPRD prescribing 
records contain treatment duration (number of days or calculated from numeric daily 
dose and quantity). Of over 15 million type 2 diabetes prescriptions for individuals 
who met the initial inclusion criteria, duration information was missing in 27% 
(4,145,944/ 15,582,351) of all prescriptions.  
To overcome this, I imputed missing durations using the most common prescription 
duration, using prescriptions that were similar based upon factors that might 
influence the length of a prescription. The factors expected to be associated with 
prescription length were chosen following discussions with a GP (Adrian Root, 
LSHTM):  
Prescription year 
Practice ID 
Drug class 
Whether it was the first prescription for the individual 
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We expected prescription year to influence duration, as GPs are likely to prescribe 
newer drug classes with more caution than those that they have many years of 
experience with. We also expected that drug class would be associated with 
prescription length, driven by typical pack sizes. The rationale for using the practice 
was that we expected GPs in a given practice to be influenced by the same 
prescribing rules, and therefore likely to use similar durations. If the drug was the 
first provided to a person, we predicted that GPs would initially prescribe for a short 
period in case of adverse reactions. We used the modal duration rather than the 
mean, as the mode would resemble the prescribing days generally used by 
prescribers, while the mean might be influenced by uncommon durations of 
treatment. Across all prescriptions, the most common duration used was 28 days 
(63%), followed by 56 days (25%) and 7 days (5%). 
First, if a prescription was missing a duration, but given on the same day as another 
diabetes drug with one, I gave both the same duration. I then matched prescriptions 
on the factors above, and found the modal duration for those with non-missing 
durations. I filled the missing durations with the calculated mode. Where a matched 
group was not available, I matched the prescription on a smaller number of factors, 
until the duration could be filled with the mode. Therefore, if a matched group was 
not available based on prescription year, practice ID, drug class, and first 
prescription (Y/N), and then I sought matches using a smaller selection of variables. 
Figure 3.5 illustrates the process. 
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Figure 3.5 Steps taken to estimate missing duration information. Using all 
records available in the therapy file for individuals identified as being in receipt 
of type 2 diabetes drug prescriptions. 
To assess the accuracy of the duration estimates, I compared the predicted durations 
to the known durations. Of 11,436,407 prescriptions with known durations, predicted 
durations underestimated duration by a mean of 0.42 days (SD: 14.61).  
2
Match therapy records according to: 
1. Practice
2. Drug class
3. Year prescribed 
4. If first prescription 
Calculate mode duration
Duration estimated for 2,438,363 
therapy records
Match therapy records according to: 
1. Drug class
2. Year prescribed 
3. If first prescription 
Calculate mode duration
Duration estimated for further 
471,923 therapy records
Match therapy records according to: 
1. Practice
2. Drug class
3. If first prescription 
Calculate mode duration
Duration estimated for 141 
therapy records
Match therapy records according to: 
1. Practice
2. Drug class
Calculate mode duration
Duration estimated for 14 therapy 
records
Match therapy records according to: 
1. Practice
Calculate mode duration
Duration estimated for 605 
therapy records
3
4
5
6
1
If two drugs are given on the same day to 
the same person, one with duration, one 
without, assign the non-missing duration 
to the missing
Duration estimated for 1,234,898 
therapy records
Total 15,582,351 prescriptions
11,436,407 prescriptions with duration available in record
4,145,944 prescriptions with missing duration information
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After we developed the method above, a study was published in 2016 that compared 
different methods for imputing missing duration: (i) replace all missing durations 
with 28 days, (ii) mode duration by drug strength and the number of tablets, and (iii) 
a machine-learning algorithm.(121) The paper compared these methods and 
concluded that both the mode duration and the machine-learning algorithm 
accurately estimated missing duration information. In addition, the subsequent effect 
estimates were comparable across all three approaches.(121)  
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4 Chapter 4: Changing use of antidiabetic drugs in the UK: 
Trends in prescribing 2000-2017 (Paper 2) 
 
 
Chapter summary 
• The treatment options for type 2 diabetes are changing. Between 2000 and 
2017, regulatory bodies removed the thiazolidinedione rosiglitazone from 
the market, and drug companies developed new drug classes, the DPP4is 
and the SGLT2is.  
• Given the changing nature of the prescribing options, the aim of this 
chapter is to describe the frequency of drug prescriptions in UK primary 
care, at treatment initiation and at the first stage of intensification, over 
time. 
• The study shows increasing use of metformin at initiation, from 41% 
(95% CI: 40, 43) in 2000 to 89% (95% CI: 88, 90) in 2017. 
• In 2017 the DPP4is were prescribed more than SUs for intensification of 
metformin monotherapy. DPP4is accounted for 42% (95% CI: 38, 47) of 
intensifications compared to the SUs at 30% (95% CI: 25, 35).  
• Recommendations differ according to kidney function, and prescribing 
also changed over time. This chapter shows that in 2016 the most 
common drugs used to initiate treatment among people with an eGFR less 
than 30 ml/min/1.73m2 were SUs (43%, 95% CI: 42, 44) and DPP4is 
(33%, 95% CI: 32, 34).  
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4.1  Introduction to Paper 2 
This chapter provides a descriptive analysis of changing prescribing practices in the 
UK in primary care for type 2 diabetes treatment, both at drug initiation and at the 
first stage of drug intensification.  
Understanding frequency of prescribing, adherence to recommendations, and 
potential channelling of drugs provides crucial information for interpretation of the 
subsequent outcomes study. Though prior research had described trends in 
prescribing, we found no published papers of prescribing trends for the most recent 
years, since SGLT2is entered the UK market at the end of 2012.(122)   
The first set of UK guidelines became available in the UK in 2002, and favoured 
metformin as first line treatment. Between 2007 and 2017, two new drug classes 
have become available in UK primary care. Whilst one drug from the TZD class, 
rosiglitazone, was suspended from the EU market. In response to this and new 
evidence of benefits, treatment guidelines changed. In 2015, NICE published the 
most recent recommendations, which added SGLT2is to the range of drugs for 
treatment intensification.  
The following paper is published in BMJ Open and describes prescribing patterns 
over time, both at treatment initiation, and for the first stage of treatment 
intensification. As part of this, I examined whether prescribing reflected changing 
guidelines. This included examining whether recommendations to avoid metformin 
for people with very poor renal function were followed. We also investigated the 
drug classes used at the first stage of treatment intensification and how prescribing 
patterns differ according to geographical area of the UK. Supplementary files 
associated with the paper are provided in Appendix 3. 
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Following Paper 2, in Section 4.4 I present a description of prescribing over time 
according to the specific drugs prescribed within each drug class. 
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ABSTRACT
Objectives Guidelines for the use of drugs for type 2 
diabetes mellitus (T2DM) have changed since 2000, and 
new classes of drug have been introduced. Our aim was 
to describe how drug choice at initiation and first stage of 
intensification have changed over this period, and to what 
extent prescribing was in accord with clinical guidelines, 
including adherence to recommendations regarding kidney 
function.
Design Repeated cross-sectional study.
Setting UK electronic primary care health records from 
the Clinical Practice Research Datalink.
Participants Adults initiating treatment with a drug for 
T2DM between January 2000 and July 2017.
Primary and secondary outcome measures The 
primary outcomes were the proportion of each class 
of T2DM drug prescribed for initiation and first-stage 
intensification in each year. We also examined drug 
prescribing by kidney function and country within the UK.
Results Of 280 241 people initiating treatment with 
T2DM drugs from 2000 to 2017, 73% (204 238/280 241) 
initiated metformin, 15% (42 288/280 241) a sulfonylurea, 
5% (12 956/280 241) with metformin and sulfonylurea 
dual therapy and 7% (20 759/280 241) started other 
options. Clinicians have increasingly prescribed metformin 
at initiation: by 2017 this was 89% (2475/2778) of drug 
initiations. Among people with an estimated glomerular 
filtration rate of ≤30 mL/min/1.73 m2, the most common 
drug at initiation was a sulfonylurea, 58% (659/1135). In 
2000, sulfonylureas were the predominant drug at the 
first stage of drug intensification (87%, 534/615) but by 
2017 this fell to 30% (355/1183) as the use of newer 
drug classes increased. In 2017, new prescriptions for 
dipeptidyl peptidase-4 inhibitors (DPP4i) and sodium/
glucose cotransporter-2 inhibitors (SGLT2i) accounted for 
42% (502/1183) and 22% (256/1183) of intensification 
drugs, respectively. Uptake of new classes differs by 
country with DPP4is and SGLT2is prescribed more in 
Northern Ireland and Wales than England or Scotland.
Conclusions Our findings show markedly changing 
prescribing patterns for T2DM between 2000 and 2017, 
largely consistent with clinical guidelines.
INTRODUCTION 
In the UK, the vast majority of prescribing for 
type 2 diabetes mellitus (T2DM) is undertaken 
within primary care. The aim of treatment is 
to reduce hyperglycaemia and morbidities 
associated with T2DM, such as cardiovascular 
disease and microvascular complications 
such as chronic kidney disease (CKD) or 
retinopathy.1 2 National Institute for Health 
and Care Excellence (NICE) and Scottish 
Intercollegiate Guidelines Network (SIGN) 
provide clinical guidance for the manage-
ment of T2DM. After lifestyle changes, both 
NICE (NG28) and SIGN (154) recommend 
a series of intensification steps, adding drugs 
to a baseline of metformin monotherapy and 
only stopping metformin if there are clinical 
reasons to do so.1 2 Estimates suggest that 
30%–50% of people who started treatment 
on metformin monotherapy in the USA and 
Europe went on to further drug intensifica-
tion.3 4 
There are an increasing number of poten-
tial drug classes for the first stage of intensi-
fication after metformin monotherapy. Two 
new drug classes have recently been intro-
duced: dipeptidyl peptidase-4 inhibitors 
(DPP4is; first licensed in the UK in 2007) and 
sodium-glucose cotransporter-2 inhibitors 
(SGLT2is first licensed in the UK in 2012). 
Guidelines have been updated to reflect these 
new options (figure 1).1 2 5 6 Sulfonylureas 
(SU), SGLT2is, DPP4is and thiazolidinedi-
ones (TZD) are the current drug options 
for the first stage of drug intensification and 
are associated with different risk profiles and 
possibly specific benefits.7 8 In light of the 
changing treatment guidelines, we aimed 
Strengths and limitations of this study
 ► This study uses contemporary UK primary care 
data to examine how prescribing at the first stage 
of treatment intensification for type 2 diabetes after 
metformin monotherapy has changed from 2000 to 
2017.
 ► Using long-term prescribing data has enabled us to 
compare people at the same stage of treatment.
 ► We may have included some patients with type 1 
diabetes, and may have wrongly classified some 
people who were changing rather than intensifying 
treatment.
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to describe patterns of prescribing using UK primary 
care data between 2000 and 2017, examining trends in 
prescribing at treatment initiation and at the point of 
first drug intensification, and to investigate the degree of 
concordance with guideline recommendations, in partic-
ular in relation to kidney function. In secondary analyses, 
we have explored whether there is variation in local prac-
tice by describing prescribing according to geographic 
location and clusters of general practices.
METHODS
Study setting
This observational study used data from the UK Clinical 
Practice Research Datalink (CPRD), a source of pseud-
onymised primary care health data which is regularly 
audited to ensure quality. CPRD data include demo-
graphic and lifestyle factors, records of prescriptions, 
clinical and test records and referrals to secondary care. 
The data come from primary care providers in England, 
Wales, Scotland and Northern Ireland and have been 
used extensively for clinical and pharmacoepidemiology 
studies, with previous validation studies suggesting that 
diagnoses coded in CPRD are highly reproducible from 
other data sources.9 10
Participants
We identified all individuals aged ≥18 years who started 
drug treatment for T2DM between 2000 and 2017. 
Although the onset of T2DM is typically over the age of 
40 years, the age of diagnosis is decreasing over time, and 
earlier onset (and longer duration) is associated with 
poorer patient outcomes. We therefore only excluded the 
very young who are substantially more likely to have type 
1 diabetes mellitus (T1DM).11 We specified that patients 
should be registered at a general practitioner (GP) 
practice recording research quality data for a period of 
12 months before starting drug treatment for diabetes to 
restrict the cohort to only new users of T2DM drugs.
We excluded women with a record of pregnancy (within 
12 months either side of baseline prescription) as UK 
prescribing guidelines recommend different drug regi-
mens for pregnant and breastfeeding women compared 
with other patients with T2DM.12 13
Codes to identify T2DM drugs were created based on 
British National Formulary T2DM chapters and drug 
codes are provided in the online supplementary file and 
on LSHTM compass, http:// datacompass. lshtm. ac. uk/ 
649/. We used the CPRD data released in July 2017.
Definition of exposure, outcome and covariates
Drug initiation cohort
We described prescribing for two cohorts of patients. The 
first included individuals who received any prescriptions 
for their first antidiabetic drug. We identified the first 
T2DM drug prescribed in their patient record. Where 
more than one drug was prescribed on the day of initi-
ation, the treatment was recorded as a combination 
therapy of the drugs prescribed.
First stage of drug intensification cohort
Metformin is the only drug recommended by NICE and 
SIGN for drug initiation, with further drugs subsequently 
added if greater glycaemic control is required at the first 
stage of intensification. Therefore, we went on to describe 
prescribing among patients who intensify treatment after 
a period of metformin monotherapy. We described the 
first new drug prescribed after metformin monotherapy 
without any time limit. We sought to do this and exclude 
those who switched treatment by requiring that included 
individuals had a further prescription for metformin 
within 60 days of the prescription for a new drug class. 
Figure 1 Changing National Institute for Health and Care Excellence (NICE) recommendations for type 2 diabetes mellitus 
(T2DM) drug treatment. CG, clinical guideline; DPP4i, dipeptidyl peptidase-4 inhibitor; GLP1, glucagon-like peptide-1; 
Ins, insulin; MTF, metformin; NG, NICE guideline; Pio, pioglitazone; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SU, 
sulfonylurea; TZD, thiazolidinedione.1 2 5 6 14 21 33 34
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We did not describe further prescribing for patients who 
switch treatment from metformin as our focus is on treat-
ment intensification rather than switching.
Covariates
For both cohorts we investigated how prescribing has 
changed over time by describing patterns for each 
calendar year, with year based on the day that the initi-
ation or first intensification drug was first recorded 
in the patient record. Metformin is contraindicated 
for those with an increased risk of lactic acidosis such 
as those with reduced kidney function. Therefore, 
we also described treatment patterns for people with 
reduced renal function: (1) in individuals whose most 
recent estimated glomerular filtration rate (eGFR) 
was ≤30 mL/min/1.73 m2 prior to drug prescription to 
reflect current treatment guidance, and (2) individuals 
with a serum creatinine higher than 130 µmol/L prior 
to drug prescription, to reflect guidance from 2002 that 
used this higher serum creatinine target.14 15 eGFR was 
calculated using the last creatinine result, recorded 
not more than 540 days (18 months) prior to the date 
of treatment prescription, since we expected creatinine 
to be measured annually as recommended during the 
study period by Quality Outcomes Framework16 and the 
National Diabetes Audit.17 We calculated eGFR using the 
CKD-EPI equation18 excluding the ethnicity factor as this 
is not entered in CPRD for a substantial proportion of 
individuals.19
To assess country-level differences, we stratified 
prescribing according to the location of each general 
practice: England, Northern Ireland, Scotland and Wales. 
We also described first stage of intensification prescribing 
according to Clinical Commissioning Group (CCG) 
groupings. CCGs are groups of GP practices that are 
responsible for commissioning local health services for 
patients, and may have shared management protocols or 
prescribing guidance. Here, GP practices are identified 
to be in the same CCG but there is no other identifiable 
information on the location of the CCG.
Statistical analysis
To examine how drug prescribing changed over time we 
first described patterns using counts of drug initiations 
between 2000 and 2017 with total prescribing for each 
year as the denominator. Then, we repeated this for the 
first stage of intensification prescribing patterns. We 
described initiation prescribing in the subgroup of indi-
viduals with reduced renal function, and we provided 
prescribing patterns for the first stage of intensification 
according to country and CCG. We calculated 95% CIs 
for the proportions using the standard normal distribu-
tion approximation. For people intensifying treatment 
in 2016, we calculated the mean time between starting 
metformin and the second treatment, we restricted to 
2016 as this was the final year with complete data, and 
restricting to a single year reduced differential lead time 
due to non-availability of newer drugs in previous years.
Data extraction and processing of CPRD data was 
completed in Stata MP (V.14). All data analyses were 
completed using R and R packages for reproducible 
research. We reported our findings according to the 
RECORD reporting guidelines.20
Ethical and scientific approval
The research protocol was approved by the Independent 
Scientific Advisory Committee (ISAC) for MHRA Data-
base Research (protocol number 16_267). The protocol 
was made available to reviewers for peer review. Ethical 
approval for observational research using CPRD GOLD 
with approval from ISAC has been granted by a Health 
Research Authority Research Ethics Committee (East 
Midlands-Derby, REC reference number 05/MRE04/87). 
This study was also approved by the London School of 
Hygiene and Tropical Medicine Ethics Committee (refer-
ence 11923).
Patient and public involvement statement
Patients were not involved in the design or conduct of 
the study. We plan to disseminate the results through 
peer review publication.
RESULTS
We identified 280 241 people initiating treatment with 
an antidiabetic drug between the start of 2000 and July 
2017. Inclusions and exclusions are shown in figure 2. 
Of those initiating treatment, 204 238/280 241 (73%) 
initiated with metformin monotherapy, 42 288/280 241 
(15%) with SU monotherapy and 12 956/280 241 (5%) 
with metformin and SU dual therapy. Insulin mono-
therapy represents 6771/280 241 (2%) of initiations for 
Figure 2 Flow diagram showing the creation of the cohorts 
and reasons for exclusion. CPRD, Clinical Practice Research 
Datalink; T2DM, type 2 diabetes mellitus. 
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the period and 13 988/280 241 (5%) started another 
drug option. Of this 5%, the most common drugs were 
insulin in combination with metformin (2850/13 988), 
TZD in combination with metformin (1405/13 988) or 
TZD alone (1393/13 988). A full list of combinations is 
provided in online supplementary table 1.
Temporal patterns of prescribing: treatment initiation
Patterns of treatment initiation drug prescribing changed 
over time (figure 3 and online supplementary table 2). In 
2000, GPs prescribed SU monotherapy more often than 
metformin monotherapy but have increasingly prescribed 
metformin which now accounts for 89% (95% CI 88% to 
90%) of drug initiations for T2DM. A small number of 
people in our drug initiation cohort start treatment on 
insulin therapy and this declines over time. Prescribing of 
insulin fell from 4% in 2000 to 0.58% in 2017.
Prescribing among people with reduced renal function
We found 145 822/280 241 (52%) people with eGFR 
measured in the 540 days prior to initiating drug therapy. 
Of these 1135/145 822 (1%) had an eGFR ≤30 mL/
min/1.73 m2 and 5395/145 822 (4%) had a serum creati-
nine ≥130 µmol/L. Among people with an eGFR ≤30 mL/
min/1.73 m2 the most common drug for initiating treat-
ment was an SU at 58% (659/1135) of total prescribing 
from 2000 to 2016. Prescribing of metformin as the first 
drug in this group fell steadily from 29% (95% CI 28% to 
30%) in 2000 to 9.5% (95% CI 9% to 10%) in 2016. Since 
being licensed in 2007, prescriptions for DPP4is as initial 
therapy for this subgroup have steadily increased to 33% 
(95% CI 32% to 34%) in 2016. Full details of prescribing 
are supplied in online supplementary table 3. A compar-
ison of initiation drug prescribing between the current 
and earlier guidance on renal function is presented 
in online supplementary figure 1.
Temporal patterns of prescribing: first stage of drug 
intensification
Of the individuals who started metformin monotherapy, 
we identified 105 348/277 232 (38%) people who started 
on metformin and then received a second class of T2DM 
drug. Of these, 79 941/105 348 (76%) were prescribed 
metformin in the 60 days after the new drug prescription, 
indicating treatment intensification rather than switching. 
Among these 79 941 people, the drugs prescribed at the 
first stage of drug intensification have changed over the 
period of the study (figure 4).
In 2000, SU prescribing dominated drug choices at the 
first stage of intensification, accounting for 87% (95% CI 
84% to 90%) of new drug intensifications. By 2017, this fell 
to 30% (95% CI 25% to 35%). Between 2000 and 2006, 
there was a rise in the use of TZD class prescribing, but after 
Figure 3 Drug prescribing at T2DM drug initiation 2000–2017.14 21 22 CG, clinical guideline; CKD, chronic kidney disease; 
eGFR, estimated glomerular filtration rate; QOF, Quality Outcomes Framework; SU, sulfonylurea; T2DM, type 2 diabetes 
mellitus.
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2006, TZD use fell. In 2017, TZD prescribing accounted for 
only 2% (95% CI 0% to 8%) of prescribing, compared with 
a peak of 45% (95% CI 43% to 47%) in 2006. Prescribing 
of two new drug classes, DPP4is and SGLT2is increased 
since their introduction in 2007 and 2012, respectively. 
In 2017, new prescriptions for DPP4is accounted for 42% 
(95% CI 38% to 47%) of first stage of intensification drug 
choices. SGLT2i prescribing is rising, accounting for 22% 
(95% CI 17% to 27%) of new drug intensifications in 2017 
(online supplementary table 4). Other than insulin (about 
21 months) the other drugs were all started after a similar 
time period following metformin monotherapy (around 
3–3.7 years) (online supplementary table 5).
REGIONAL DIFFERENCES
Prescribing practice differs between countries within the UK 
(figure 5, online supplementary table 6). For 2013–2017, 
GPs in Wales and Northern Ireland prescribed DPP4is in 
45% (95% CI 42% to 48%) and 46% (95% CI 41% to 51%) 
of intensifications whereas in Scotland and England GPs 
prescribed DPP4is in just 30% (95% CI 26% to 34%) and 
Figure 4 First-stage intensification prescribing as a percentage of total prescribing 2000–2017.31 35 36 DPP4i, dipeptidyl 
peptidase-4 inhibitor; EU, European Union; GLP1, glucagon-like peptide-1; MI, myocardial infarction; SGLT2i, sodium/glucose 
cotransporter-2 inhibitor; SU, sulfonylurea; TZD, thiazolidinediones.
Figure 5 Proportions of patients at first-stage intensification prescribed a DPP4i, SU, SGLT2i and other drugs, by country, 
2013–2017. DPP4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium/glucose cotransporter-2 inhibitor; SU, sulfonylurea.
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36% (95% CI 34% to 38%) of patients intensifying treat-
ment. GPs in Northern Ireland prescribed SGLT2is in 18% 
(95% CI 11% to 24%) of intensifications compared with 
13% (95% CI 9% to 16%) in Wales, 12% (95% CI 8% to 
16%) in Scotland and 9% (95% CI 7% to 11%) in England. 
We also found marked heterogeneity of prescribing practice 
across CCG groupings (online supplementary figure 2).
DISCUSSION
Our results show that prescribing of metformin has increased 
and prescribing of SUs has fallen at drug initiation for T2DM 
between 2000 and 2017, and shows increasing accordance 
with recommendations from national and international 
guidelines. In patients with an eGFR ≤30 mL/min/1.73 m2 
the most commonly prescribed initiation drug class was 
SUs until 2015, but since then DPP4is are more commonly 
prescribed. Of note, we found that approximately 1 in 10 
people are prescribed metformin despite an eGFR ≤30 mL/
min/1.73 m2. Prescribing patterns at the first stage of drug 
therapy intensification have also changed, with prescribing 
of SUs and TZDs falling, while that of newer drug classes 
has risen. By 2017, the most commonly prescribed addi-
tion to metformin was a DPP4i. Prescribing practice differs 
by country within the UK. We identified large differences 
in prescribing practice between countries in the UK, with 
Northern Ireland and Wales prescribing both DPP4is and 
SGLT2is more commonly than in England or Scotland. We 
also show large variations in prescribing practice between 
CCGs.
Our large study uses data from a source of population 
representative primary care records from across the UK 
to provide great insight into real-world clinical practice 
from 2000 to 2017. We have attempted to improve direct 
comparability by developing cohorts that reflect distinct 
stages of the management of patients with T2DM, rather 
than examining total prescribing. We have been able to 
characterise renal function prior to drug initiation for 
the majority of patients to explore changing concordance 
with prescribing recommendations.
However, there are limitations to this analysis. We do 
not know if the prescribing was initiated in primary or 
secondary care. In the absence of wider demographic 
features about the CCGs such as age, socioeconomic status 
or ethnicity distributions we cannot explore factors that 
might drive variation in prescribing. For some patients, 
more recent eGFR measures may have been available 
to the prescribing GP in letters or discharge summaries 
from secondary care, while the result available to us from 
serum creatinine tests could have been measured during 
a previous acute illness. This misclassification may in part 
explain why, even in recent years, nearly 10% of patients 
appear to initiate treatment with metformin despite levels 
of renal function that should have contraindicated its use. 
We have not analysed drug intensification patterns for 
patients who did not initiate treatment with a period of 
metformin monotherapy although this is a small minority 
over recent years. We may have included a proportion of 
patients with T1DM, both those who commenced treat-
ment with insulin, and those who started on drug therapy 
but were later reclassified. However, people commencing 
insulin accounted for only 2% of drug initiations over the 
whole period so this is unlikely to have a substantial impact 
on our results. Finally, since our definition of intensifica-
tion was based on receiving a further metformin prescrip-
tion, we may have misclassified some patients as switching 
from metformin monotherapy rather than intensifying 
treatment. For example, we will have excluded some 
patients who died after intensifying treatment before 
receiving a further metformin prescription.
The prescribing trends we identified are in keeping 
with a study completed using a different source of UK 
primary care data that examined prescribing up to 2013.23 
International comparisons also show similar trends with 
falls in SU prescriptions and increases in metformin use, 
accounting for 68% of treatment initiations in Italy in 2012, 
77% in the USA in 2016, while our estimate was 84%.3 24
Our work has also highlighted an increase in prescribing 
of DPP4is for treatment intensification, similar to find-
ings in the UK and the USA.23 25 The additional period 
to 2017 covered by our analysis shows that these trends 
continued, with additional growth in SGLT2i prescribing.
Our results are also consistent with data from OpenPre-
scribing, a website that allows access to absolute numbers 
of near real-time GP prescriptions.26 OpenPrescribing 
shows increased prescribing of DPP4is and SGLT2is but 
does not distinguish prescribing at different stages of 
treatment as we present here.
In relation to prescribing for patients with reduced renal 
function, our work mirrors prescribing trends from a recent 
US study that described prescribing over time in people 
with CKD, in particular the increasing use of DPP4is.27 
Our finding that metformin continues to be prescribed 
for patients with T2DM and severely impaired renal func-
tion echoes work from France which found that for a 
cohort of people with reduced renal function prescribed 
metformin, the prescription was against contraindica-
tions in 49% of cases, and Italy where 15% of participants 
with an eGFR <30 mL/min/1.73 m2 were still prescribed 
metformin.28 29
Encouragingly, we have found that prescribing at initia-
tion of drug treatment for T2DM largely follows national 
guidelines and concordance has improved over time. We 
have highlighted that uptake of new drugs at the first 
stage of intensification has increased rapidly over recent 
years with marked regional variation suggesting factors 
outside of clinical indication may be important; guidance 
from local bodies to CCGs, drug company marketing, 
local secondary care practice and patient demand may all 
influence prescribing.30 Growing evidence that SGLT2is 
may offer long-term benefits for prevention of cardiovas-
cular disease, results not previously seen for other treat-
ments, may also have influenced prescribing, although 
guidelines have not yet been altered.20 31 Increasing use 
of patented drugs will drive up prescribing costs, an 
issue of concern as drugs for diabetes now account for 
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approximately 10% of the total cost of National Health 
Service primary care prescribing spending.32
In conclusion, our results showed marked changes in 
prescribing for T2DM since 2000 with large increases in 
prescribing of the new agents. There is substantial variation 
between regions and CCGs, despite no national guidance 
towards prescribing of specific agents. The factors under-
lying choice of drug options for the first stage of intensi-
fication are unexplained, and whether drug choice affects 
future clinical outcomes needs to be determined.
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4.4 Description of specific drugs within each class, and changes over 
time 
4.4.1 Drug agent prescribing according to drug class 
Paper 2 provided a summary of the changing prescribing practice according to 
diabetes drug class. In this thesis, I have grouped products under drug classes 
because NICE guidance only references classes and does not specify which drug to 
use. However, many clinical trials investigated a single agent. This summary 
describes drug prescribing according to the agent within each class. 
Table 4.1 describes the frequency of drug agent prescribing according to product 
class. This is restricted to individuals eligible for inclusion in the study presented in 
Chapter 6, at the first stage of treatment intensification. 
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Table 4.1 Drug agent prescribed at first stage intensification according to drug 
class, for individuals eligible for inclusion in Paper 4, presented in Chapter 6 
 
 
Drug Frequency Percentage 
Sulfonylurea 5,010 100.00 
gliclazide 4,626 92.34 
glimepiride 320 6.39 
glipizide 54 1.08 
glibenclamide 9 0.18 
tolbutamide <5 <0.1% 
DPP4i 4,434 100.00 
sitagliptin 2,348 52.95 
linagliptin 941 21.22 
saxagliptin 573 12.92 
alogliptin 541 12.20 
vildagliptin 31 0.70 
SGLT2i 1,187 100.00 
dapagliflozin 841 70.85 
empagliflozin 202 17.02 
canagliflozin 144 12.13 
Total 10,631 
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Of the DPP4i drug class, GPs prescribed sitagliptin to 53% of people in receipt of 
DPP4is, and 21% received linagliptin. For those prescribed SGLT2is, dapagliflozin 
was the drug most commonly prescribed (71%), followed by empagliflozin (17%) 
and canagliflozin was prescribed for only 12% of individuals. For the SU group, 
gliclazide was prescribed for 92% of the SU group and glimepiride prescribed in 6% 
of cases.  
The EMPA-REG (123) study and the CANVAS (55) study are two highly cited 
studies that show positive effects of empagliflozin and canagliflozin on blood 
pressure, eGFR, BMI and HbA1c compared to placebo. However, over the period 
studied, representation of these two drugs is low in clinical practice. Dapagliflozin 
was the first SGLT2i introduced to the UK market at the end of 2012, which may 
have driven this.(122)  
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4.4.2 Changes in drug prescribing over time according to drug agent 
Figure 4.1 shows the products prescribed for SU, DPP4i and SGLT2i drug classes, 
from 2000 to 2017. Since 2015, empagliflozin has been prescribed with increasing 
frequency compared to the older dapagliflozin. This increasing share of SGLT2i 
prescribing may be influenced by the EMPA-REG results published in 2015. In 
addition to clinical trials, factors such as local guidance, familiarity with drugs and 
communication with pharmaceutical companies may influence the uptake of new 
drug agents.
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Over time, prescribing within the SU class has altered. Gliclazide is a second 
generation SU, associated with fewer hypoglycaemic events than glimepiride.(124) 
Small increases in the prescribing of gliclazide compared to glimepiride over recent 
years may have been driven by improved understanding of higher risks of 
hypoglycaemia, and the potential dangers of these events for the elderly, frail or 
those with reduced renal function.  
In the DPP4i group, new drug agents account for higher proportions of DPP4i 
prescribing. GP prescribing of vildagliptin peaked in 2009 and by 2017, GPs appear 
to prescribe it only rarely. To validate these findings, I checked raw prescribing 
numbers on the OpenPrescribing website. OpenPrescribing showed low relative 
prescribing of vildagliptin in 2017 compared to sitagliptin (119,348 items for 
vildagliptin vs. 2,686,119 items for sitagliptin).(125) Low prescribing of vildagliptin 
may be driven by additional requirements to test liver function at three monthly 
periods during the first year of use, as hepatic dysfunction is a potential side 
effect.(126) These data suggest changing perceptions of drugs, both at the class 
level, and within drug classes. The full drug code list used in this follow-up work is 
presented in Appendix 4. 
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5 Chapter 5: Factors associated with choice of intensification 
treatment for type 2 diabetes mellitus after metformin 
monotherapy: a cohort study in UK primary care (Paper 3) 
 
Chapter summary 
• In the previous chapters we have seen that GPs are increasingly 
prescribing new drugs, the DPP4is and the SGLT2is, to intensify 
treatment after metformin monotherapy.  
• National Guidance does not direct GPs as to which of the drug options to 
choose, despite each drug class exerting glucose lowering effects in 
different ways, and with different risk profiles and restrictions on their 
use. It is not known what factors influence GPs choosing drug classes. 
• Therefore, in this chapter I discuss Paper 3 that investigates associations 
between patient-level factors and prescribing practice of GPs at the first 
stage of treatment intensification.  
• The study shows that both clinical and non-clinical patient characteristics 
independently predict prescribing of newer drug options. Obese people 
were more likely to be prescribed SGLT2is (OR: 5.6, 95% CI: 3.9, 8.1) 
and DPP4is (OR: 1.7, 95% CI: 1.5, 2.0) compared to SUs.  
• Ethnicity and lower socioeconomic status were associated with reduced 
use of newer drug options. People of South Asian ethnicity had smaller 
odds of receiving SGLT2is compared to SUs, with an odds ratio of 0.6 
(95% CI: 0.4, 0.9). 
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5.1 Introduction to Paper 3 (Patient level factors associated with 
prescribing) 
Given the findings from Paper 2 (Study of prescribing trends) that drug choice at 
initiation is associated with renal function, and that prescribing practice differs 
according to region, the aim in Paper 3 (Patient level factors associated with 
prescribing) was a more thorough investigation of which patient factors were 
associated with drug treatment decisions. Systematic differences in the way GPs 
prescribe drugs may introduce bias to outcome studies. If one drug class is used only 
in people with very poor HbA1c, confounding by indication will mean that effect 
estimates comparing choice of treatment on HbA1c as an outcome may be non-
causally associated with the treatment choice. A full understanding of the differences 
between individuals prescribed each treatment option is therefore imperative prior to 
outcomes research.  
The following paper was published in Clinical Epidemiology. It describes clinical, 
demographic and social patient characteristics associated with each of the commonly 
prescribed intensification options used in the UK: SUs, DPP4is and SGLT2is.  
There was substantial missingness for some variables of interest. Rather than 
restricting the analysis to only individuals without missing data (a complete-case 
analysis) I applied multiple imputation in the primary analysis. Complete case 
analysis will give unbiased estimates if the missing data is missing completely at 
random (MCAR), or missingness is not associated with the outcomes. This may be a 
reasonable assumption to make; the outcome of interest in Paper 3 is prescribing 
choice. However, even under these circumstances, complete-case analysis will result 
in less efficient analyses as data from a large proportion of eligible individuals is 
discarded.(127)  
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Multiple imputation, assumes that missing data is missing is random (MAR). Under 
the assumption of MAR, the probability that the data is missing, depends on 
observed data.(128, 129)  
Then, to estimate the odds of receiving each drug of interest I applied multinomial 
logistic regression with drug prescribing as the outcome and a range of patient 
characteristics as covariates. Multinomial regression is an extension of logistic 
regression that allows the outcome variable to have more than two levels, in this case 
a nominal three level outcome (SU, DPP4i or SGLT2i).(130) The SU group was the 
referent category as it was the largest group. 
We found associations between drug options and both clinical and non-clinical 
characteristics. Some associations were unexpected, and not explained by clinical 
need. These findings suggest disparity in treatment, and channelling of new drugs to 
more privileged sections of society. Channelling is a type of selection bias that 
influences prescribing of new drugs to specific subgroups of the populations for 
reasons such as perceived improved safety. Channelling can result in new drug 
options being reserved for the highest (or lowest) risk groups. Channelling can 
therefore create bias by creating an association between baseline patient 
characteristics and future outcomes.(131) 
It is possible that other factors may drive this disparity such as patient preference, 
practice-level differences, and local guidance but we could not explore these 
possibilities with the data available. This study provided crucial information for the 
design of the cohort study presented in Chapter 6. The study highlighted evidence 
of differential prescribing, and identified baseline factors that were important to 
account for when addressing confounding using propensity scores. 
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The supplementary files associated with the paper are provided in Appendix 5. 
These include a description of the drugs prescribed at the first stage of intensification 
other than SUs, DPP4i and SGLT2is and the results of sensitivity analyses to address 
the assumptions made in the primary analyses. Following the paper, in Section 5.4, I 
have provided further details of one of the sensitivity analyses. It shows the impact 
of the inclusion criteria that ensured people were intensifying treatment rather than 
switching treatment. As discussed earlier, this criterion relied upon information 
‘from the future’ being used to inform inclusion and raises the possibility of 
immortal time bias.
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Purpose: To understand the patient characteristics associated with treatment choice at the first 
treatment intensification for type 2 diabetes.
Patients and methods: This is a noninterventional study, using UK electronic primary care 
records from the Clinical Practice Research Datalink. We included adults treated with met-
formin monotherapy between January 2000 and July 2017. The outcome of interest was the 
drug prescribed at first intensification between 2014 and 2017. We used multinomial logistic 
regression to calculate the ORs for associations between the drugs and patient characteristics.
Results: In total, 14,146 people started treatment with an intensification drug. Younger people 
were substantially more likely to be prescribed sodium-glucose co-transporter-2 inhibitors 
(SGLT2is), than sulfonylureas (SUs): OR for SGLT2i prescription for those aged <30 years was 
2.47 (95% CI 1.39–4.39) compared with those aged 60–70 years. Both overweight and obesity 
were associated with greater odds of being prescribed dipeptidyl peptidase-4 inhibitor (DPP4i) 
or SGLT2i. People of non-white ethnicity were less likely to be prescribed SGLT2i or DPP4i: 
compared with white patients, the OR of being prescribed SGLT2i among South Asians is 0.60 
(95% CI 0.42–0.85), and for black people, the OR is 0.54 (95% CI 0.30–0.97). Lower socioeco-
nomic status was also independently associated with reduced odds of being prescribed SGLT2is.
Conclusion: Both clinical and demographic factors are associated with prescribing at the first 
stage of treatment intensification, with older and non-white people less likely to receive new 
antidiabetic treatments. Our results suggest that the selection of treatment options used at the 
first stage of treatment intensification for type 2 diabetes is not driven by clinical need alone.
Keywords: drug prescriptions, diabetes mellitus, type 2, hypoglycemic agents, primary health 
care, practice patterns, physicians
Introduction
Current UK and international guidelines endorse metformin as the first-line treatment 
for most patients with type 2 diabetes.1–4 In the UK, if further treatment is needed, 
National Institute for Health and Care Excellence (NICE) guidance suggests the addi-
tion of sulfonylureas (SUs), sodium-glucose co-transporter-2 inhibitors (SGLT2is), 
dipeptidyl peptidase-4 inhibitors (DPP4is), and thiazolidinediones (TZD) that have 
different risk profiles and restrictions.1 The most commonly prescribed drug options 
are SUs, DPP4is, and SGLT2is.5 Two of these drug classes have been available only 
recently, DPP4is since 2007 and SGLT2is since 2013.1–4 Another drug class recom-
mended by NICE at this stage of treatment are the TZDs; however, prescribing of TZDs 
has fallen substantially over recent years and is now rarely used at the first stage of 
treatment intensification in the UK.5,6
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At present, guidelines do not present evidence of superior-
ity for any of these first-stage intensification drug choices. The 
factors influencing prescribing are not known but may include 
reported adverse events, growing familiarity with new agents, 
evidence from clinical trials, and influence of pharmaceutical 
companies.6,7 Therefore, our aim was to examine the patient 
characteristics associated with the class of drug prescribed 
within primary care in the United Kingdom National Health 
Service (NHS). To ensure comparability and to reflect recent 
changes in practice, we focused only on commonly used drug 
classes at the first stage of drug intensification for type 2 dia-
betes: SUs, DPP4is, and SGLT2is, between 2014 and 2017.
Materials and methods
Study design and setting
This noninterventional study used data from the UK Clinical 
Research Datalink (CPRD), a database of pseudonymized 
primary care health data broadly representative of the UK 
population. CPRD data include demographic and lifestyle 
factors, prescribing records, clinical diagnoses test records, 
and referrals to secondary care. Data are regularly audited to 
ensure quality.8 In the UK, most people with type 2 diabetes 
are managed in primary care with specialist input only for 
those with complications or very poor glycemic control.1
Participants, exposures, and outcomes
We identified all individuals aged 18 years and over. Although 
type 2 diabetes is typically associated with people over the age 
of 40 years, we chose to include younger patients since the 
age of diagnosis is decreasing over time, and earlier onset is 
associated with poorer patient outcomes.9,10 We included only 
patients registered at the practice for 12 months without treat-
ment for type 2 diabetes in order to restrict the cohort to new 
users of type 2 diabetes drugs, and to limit inclusion of patients 
with type 1 diabetes mellitus. We excluded women with type 
2 diabetes and a history of pregnancy within 12 months of 
potential inclusion as prescribing guidelines recommend dif-
ferent drug regimens for pregnant and breastfeeding women.11
To be eligible, individuals must have initiated treatment 
with metformin monotherapy between 2000 and 2017. Met-
formin is the only drug recommended by NICE as a first-line 
drug treatment for type 2 diabetes unless contraindicated, 
usually for patients with estimated glomerular filtration rate 
(eGFR) below 30 mL/min/1.73 m2.1,12
Outcomes
We investigated the drug prescribed at the first stage of 
intensification as our study outcome and focused on three 
classes of drug recommended by clinical guidelines: SU, 
DPP4i, and SGLT2i. TZDs are now infrequently prescribed 
for new users, so we did not investigate this class of drug as 
an outcome.5 As SGLT2is only became available recently, we 
limited the period to individuals who commenced treatment 
after 2013.5 Insulin is not recommended at the first stage of 
drug intensification so a prescription for insulin may suggest 
a change of diagnosis to type 1 diabetes mellitus, or very 
poor glycemic control. We therefore did not include it as an 
outcome but provide a descriptive analysis of individuals 
prescribed insulin in the Supplementary files. Intensification 
of treatment was defined as prescriptions for type 2 diabe-
tes drugs other than metformin after the day of metformin 
initiation. To minimize misclassification from individuals 
switching drug regimens rather than intensifying treatment, 
we required that a further prescription for metformin was 
issued within 60 days of the first-stage intensification drug 
prescription (Figure 1).
Descriptive variables and covariates
We defined characteristics that we considered may influence 
prescribing choice based on clinical knowledge of type 2 
diabetes, current treatment guidelines, and recommendations 
for individual drugs. We defined these covariates as those 
Metformin monotherapy
Example therapy record showing temporal changes in prescribing indicating intensification
First stage of intensification
Further metformin indicates
intensification rather than switching
Prescription issued for new
antidiabetic drug
Prescribing data:
Interpretation:
Where:
= Index drug: second type 2 diabetes drug, = Metformin
Figure 1 'LDJUDPRILGHQWLÀFDWLRQRILQGLYLGXDOVDWWKHÀUVWVWDJHRILQWHQVLÀFDWLRQRIWUHDWPHQWIRUW\SHGLDEHWHVIURPSUHVFULELQJUHFRUGV
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recorded prior to the day the first-stage intensification drug 
was prescribed. For the regression analysis, we considered 
age, sex, body mass index (BMI), ethnicity,13 socioeco-
nomic status, smoking, hemoglobin A1c (HbA1c), eGFR,14 
albumin:creatinine ratio (ACR), indicators of microvascular 
disease, and number of days taking metformin prior to change. 
For all biochemical variables, we included only the last record 
of each covariate in the patient record prior to drug intensifica-
tion, as we considered this was most likely to influence the pre-
scribing clinician at the point of changing treatment. Comorbid 
conditions, cardiovascular disease (CVD), retinopathy,15 prior 
amputations,16,17 diagnoses for neuropathy,18 proteinuric kidney 
disease, heart failure,19,20 and blindness16,20 were defined as 
present if they were recorded in the medical record on or prior 
to the date of drug intensification. We defined drug exposures 
(ACEI/ARB or statins) as any prescription in the year before 
baseline. Patient-level socioeconomic status was assigned 
with quintiles of index of multiple deprivation (IMD) scores 
that were collated in 2015 as the most recent available data.21
For HbA1c test results, all units were converted to mmol/
mol.1 We excluded values less than 20 mmol/mol (4.0%), or 
greater than 200 mmol/mol (20.4%) as invalid. Results older 
than 540 days were classed as “missing” since they were 
unlikely to represent current glycemic control. We classified 
HbA1c into three groups: ≤53 mmol/mol (7%), 54–74 mmol/
mol, and ≥75 mmol/mol (9%) to fit with NICE intensification 
target guidance (guidance recommends a target of 53 mmol/
mol with insulin if HbA1c rises to 75 mmol/mol).
We calculated eGFR using the last serum creatinine result 
within 2 years. We assumed all creatinine measures were 
isotope-dilution mass spectrometry (IDMS)-standardized 
and calculated eGFR using the Chronic Kidney Disease 
Epidemiology Collaboration equation (CKD-EPI) equation.14 
We excluded ethnicity from the estimate of eGFR as General 
Practitioners (GPs) receive unadjusted eGFRs in laboratory 
reports. We grouped eGFR results as analogous to CKD stage: 
0 to <60 mL/min/1.73 m2, 60 to <90 mL/min/1.73 m2, and 
≥90 mL/min/1.73 m2.
To classify proteinuria, we used diagnostic codes for pro-
teinuric kidney disease and continuous measures of ACR. We 
considered patients to have ACR above the normal range if 
ACR test records had a positive qualifier, or where the value 
was greater than 3 mg/mmol. We created a count variable 
of microvascular disease markers that included a positive 
ACR test result, a diagnosis of retinopathy, a diagnosis of 
neuropathy, or a diagnosis of proteinuric kidney disease.22 
To calculate the daily dose of metformin prior to treatment 
change, we used the last metformin prescription prior to 
treatment change and calculated daily dose as the strength 
prescribed multiplied by the number provided each day. We 
included calendar year, split into 6 monthly periods, as a 
covariate to account for prescribing trends in the UK.5 All 
codes used in this analysis are publicly available on the EHR 
data compass website: http://datacompass.lshtm.ac.uk/692/.
Statistical analysis
We describe the patients prescribed each drug (SU, DPP4i, 
SGLT2i) at first intensification according to clinical, demo-
graphic, and lifestyle factors. We then used multinomial 
logistic regression modeling to better understand the relation-
ships between drug usage and baseline covariates.23 The OR 
for the explanatory variables denotes the association between 
each variable and each drug class at first-stage intensification 
compared with SU (baseline treatment).
The aim of the multinomial models is not to predict drug 
choice, but to identify which variables might be important to 
clinicians prescribing drugs for first-stage intensification. There-
fore, we did not aim to find the most parsimonious model but 
drew conclusions from a model with as many relevant covari-
ates as possible while ensuring the model would converge.24 
A priori, we defined a wide range of factors that we expected 
to be important to clinical decision-making, including patient 
demographic information, clinical measures, comorbidities, and 
lifestyle measures. We examined variables with strong collinear-
ity and selected the variables for inclusion that were most valid 
given the data available. For example, we chose retinopathy as 
a marker of microvascular disease as a sensitive and validated 
measure that is well screened for in primary care,15 and CVD 
as a marker of macrovascular disease that is well recorded.25 We 
found low numbers of people with reduced kidney function, so 
we used wide eGFR classes to avoid zero-count cells.
To handle missing data, we used multiple imputation with 
chained equations under the assumption of data being missing 
at random (MAR).26 We generated 40 imputed datasets. We 
used predictive mean matching to model continuous variables 
to better account for non-normality than linear regression: 
imputed values were drawn from the nearest ten non-missing 
observations.27 We modeled categorical variables using mul-
tinomial logistic regression and ordered categorical variables 
using ordinal logistic regression. For missingness in continuous 
variables, HbA1c, BMI, and eGFR, we imputed the variables 
on the continuous scale and then converted to categorical 
variables after imputation. The imputation models included all 
covariates in the analysis model, as well as auxiliary variables 
including dementia, heart failure, and blindness diagnoses.
Data extraction and processing of CPRD data were com-
pleted in Stata MP (version 14). All data analysis has been 
completed using Stata MP 14 and R version 3.4.1.
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Sensitivity analyses
Patient-level IMD data are only available for practices in Eng-
land, effectively excluding patients in other countries in the 
UK. Therefore, for our primary analysis, we did not include 
IMD to maximize the representativeness of the findings. In 
our first sensitivity analysis, we repeated the primary model 
for England, including patient-level IMD data to explore the 
impact of this on treatment intensification.
In addition, to examine the sensitivity of our results to the 
assumptions made, we conducted further sensitivity analyses. 
If the patient was censored or died in the 60 days after an 
alternate drug was prescribed, it is not known whether further 
metformin therapy was intended by the GP, and therefore these 
individuals could be mistakenly excluded as drug “switchers”. 
Therefore, in a sensitivity analysis, we included all patients 
who died in this period. Finally, retinopathy represents only 
one microvascular complication associated with type 2 diabe-
tes but multiple complications may independently influence 
prescribing. Therefore, we repeated the primary analysis, 
replacing retinopathy with a count of microvascular disease 
markers including a positive ACR test result, diagnosis of 
retinopathy, neuropathy, or proteinuric kidney disease.
Post hoc analyses
We observed a strong calendar time interaction in the logis-
tic regression. We therefore repeated the analysis for each 
individual year 2014–2016 (excluding time as a covariate) 
and compared ORs of interest using forest plots.
(WKLFDODQGVFLHQWLÀFDSSURYDO
The research protocol was approved by the Independent 
Scientific Advisory Committee (ISAC) of the Medicines & 
Healthcare products Regulatory Agency Database Research 
(protocol number 16_267). The protocol was made available 
to journal reviewers. This study was also approved by the 
London School of Hygiene and Tropical Medicine Ethics 
Committee, reference 11923.
Data availability
All codes used in this analysis are publicly available on 
the EHR data compass website: http://datacompass.lshtm.
ac.uk/692/; no further data sharing is possible.
Results
We identified 307,554 people who started antidiabetic treat-
ment, between 2000 and 2017, of whom 280,241 people 
were aged 18 years and over, with no recent evidence of 
pregnancy. Of these, 204,238 (73%) initiated treatment 
with metformin monotherapy and 38,739 people received 
SU monotherapy (14%). Of those starting treatment with 
metformin monotherapy, we identified 79,941 (39%) that 
intensified treatment with any further antidiabetic drug. We 
then restricted this group to 14,149 individuals who intensi-
fied treatment between 2014 and 2017 to reflect only con-
temporary prescribing decisions. In our selected cohort, 44% 
(6,294/14,149) received SU, 37% (5,285/14,149) received 
DPP4i, 11% (1,488/14,149) received SGLT2i, and 8% 
(1,082/14,149) received insulin or other combinations (Table 
S1). In keeping with our decision to focus on SUs, DPP4i, and 
SGLT2is, only 2% (290/14,149) of the cohort were prescribed 
TZDs between 2014 and 2017. Full inclusions and exclusions 
are presented in the flowchart in Figure 2.
Start type 2 diabetes drug
n=307,554
No evidence of pregnancy
within 365 days
Initiated treatment with
metformin monotherapy
n=204,238
Intensified treatment
First stage intensification
between January 1, 2014
and July 31, 2017
n=14,149
Outside of period of
interest
n=65,792
Switched treatment
No therapy changes
Initiated treatment on other
therapy
Other options include:
Evidence of pregnancy or
aged <18 years
n=27,313
SU=38,739
met and SU=11,742
insulin=6,771
Stayed on metformin
n=98,890
No metformin in 60 days
after new drug class added
n=25,407
Metformin monotherapy
intensified
Metformin in 60 days after
new drug class added
n=79,941
Further drug added to treatment
n=105,348
Aged 18 years and over
n=280,241
Between January 1, 2000
and July 31, 2017
Marked acceptable by CPRD
12 months of follow-up prior
to first prescription
n=76,003
Figure 2 Flow diagram showing the creation of the study population and reasons 
for exclusion.
Abbreviation: CPRD, UK Clinical Research Datalink.
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Table 13DWLHQWGHPRJUDSKLFDQGOLIHVW\OHIDFWRUVDFFRUGLQJWRÀUVWVWDJHLQWHQVLÀFDWLRQGUXJSUHVFULELQJ
SU
N=6,294
Freq (%)a
DPP4i
N=5,285
Freq (%)a
SGLT2i
N=1,488
Freq (%)a
Age category (years) <30 40 (0.6) 37 (0.7) 22 (1.5)
30–39 224 (3.6) 168 (3.2) 71 (4.8)
40–49 960 (15.3) 735 (13.9) 309 (20.8)
50–59 1,719 (27.3) 1,442 (27.3) 554 (37.2)
60–69 1,749 (27.8) 1,541 (29.2) 417 (28)
70–79 1,140 (18.1) 1,010 (19.1) 106 (7.1)
≥80 462 (7.3) 352 (6.7) 9 (0.6)
Gender Female 2,561 (40.7) 2,093 (39.6) 614 (41.3)
BMI Underweight/normal 742 (12) 411 (7.9) 33 (2.2)
Overweight 1,970 (31.9) 1,488 (28.6) 236 (16)
Obese 3,465 (56.1) 3,307 (63.5) 1,205 (81.8)
Missing from complete cohort 117 (1.9) 79 (1.5) 14 (0.9)
Ethnicity White 3,348 (84.3) 2,826 (89.2) 736 (92)
South Asian 351 (8.8) 197 (6.2) 39 (4.9)
Black 166 (4.2) 82 (2.6) 13 (1.6)
Other 87 (2.2) 48 (1.5) 9 (1.1)
Mixed 18 (0.5) 16 (0.5) N<5
Missing from complete cohort 2,324 (36.9) 2,116 (40) 688 (46.2)
Patient-level index of 1 LEAST deprived 593 (17.1) 491 (19) 130 (20.7)
multiple deprivation 2 634 (18.3) 473 (18.3) 132 (21.1)
3 705 (20.4) 516 (20) 147 (23.4)
4 802 (23.2) 520 (20.1) 120 (19.1)
5 MOST deprived 729 (21.1) 581 (22.5) 98 (15.6)
Missing from complete cohort 2,831 (45) 2,704 (51.2) 861 (57.9)
Alcohol status Nondrinker 1,000 (16.5) 669 (13.1) 171 (12)
Ex-drinker 879 (14.5) 757 (14.8) 207 (14.5)
Current drinker 4,178 (69.1) 3,699 (72.2) 1,052 (73.6)
Missing from complete cohort 237 (3.8) 160 (3) 58 (3.9)
Smoking status Nonsmoker 2,386 (38) 1,968 (37.3) 589 (39.6)
Current 1,041 (16.6) 813 (15.4) 238 (16)
Ex-smoker 2,854 (45.4) 2,501 (47.3) 660 (44.4)
Missing from complete cohort 13 (0.2) N<5 N<5c
'D\VVLQFHÀUVW
metformin prescription
Mean (SD) 1,182 (1,103) 1,320 (1,105) 1,137 (1,023)
Dose of previous 
metformin prescription 
(mg/day)
Mean (SD) 1,675 (525) 1,742 (484) 1,712 (470)
Missing from complete cohort 2,165 (34) 1,757 (33) 529 (36)
HbA1c (mmol/mol) Mean (SD) 80 (21) 73 (16) 76 (18)
<53 (7%)b 182 (4.5) 146 (4.3) 34 (3.9)
53–74 1,864 (45.7) 2,087 (61.5) 444 (51.4)
>75 (9%) 2,030 (49.6) 1,164 (34.3) 386 (44.7)
Missing from complete cohort 2,218 (35) 1,888 (36) 625 (42)
eGFR (mL/min/1.73 m2) Mean (SD) 87 (19) 85 (19) 94 (15)
eGFR category <60 448 (10.7) 378 (11) 11 (1.2)
(mL/min/1.73 m2) 60–89 1,694 (40.4) 1,457 (42.4) 314 (35.6)
≥90 2,051 (48.9) 1,605 (46.7) 558 (63.2)
Missing from complete cohort 2,101 (33.4%) 1,845 (34.9%) 605 (40.7%)
Proteinuric renal 
disease
159 (2.5) 101 (1.9) 23 (1.5)
Raised ACR 828 (28.9) 611 (24.9) 157 (24.9)
Missing from complete cohort 3,431 (54.5) 2,836 (53.7) 858 (57.7)
(Continued)
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Baseline characteristics of patients 
at point of type 2 diabetes drug 
LQWHQVLÀFDWLRQ²
Patient demographic and lifestyle factors for patients pre-
scribed SUs, DPP4is, and SGLT2is are shown in Table 1. 
Details of patients prescribed insulin or other drug combi-
nations are given in Table S2. The mean age of individuals 
intensifying treatment was 60 years, mean BMI was 33 kg/
m2, and mean eGFR was 87 mL/min/1.73 m2. Individuals 
prescribed SGLT2is were younger, had higher BMIs, a higher 
representation of white people, and fewer people classed as 
more deprived. The DPP4i group had a higher proportion of 
obese people and white people compared with the SU group. 
Of the clinical factors, people prescribed SGLT2is had less 
impaired kidney function compared with people receiving SUs 
and DPP4i (Table 1). The prevalence of neuropathy, blindness, 
heart failure, dementia, and proteinuria was low, and similar, 
across the drug classes. The SGLT2i group had the lowest 
prevalence of CVD (10%) vs 14% in the SU and DPP4i groups.
Multinomial logistic regression
The results of the primary multinomial regression analysis 
are presented in Table 2. Age was associated with prescrib-
ing choice, with younger people substantially more likely 
to be prescribed SGLT2is than SUs. The OR for SGLT2i 
prescription for those aged <30 years was 2.47 (95% CI 
1.39–4.39), compared to those aged 60–70 years, and there 
was a trend towards SU prescribing as age increases. SUs 
were more commonly prescribed for people with very poor 
glycemic control: among people with HbA1c >75, the OR 
for DPP4i prescription was 0.70 (95% CI 0.56–0.88) and 
that for SGLT2is prescription was 0.76 (95% CI 0.52–1.12) 
compared with that for SU prescription. For people with an 
eGFR >90 mL/min/1.73 m2, the odds of receiving SGLT2is 
was 6.72 (95% CI 3.71–12.20) times greater than someone 
with an eGFR <60 mL/min/1.73 m2. The presence of micro-
vascular  and macrovascular diseases was not associated with 
drug prescribing but both being overweight and obese were 
associated with greater odds of being prescribed both DPP4is 
and SGLT2is. Compared with white patients, the odds of 
being prescribed SGLT2i among South Asians was 0.60 (95% 
CI 0.42–0.85) and for black people the OR was 0.54 (95% 
CI 0.30–0.97). The odds of receiving DPP4i was also lower 
for South Asian and black people, 0.71 (95% CI 0.58–0.87) 
and 0.69 (95% CI 0.51–0.95), respectively. In the sensitivity 
analysis also including socioeconomic status, people from 
the two most deprived groups were also less likely to be 
prescribed SGLT2is (eg, OR 0.59 [95% CI 0.44–0.80] for 
the lowest fifth of IMD compared with the highest) while the 
findings for ethnicity were unchanged (Table S3). As we have 
shown previously, prescribing of DPP4i and SGLT2i drugs 
is increasing rapidly over time.5
Table 1 (Continued)
SU
N=6,294
Freq (%)a
DPP4i
N=5,285
Freq (%)a
SGLT2i
N=1,488
Freq (%)a
Neuropathy 408 (6.5) 326 (6.2) 70 (4.7)
Amputation 51 (0.8) 31 (0.6) 10 (0.7)
Retinopathy 1,061 (16.9) 1,018 (19.3) 227 (15.3)
Blindness 41 (0.7) 42 (0.8) N<5
>1 sign of 
microvascular disease
2,073 (32.9) 1,721 (32.6) 416 (28)
Systolic BP (mmHg) Mean (SD) 132 (14) 133 (14) 134 (14)
Missing from complete cohort 20 (0.3) 11 (0.2) N<5
CVD 878 (13.9) 744 (14.1) 150 (10.1)
Heart failure 103 (1.6) 57 (1.1) 14 (0.9)
ACEI or ARB 
prescription
3,342 (53.1) 2,973 (56.3) 828 (55.6)
Statin prescription 4,558 (72.4) 4,127 (78.1) 1,085 (72.9)
Notes: Numbers are N (%) unless otherwise stated. a8QOHVVRWKHUZLVHVSHFLÀHGDUHRIQRQPLVVLQJYDOXHVZKHUHPLVVLQJFDWHJRULHVDUHSURYLGHGSHUFHQWDJHLQGLFDWHV
percentage from the entire cohort. bHbA1c % represents HbA1c group according to the National Glycohemoglobin Standardization Program percentage. cFrequencies below 
ÀYHQRWVWDWHGDVSHU,QGHSHQGHQW6FLHQWLÀF$GYLVRU\&RPPLWWHHIRU0+5$'DWDEDVH5HVHDUFKSROLF\
Abbreviations: ACEI, angiotensin-converting-enzyme inhibitor; ACR, albumin:creatinine ratio; ARB, angiotensin II receptor blockers; BMI, body mass index; CVD, 
cardiovascular disease; BP, blood pressure; DPP4i, dipeptidyl peptidase-4 inhibitors; HbA1c, hemoglobin A1c; SGLT2i, sodium-glucose co-transporter-2 inhibitors; SU, 
VXOIRQ\OXUHDH*)5HVWLPDWHGJORPHUXODUÀOWUDWLRQUDWH
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Table 2 Fully adjusted ORs (95% CIs) for prescription of DPP4i or SGLT2i compared with SUs
Variable SU, Ref DPP4i, OR (95% CI) SGLT2i, OR (95% CI)
N= 6,294 5,285 1,488
Age, years
<30 1 1.37 (0.85–2.19) 2.47 (1.39–4.39)
30≤40 1 1.02 (0.82–1.28) 1.33 (0.97–1.82)
40≤50 1 0.98 (0.86–1.11) 1.27 (1.05–1.53)
50≤60 1 0.98 (0.88–1.08) 1.22 (1.04–1.42)
60≤70 1 1 1
70≤80 1 0.96 (0.86–1.08) 0.48 (0.37–0.60)
80 + 1 0.89 (0.75–1.06) 0.15 (0.07–0.29)
Gender
Male 1 1 1
Female 1 0.92 (0.85–0.99) 0.99 (0.87–1.12)
HbA1c (mmol/mol)
 1 1 1
53–75 1 1.34 (1.07–1.67) 1.12 (0.77–1.63)
>75 1 0.70 (0.56–0.88) 0.76 (0.52–1.12)
eGFR (mL/min/1.73 m2)
<60 1 1 1
60–89 1 1.05 (0.90–1.23) 5.86 (3.25–10.58)
>90 1 1.01 (0.86–1.18) 6.72 (3.71–12.20)
Time taking metformin (years)
<1 1 1 1
1 to <3 1 1.27 (1.14–1.40) 1.40 (1.19–1.64)
>3 1 1.31 (1.18–1.44) 1.23 (1.05–1.44)
Cardiovascular disease (CVD)
No CVD 1 1 1
CVD diagnosis 1 0.95 (0.85–1.06) 0.95 (0.77–1.16)
Retinopathy
No retinopathy 1 1 1
Retinopathy diagnosis 1 1.09 (0.99–1.21) 1.02 (0.86–1.21)
BMI (kg/m2)
Normal/underweight 1 1 1
Overweight 1 1.30 (1.12–1.50) 2.22 (1.51–3.25)
Obese 1 1.70 (1.48–1.96) 5.61 (3.90–8.09)
Smoking status
None 1 1 1
Ex 1 0.99 (0.90–1.08) 1.00 (0.87–1.15)
Current 1 0.94 (0.84–1.06) 0.81 (0.67–0.97)
Ethnicity
White 1 1 1
South Asian 1 0.71 (0.58–0.87) 0.60 (0.42–0.85)
Black 1 0.69 (0.51–0.95) 0.54 (0.30–0.97)
Other 1 0.77 (0.52–1.14) 0.86 (0.39–1.88)
Mixed 1 1.14 (0.48–2.72) 2.08 (0.60–7.29)
Calendar time
Early 2014 1 1 1
Late 2014 1 1.14 (1.00–1.29) 1.80 (1.38–2.36)
Early 2015 1 1.36 (1.20–1.53) 2.62 (2.04–3.37)
Late 2015 1 1.58 (1.38–1.80) 3.87 (3.01–4.98)
Early 2016 1 2.00 (1.75–2.28) 5.67 (4.42–7.27)
Late 2016 1 2.16 (1.86–2.51) 7.91 (6.13–10.20)
Early 2017 1 2.43 (2.06–2.86) 11.02 (8.46–14.36)
Note: Results of primary analysis, using multinomial logistic regression with multiple imputation to account for missing data.
Abbreviations: BMI, body mass index; DPP4i, dipeptidyl peptidase-4 inhibitors; HbA1c, hemoglobin A1c; SGLT2i, sodium-glucose co-transporter-2 inhibitors; SU, 
VXOIRQ\OXUHDH*)5HVWLPDWHGJORPHUXODUÀOWUDWLRQUDWH
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Taking a complete case analysis approach to the model, 
or including individuals who were censored or died in the 
60 days after prescribing of the intensification  treatment 
for type 2 diabetes, produced no material differences from 
the primary analysis (Table S4). Redefining microvascular 
disease as a count of disease indicators also had no effect on 
the results (data not shown).
Post hoc analyses
Comparison of ORs for ethnicity for each individual year 
2014–2016 (Figure S1) showed that for both South Asian and 
black people, the OR for receiving either SGLT2i or DPP4i 
was below 1.0 in every year, though for black patients the 
point estimate moves closer to 1.0 over time.
Discussion
We have identified clinical and nonclinical patient factors 
associated with drug prescribing between 2014 and 2017, a 
period when prescribing of the new drug classes, DPP4is and 
SGLT2is, rapidly increased.5 Compared with SUs, SGLT2is 
were more commonly prescribed for younger people, for 
people who are overweight and obese, and for people who 
are white and of higher socioeconomic status. Findings for 
DPP4is are similar, although less marked. SUs are more com-
monly prescribed for patients with very poor diabetic control.
To our knowledge, this is the first analysis of factors 
associated with prescribing choice for the new type 2 diabetes 
drugs in the UK. Our findings reflect contemporary data, col-
lected from a large primary care cohort from January 2000 
to July 2017. We have identified patients starting additional 
treatments at a similar stage in their disease course, enabling 
direct comparability. However, there are limitations to this 
analysis. First, we may have misclassified some patients 
with type 1 diabetes, and as SGLT2is are used off-label as 
an adjunct therapy, this could in part explain our findings of 
an association with prescribing for the youngest patients. 
However, we excluded patients who were prescribed insulin at 
intensification, and required that metformin was re-prescribed 
after drug intensification, so any degree of misclassification 
is likely to be minimal. Second, drug prescribing may be 
influenced by local prescribing guidance such as preap-
proval restrictions issued by clinical-commissioning groups 
(CCGs).28 In turn, CCGs may have varying proportions of 
residents of different ethnicities, so this again may influence 
our findings related to ethnicity and, similarly, to socioeco-
nomic status. Restrictions related to maintaining anonymity 
of the data limit this level of data analysis. Third, we used 
prescribing data collected from primary care and we do not 
know which prescriptions were initiated in secondary care or 
specialist community care. Individuals intensified in special-
ist care environments may be more likely to receive newer 
drug options, which their GP then continues in primary care. 
Therefore, factors leading to inequity of access to new medi-
cations may occur by variation in who is referred to secondary 
care but we could not address this in our analysis. Finally, 
due to low numbers, we did not examine the characteristics 
associated with prescribing of TZDs, although these are a 
comparable choice in current prescribing guidance. Follow-
ing a number of issues including concern about increased 
risk of heart failure and the 2011 MHRA warning of bladder 
cancer risk associated with use of pioglitazone, the TZDs have 
been infrequently prescribed for new users.5,29,30
Of the clinical factors assessed, some of the associations are 
expected. DPP4is are widely accepted to be weight neutral, and 
SGLT2is may aid weight loss, whereas SUs are associated with 
weight gain.2 This may in part explain the independent associa-
tion of being overweight and obese with being prescribed the 
new drugs. We found no SGLT2i prescriptions used in people 
with eGFR <45 mL/min/1.73 m2. This suggests that prescribing 
of SGLT2is is aligned with clinical guidelines and prescribing 
information which restrict SGLT2i prescribing when kidney 
function is low.31 SUs are also prescribed to the patients with 
the poorest glycemic control. This may reflect NICE guidance 
that recommends SUs for patients with symptomatic hypergly-
cemia, or clinicians may perceive that SUs are more effective 
at reducing HbA1c compared with DPP4is and SGLT2is.1,32
Our findings that age, ethnicity, and levels of deprivation 
are associated with choice of treatment are in line with other 
evidence regarding factors that influence prescribing of new 
drugs.33 Younger patients are known to receive newer drugs 
more, perhaps driven by patient information and expectations, 
or by concern that older patients are more likely to experience 
side effects. However, SUs may not be the most appropriate 
treatment choice for older people, given their higher risks 
for hypoglycemia.33–36 Globally, higher income patients often 
receive newer and more expensive drugs due to their ability 
to pay more for treatment.33 However, in our study, all indi-
viduals are under the care of the NHS, and hence the ability 
to pay should have no bearing on prescribing, yet level of 
deprivation is still an independent predictor of drug choice. 
South Asian and black people received newer drug options 
(DPP4is and SGLT2is) less often than white people. Dispar-
ity in diabetes treatment by ethnicity is well established.37 
However, our finding that this extends to prescribing of new 
treatments is novel. The reasons for these differences are 
likely to be complex and could include patient awareness of 
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new drug choices, language barriers, or practice-level dif-
ferences which we were unable to investigate.
An additional finding of our study is the marked dif-
ferences between the characteristics of people prescribed 
SGLT2i in routine clinical use compared with randomized 
trials. The mean age of participants prescribed SGLT2i in our 
study was 55 years compared with 63.2 years in CANVAS 
and 63.1 years in EMPA-REG.38,39 In addition, 68% of people 
in CANVAS randomized to SGLT2i had a prior history of 
CVD, compared with 10% of people with coded CVD who 
received SGLT2i in routine care in our study. The reason for 
the preferential prescribing of these drugs to younger people 
without ischemic heart disease in routine clinical care, despite 
the evidence base generated among people with CVD or high 
cardiovascular risk, is unclear.
This study demonstrates that where there is a choice 
between well-established and more novel treatments for 
type 2 diabetes, both clinical and nonclinical factors are 
associated with prescribing. These include age, ethnicity, 
and socioeconomic status, suggesting there is disparity in 
care unrelated to clinical need. The patient characteristics 
of those taking the newer drugs vary markedly from those 
studied in clinical trials. The impact of these factors on the 
clinical outcomes of patients with type 2 diabetes in a diverse 
population is not yet understood.
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5.4 Sensitivity analyses of cohort definition 
As detailed in Section 1.1, only individuals for whom GPs prescribed a first stage 
intensification drug, followed by a further metformin prescription were eligible for 
this study. I considered people without a record of metformin following treatment 
intensification to be treatment switchers, and excluded them from the analysis. When 
GPs switch treatment after metformin, rather than add another drug alongside 
metformin, as recommended in NICE guidance, they are probably doing so because 
the patient is intolerant of metformin. Therefore, people who are switching are likely 
to be clinically different to people intensifying treatment.(18)  
As outlined in Section 1.1, this criterion may lead to bias. To be included in the 
study people needed to survive long enough to receive a further prescription for 
metformin. Therefore, in supplementary analyses I repeated the analysis including 
people that died or were censored for other reasons (e.g. leaving a GP practice) in the 
60 day window where I checked for further metformin prescribing, Table 5.1.
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Variable SU, Ref DPP4i, OR (95% CI) SGLT2i, OR (95% CI) 
Age at baseline, years    
 < 30 1 1.36 (0.85, 2.17) 2.48 (1.39, 4.40) 
 30-<40 1 1.01 (0.81, 1.26) 1.32 (0.97, 1.81) 
 40-<50 1 0.98 (0.86, 1.11) 1.27 (1.04, 1.52) 
 50-<60 1 0.98 (0.88, 1.08) 1.21 (1.04, 1.42) 
 60-<70 1 1 1 
 70-<80 1 0.96 (0.85, 1.08) 0.47 (0.37, 0.60) 
 80 + 1 0.88 (0.74, 1.04) 0.14 (0.07, 0.28) 
Gender    
 Male 1 1 1 
 Female 1 0.92 (0.85, 1) 0.99 (0.87, 1.12) 
HbA1c at baseline (mmol/mol)   
 < 54 1 1 1 
 54-75 1 1.41 (1.14, 1.73) 1.17 (0.79, 1.71) 
 75+ 1 0.73 (0.59, 0.90) 0.79 (0.54, 1.16) 
eGFR at baseline 
(ml/min/1.73m2) 
   
 < 60 1 1 1 
 60-89 1 1.05 (0.90, 1.23) 5.88 (3.29, 10.50) 
 90 + 1 1.02 (0.86, 1.21) 6.77 (3.75, 12.23) 
Time taking metformin prior to intensification 
(years) 
  
 < 1 1 1 1 
 1 to <3 1 1.26 (1.13, 1.40) 1.40 (1.19, 1.64) 
 > 3 1 1.30 (1.17, 1.43) 1.23 (1.05, 1.44) 
Diagnosis of cardiovascular disease   
 No CVD 1 1 1 
 CVD diagnosis 1 0.94 (0.84, 1.06) 0.95 (0.78, 1.16) 
Diagnosis of retinopathy    
 No retinopathy 1 1 1 
 Retinopathy diagnosis 1 1.09 (0.99, 1.21) 1.02 (0.86, 1.21) 
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Variable SU, Ref DPP4i, OR (95% CI) SGLT2i, OR (95% CI) 
BMI at baseline, kg/m2    
 Normal/underweight 1 1 1 
 Overweight 1 1.31 (1.14, 1.51) 2.22 (1.52, 3.26) 
 Obese 1 1.72 (1.50, 1.98) 5.66 (3.93, 8.17) 
Smoking status    
 None 1 1 1 
 Ex 1 0.98 (0.90, 1.07) 1.00 (0.87, 1.15) 
 Current 1 0.93 (0.83, 1.05) 0.80 (0.67, 0.96) 
Ethnicity    
 White 1 1 1 
 South Asian 1 0.70 (0.57, 0.86) 0.60 (0.42, 0.89) 
 Black 1 0.66 (0.49, 0.90) 0.55 (0.29, 1.06) 
 Other 1 0.78 (0.50, 1.24) 0.87 (0.40, 1.67) 
 Mixed 1 1.17 (0.55, 2.49) 2.05 (0.61, 6.91) 
Calendar time    
 Early 2014 1 1 1 
 Late 2014 1 1.13 (1.00, 1.29) 1.80 (1.37, 2.35) 
 Early 2015 1 1.35 (1.20, 1.53) 2.62 (2.04, 3.36) 
 Late 2015 1 1.58 (1.38, 1.80) 3.87 (3.01, 4.98) 
 Early 2016 1 2.00 (1.75, 2.29) 5.68 (4.43, 7.28) 
 Late 2016 1 2.17 (1.87, 2.52) 7.90 (6.12, 10.20) 
 Early 2017 1 2.44 (2.07, 2.88) 11.11 (8.53, 14.47) 
Table 5.1 Results of sensitivity analysis for censoring criteria. Includes 
individuals that died or were censored in the 60-day check window for further 
metformin prescribing. Abbreviations: DPP4is: Dipeptidyl peptidase 4 inhibitors, 
SGLT2is: Sodium-glucose cotransporter-2 inhibitors, SU: Sulfonylureas
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 The result of the sensitivity analysis showed that including the censored  individuals 
had almost no impact on the estimates compared to the primary analysis. Of the 
people that were excluded as being treatment switchers from the primary analysis, 
only 65 people were censored in the check period. This suggests that the potential for 
bias is very low.  
For the people included in the primary analysis, approximately one third received 
further metformin on the same day as the treatment intensification prescription, and 
were therefore selected for inclusion without using information from the future. I 
found most follow-up metformin prescriptions within the duration of prescription of 
the index drug. For each of the drug classes that I focussed on in this study, 
sulfonylureas, DPP4is and SGLT2is, the timing of metformin co-prescribing was 
similar, Table 5.2. 
Metformin prescription found: SU, n (%) DPP4i, n (%) SGLT2i, n (%) 
On the same day as index drug 1869 (29.7) 1666 (31.5) 472 (31.7) 
Within duration of index drug 3696 (58.7) 3046 (57.6) 818 (55.0) 
Within duration of index drug + 60 days 729 (11.6) 573 (10.8) 198 (13.3) 
Total 6294 5285 1488 
Table 5.2 Timing of metformin prescribing in the check period following 
treatment intensification, for individuals selected for inclusion in Paper 3. 
Abbreviations: DPP4is: Dipeptidyl peptidase 4 inhibitors, SGLT2is: Sodium-glucose 
cotransporter-2 inhibitors, SU: Sulfonylureas 
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5.5 Addition of interaction term between age and ethnicity 
To investigate whether there was a differential association between drug prescribing 
and ethnicity according to age, I have included a post hoc analysis. This analysis is a 
repeat of the primary analysis with the addition of an interaction term between age 
and ethnicity. I could not include the interaction in the same model as the primary 
analysis as it would not converge due to the limited sample size. Instead, I have used 
smaller categories of age and ethnicity. Point estimates for ethnicity appear largely 
similar to the primary analysis. The interaction terms between older and being of 
south Asian ethnicity suggests some interaction with age, however 95% confidence 
intervals are wide and inconclusive, Table 5.3. This model is underpowered to 
investigate the marginal effects of ethnicity on drug prescribing, for each age 
category. 
Variable SU, Ref DPP4i, OR (95% CI) SGLT2i, OR (95% CI) 
N= 6294 5285 1488 
Age, years    
 < 40 1   
 40-<60 1 0.93, (0.74, 1.18) 0.77, (0.57, 1.03) 
 60-<80 1 0.93, (0.73, 1.18) 0.50, (0.36, 0.68) 
 80 + 1 0.85, (0.63, 1.12) 0.09, (0.04, 0.20) 
Gender    
 Male 1   
 Female 1 0.92, (0.85, 0.99) 0.98, (0.86, 1.11) 
HbA1c (mmol/mol)    
 ≤53 1   
 53-75 1 1.32, (1.06, 1.64) 1.09, (0.77, 1.56) 
 >75  1 0.69, (0.56, 0.86) 0.76, (0.53, 1.09) 
eGFR (ml/min/1.73m2)    
 <60 1   
 60-89 1 1.06, (0.90, 1.23) 6.47, (3.60, 11.63) 
 >90 1 1.01, (0.86, 1.19) 7.85, (4.29, 14.35) 
Time taking metformin (years)    
 <1 1   
 1 to <3 1 1.27, (1.14, 1.41) 1.40, (1.20, 1.65) 
 >3 1 1.30, (1.18, 1.44) 1.22, (1.04, 1.43) 
Cardiovascular disease (CVD)    
 No CVD 1   
 CVD diagnosis 1 0.95, (0.84, 1.06) 0.93, (0.76, 1.13) 
Retinopathy    
 No retinopathy 1   
 Retinopathy diagnosis 1 1.09, (0.99, 1.21) 1.01, (0.85, 1.19) 
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Variable SU, Ref DPP4i, OR (95% CI) SGLT2i, OR (95% CI) 
BMI kg/m2    
 Normal/underweight 1   
 Overweight 1 1.30, (1.13, 1.50) 2.32, (1.58, 3.40) 
 Obese 1 1.71, (1.49, 1.96) 5.96, (4.14, 8.59) 
Smoking status    
 None 1   
 Ex 1 0.94, (0.84, 1.06) 0.82, (0.69, 0.99) 
 Current 1 0.99, (0.90, 1.08) 0.99, (0.86, 1.14) 
Ethnicity    
 White 1   
 South Asian 1 0.82, (0.46, 1.47) 0.24, (0.06, 0.93) 
 Black 1 0.50, (0.14, 1.79)                                                           0.41, (0.05, 3.07) 
 Other 1 0.90, (0.25, 3.20) - 
Calendar time    
 Early 2014 1 1.14, (1.00, 1.29) 1.82, (1.39, 2.38) 
 Late 2014 1 1.36, (1.20, 1.54) 2.63, (2.05, 3.38) 
 Early 2015 1 1.58, (1.39, 1.81) 3.90, (3.04, 5.02) 
 Late 2015 1 2.00, (1.75, 2.28) 5.69, (4.44, 7.29) 
 Early 2016 1 2.16, (1.86, 2.51) 7.91, (6.13, 10.21) 
 Late 2016 1 2.44, (2.07, 2.87) 10.95, (8.41, 14.26) 
 Early 2017 1 1.14, (1.00, 1.29) 1.82, (1.39, 2.38) 
Interaction    
 S Asian * 40<60 1 0.89, (0.48, 1.65) 2.41, (0.58, 10.00) 
 S Asian * 60<80 1 0.80, (0.41, 1.55) 3.37, (0.81, 13.96) 
 S Asian * 80+ 1 0.74, (0.21, 2.60) - 
 Black * 40<60 1 1.07, (0.29, 3.91) 0.98, (0.12, 7.84) 
 Black * 60<80 1 1.82, (0.46, 7.16) 2.40, (0.26, 22.39) 
 Black * 80+ 1 - - 
 Other * 40<60 1 0.87, (0.23, 3.33) - 
 Other * 60<80 1 0.95, (0.23, 3.87) - 
 Other * 80+ 1 1.67, (0.20, 14.19) - 
 
Table 5.3 Fully adjusted odds ratios (95% CIs) for prescription of DPP4i or 
SGLT2i compared to SUs. Results of extra analysis with interaction between 
ethnicity and age. Multinomial logistic regression with multiple imputation to 
account for missing data. Abbreviations: SU: Sulfonylurea, DPP4i: dipeptidyl 
peptidase 4inhibitors, SGLT2i: Sodium-glucose co-transporter-2 inhibitors, HbA1c: 
Hemoglobin A1c, eGFR: estimated Glomerular Filtration Rate, BMI: Body mass 
inde
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6 Chapter 6: Routine clinical use of SGLT2is, sulfonylureas or 
DPP4is to intensify metformin monotherapy: Changes in blood 
glucose, kidney function, blood pressure and weight in UK 
primary care (Paper 4) 
 
Chapter summary 
• Recent clinical trials have suggested that the new SGLT2i drug class may 
be beneficial for people with type 2 diabetes, for reducing long-term 
adverse cardiovascular and renal outcomes. 
• Comparative evidence for the SU, SGLT2i and DPP4i drug classes is 
limited. The aim of this chapter is to compare changes in eGFR, HbA1c, 
BMI and systolic BP, for people prescribed SUs, DPP4i or SGLT2is to 
intensify metformin monotherapy.  
• Results indicate differences between the drug options, most notably in 
changes in HbA1c and BMI. People prescribed SGLT2i showed decreases 
in BMI of 1.7 kg/m2 (95% CI: 1.4, 2.1), the DPP4i group fell by 0.8 kg/m2 
(95% CI: 0.6, 1.0) but BMI in the SU group did not change, 0.2 kg/m2 
(95% CI: 0.0, 0.4). 
• This chapter opens with a synopsis of the steps taken to develop 
propensity score matched cohorts to account for differences at baseline. I 
matched cohorts on baseline factors given findings from Chapter 5.  
• After the paper, I present a summary of outcome rates for kidney function 
decline, cardiovascular disease, heart failure and urinary tract infection, 
comparing SUs to DPP4is and SGLT2is. The results show that data from 
the July 2017 extract of CPRD GOLD provided inadequate power to 
undertake a cohort study with hard clinical endpoints.  
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6.1 Selection of method for Propensity Score matching across more than 
two treatment groups  
In Paper 3, I identified several important patient factors that were associated with 
prescribing of the three treatments, SU, SGLT2i and DPP4i. Some of these variables 
were likely to be also associated with the outcomes, inducing confounding by 
indication. One example was baseline kidney function. We showed that GPs only 
prescribed SGLT2is to people with higher kidney function (eGFR). Given that 
baseline eGFR will likely impact change in kidney function after the start of 
treatment, we needed to adjust for baseline level. This would ensure that people 
prescribed different drugs are exchangeable at baseline and therefore reduce 
confounding by indication.  
In Paper 4, to achieve a balance in baseline characteristics and to limit confounding, 
I applied propensity score matching. This is a commonly implemented method to 
compare treatment groups. Where patients with certain clinical factors have a higher 
chance of receiving one treatment over another, and where these factors are 
associated with outcomes, confounding by indication is likely.(132) Propensity 
scores (PS) act as a balancing score that allow researchers to use baseline covariates 
to adjust for confounders.  
Researchers using PS matching generally compare one treatment with another. 
Given that three drug options are commonly prescribed in primary care at the first 
stage of treatment intensification, comparison of three groups is of clinical interest 
for this study. However, the process of creating matched cohorts for more than two 
treatment groups is not well defined. Imbens et al. recommends the use of multiple 
multinomial logistic regression models to calculate the propensity score, but using 
the PS to create matched cohorts is uncommon.(133, 134) Instead, more often, 
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researchers apply these propensity scores in PS adjusted regression, PS weighted 
regression or PS stratification.(133, 134) In Paper 4, creating matched samples is 
preferable to other methods to adjust for baseline covariates, as the aim is to compare 
longitudinal changes in HbA1c, BMI, systolic BP and eGFR. Matched cohorts mean 
that treatment groups are balanced in terms of baseline covariates and so the 
treatment effect models will not require further adjustment. Moreover, interpretation 
of the outcome models will be similar to the RCTs, showing changes in means over 
time. A further challenge to the analysis of comparative changes for three different 
drug classes is the small number of SGLT2i-treated individuals compared to the 
older drug options DPP4is and SUs. An important aspect of the selected statistical 
model is to maximise the power of the study population by using as many 
individuals from the SGLT2i group as possible.  
A recent paper approached the challenge of three-way PS-score matching, 
suggesting a 1:1:1 matching technique that identifies groups of three individuals with 
the similar PS.(135) However, the technique suggested allows only 1:1:1 matching. 
Where one treatment group has low numbers, as is the case when comparing 
SGLT2is to SUs and DPP4is, this technique would limit the study sample size. Other 
authors have applied approaches referred to as ‘common referent’ whereby 
propensity scores are estimated using logistic regression, using one treatment arm as 
the same referent group, then only including matched pairs where the referent group 
had matches across all treatment arms.(136) 
In collaboration with Dr Elizabeth Williamson, a statistician at LSHTM I developed 
the following approach. Initially I used logistic regression to estimate propensity for 
prescription of SGLT2i for each treatment group, SU and DPP4i. I selected the 
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SGLT2i treated group as the referent because this category was the smallest 
treatment arm. Then, I used an iterative process to identify the optimum balance in 
terms of baseline covariates. To further achieve close matching at baseline for the 
covariate of interest; eGFR, HbA1c, systolic BP and BMI I applied additional exact-
matching criteria for baseline measure. The ‘exact measure’ was achieved by 
grouping the baseline measure, for example, grouping baseline eGFR according to 
quintiles, and only selected individuals that matched to eGFR quintiles at baseline.  
To improve the power of the study, as there were many more people treated with 
SUs and DPP4is than SGLT2is, I sought more than one match to each SGLT2i 
treated individual. To reflect the ratio of people treated with SUs and DPP4is, I 
sought five SU treated and four DPP4i treated individuals for each person treated 
with SGLT2is. To balance the contribution of each individual, where too few 
matches were found for a SGLT2i treated person, greater weights were given to the 
matches found. The steps taken to create the final matched sets are illustrated in 
Table 6.1. 
After  matching on propensity score I applied a linear mixed model to model changes 
in BMI, systolic blood pressure, eGFR and HbA1c after starting the drugs of interest. 
The equation for the linear mixed model is given for the eGFR regression below: 
!"#$%& = () + (+,-$." = 20 + (1,-$." = 30 + (34556 +	(845561+ (945563 + (:,4556;<= = 10 ×	,-$." = 20+	( ,4556;<= = 10 × ,-$." = 30 +⋯+	")% +	#%& 
, for repeated eGFR measure j in patient i.   
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Summary Graphical representation 
1 
Estimate propensity score for SGLT2i in 
pairwise regressions. 
Identify nearest neighbour matches for 
each SGLT2i, without replacement. In 
both groups, SGLT2i vs Su and vs. 
DPP4i. 
Find 1 match for each SGLT2i.  
2 
Try to find additional matches for the 
SGLT2i cases chosen in step one. 
Select further matches only from pool of 
SUs or DPP4i not previously selected. 
Aim for 5 SU matches for each SGLT2i 
and 4 DPP4i matches. 
Repeat process until enough matches 
found, or no further matches found within 
calliper. 
 
3 Discard SGLT2i treated individuals not found a match in the SU and DPP4i sets   
4 
Where 5:1:4 matching was not achieved; 
I assigned weights to under-matched 
groups. 
 
Table 6.1 Detail of steps taken to create propensity score matched sets of 
individuals prescribed DPP4is, SGLT2is or SU. The aim for number of 
matches, m and n, was five and four respectively to reflect the ratio of SU and 
DPP4i users compared to SGLT2i group.  
Abbreviations: SU: Sulfonylureas, SGLT2is: Sodium-glucose cotransporter-2 
inhibitors, DPP4is: Dipeptidyl peptidase 4 inhibitors
SU
1:1 1:1
SGLT2i 
recipients
DPP4i
Pool of previously 
unselected SU 
Pool of previously 
unselected DPP4i 
+SU
+DPP4i
n:1
1:m
SGLT2i
SGLT2i
n:1:m
Matched sets
5:1:4 Optimum matched set achievedWeights assigned 1/5 : 1 : 1/4
2:1:4 Too few matched achieved for SUsWeights assigned (1/5 x 5/2 ): 1 : 1/4
5:1:3 Too few matched achieved for DPP4isWeights assigned 1/5 : 1 :  (1/4 x 4/3)
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Abstract
Aim: To assess the comparative effects of sodium-glucose co-transporter-2 (SGLT2)
inhibitors, sulphonylureas (SUs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on car-
diometabolic risk factors in routine care.
Materials and methods: Using primary care data on 10 631 new users of SUs, SGLT2
inhibitors or DPP-4 inhibitors added to metformin, obtained from the UK Clinical
Practice Research Datalink, we created propensity-score matched cohorts and used
linear mixed models to describe changes in glycated haemoglobin (HbA1c), estimated
glomerular filtration rate (eGFR), systolic blood pressure (BP) and body mass index
(BMI) over 96 weeks.
Results: HbA1c levels fell substantially after treatment intensification for all drugs:
mean change at week 12: SGLT2 inhibitors: −15.2 mmol/mol (95% confidence inter-
val [CI] –16.9, −13.5); SUs: −14.3 mmol/mol (95% CI –15.5, −13.2); and DPP-4
inhibitors: −11.9 mmol/mol (95% CI –13.1, −10.6). Systolic BP fell for SGLT2 inhibi-
tor users throughout follow-up, but not for DPP-4 inhibitor or SU users: mean
change at week 12: SGLT2 inhibitors: −2.3 mmHg (95% CI –3.8, −0.8); SUs:
−0.8 mmHg (95% CI –1.9, +0.4); and DPP-4 inhibitors: −0.9 mmHg (95% CI
–2.1,+0.2).
BMI decreased for SGLT2 inhibitor and DPP-4 inhibitor users, but not SU users:
mean change at week 12: SGLT2 inhibitors: −0.7 kg/m2 (95% CI –0.9, −0.5); SUs:
0.0 kg/m2 (95% CI –0.3, +0.2); and DPP-4 inhibitors: −0.3 kg/m2 (95% CI –0.5, −0.1).
eGFR fell at 12 weeks for SGLT2 inhibitor and DPP-4 inhibitor users. At 60 weeks,
the fall in eGFR from baseline was similar for each drug class.
Conclusions: In routine care, SGLT2 inhibitors had greater effects on cardiometabolic
risk factors than SUs. Routine care data closely replicated the effects of diabetes
drugs on physiological variables measured in clinical trials.
Received: 10 October 2019 Revised: 10 January 2020 Accepted: 15 January 2020
DOI: 10.1111/dom.13970
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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1 | INTRODUCTION
Type 2 diabetes mellitus is a leading cause of morbidity and mortality
worldwide, resulting in one million deaths worldwide in 2017.1 Drug
treatments often provide benefits for glycaemic control and surrogate
outcomes but, recently, clinical trials of sodium-glucose co-transporter
2 (SGLT2) inhibitors have shown substantial reductions in adverse car-
diovascular and renal outcomes.2-5 In these major outcome trials, SGLT2
inhibitors have been compared to placebo, contrasting with the way the
drugs have been recommended for use in clinical practice: international
guidelines have recommended SGLT2 inhibitors as an option to intensify
glycaemic control after metformin monotherapy, but with sulphonylureas
(SUs), thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors or
glucagon-like peptide-1 (GLP-1) receptor agonists as alternate choices.6,7
The SGLT2 inhibitors work by inhibiting reabsorption of glucose in
the proximal renal tubule and thus lowering blood glucose levels. As well
as improved glycaemic control, this results in weight loss, blood pressure
reduction and diuresis.8 In clinical trials of SGLT2 inhibitors, patients in
the active treatment arm have shown lower blood pressure and better
glycaemic control compared to patients in the placebo arm.2-5 There is
limited evidence, however, that lower blood pressure or tighter diabetic
control is associated with better cardiovascular outcomes9,10; therefore,
it is not clear whether the improved clinical outcomes in SGLT2
inhibitor-treated patients are explained by improvements in known car-
diovascular and renal risk factors, which might also occur for other drug
classes in direct comparator trials, or whether other mechanisms exist.11
Observational studies have compared major outcomes in SGLT2
inhibitor users with those in people who have no additional treatment,
and also with those in people using active comparator agents.12-17
These studies also report substantial outcome benefits for SGLT2 inhib-
itor users but have been criticised for failing to adequately account for
sources of bias and confounding, in particular, for the fact that SGLT2
inhibitors were prescribed to younger patients with fewer com-
orbidities.18 Only few observational studies have examined the effects
of first-line intensification drugs for type 2 diabetes on biological vari-
ables and these have mainly focused on the comparative effects of drug
classes on glycaemic control.19-21 The effects of SGLT2 inhibitor drugs
on physiological variables, such as blood pressure, measured in routine
care, and how these relate to the results observed within the standard-
ized setting of clinical trials, are currently unknown.
The use of DPP-4 or SGLT2 inhibitors for first-stage intensification
of control of type 2 diabetes has been increasing rapidly in routine clini-
cal care over recent years, with wide variation in prescribing patterns.22
There has been relative equipoise for choice of intensification drug
offered by current clinical guidelines, and limited differences in the
characteristics of people prescribed different drugs which are well
understood and measureable.23 This combination of circumstances
means that observational data lend themselves to a natural experiment:
making direct comparisons of medication effects on important diabetes
outcomes in a routine care population at the first stage of treatment
intensification when SGLT2 inhibitors are commonly used.
Incentivised by the Quality Outcomes Framework, people with
type 2 diabetes are regularly monitored in UK primary care, and
measures of diabetic control, cardiovascular risk and renal function
are recorded well in routine data.24 We conducted a propensity-score
matched, new-user cohort study to determine the effects of the three
most commonly used drugs for intensification of glycaemic control
after metformin monotherapy, SGLT2 inhibitors, DPP-4 inhibitors and
SUs, on measures of cardiovascular and renal risk.22
2 | MATERIALS AND METHODS
2.1 | Data sources
We used data from the Clinical Practice Research Datalink (CPRD),
which covers ~7% of the UK population and is representative in terms
of age, sex and ethnicity.25 The data contain information collected by
general practitioners and primary care practitioners for routine patient
care in primary care settings. Data collected include demographic
information, medical diagnoses, prescriptions, laboratory test results
and diagnoses made in secondary care. Our data were linked to
patient-level quintiles of index of multiple deprivation (IMD) scores
collated in 2015 as a measure of socioeconomic deprivation, provided
by the Office of National Statistics.26
2.2 | Study population
To reflect prescribing of drugs used to intensify treatment of type
2 diabetes in contemporary routine clinical practice, we selected a
new-user cohort of adults adding additional treatment to metformin
monotherapy (study population). We first identified a study popula-
tion of individuals aged ≥18 years with a new record of metformin
use before any other antidiabetic medication between January 2000
and July 2017. We restricted the study to people with a minimum of
12 months of prior registration in the CPRD to allow complete data
entry and to ensure they were new-users of antidiabetic drugs. From
this group, we identified people prescribed one of the potential anti-
diabetic drug choices recommended by the National Institute of
Health and Care Excellence (NICE) at the first stage of treatment
intensification, defined as the “index” drug, between January 2014
and July 2017. Based on previous work we excluded people intensify-
ing treatment with a thiazolidinedione, insulin or a GLP-1 receptor
agonist as these treatments have been infrequently used in recent
years and/or fall outside the standard first-stage guidance.22 We
excluded women who were pregnant before and after treatment
change as guidelines are different for pregnant or breastfeeding
women.
To limit the study population to people who intensified rather
than changed treatment, we required that 1) a second prescription for
the index drug was recorded within 60 days after the end of the first
prescription and 2) the individual received a further metformin pre-
scription between the first and second prescription for an intensifica-
tion drug. We used the date of the first prescription for the first-stage
intensification drug as baseline/study entry.
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2.3 | Outcomes
We chose four clinical measures that are associated with future risk
of cardiovascular disease or diabetic complications: glycated
haemoglobin (HbA1c); systolic blood pressure (BP); body mass index
(BMI); and estimated glomerular filtration rate (eGFR).27,28 For each
measure we extracted all test results for HbA1c, systolic BP, weight
and height to calculate BMI, and serum creatinine to calculate eGFR
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation.29 We then created four cohorts which are subsets of
the study population for each clinical measure (Figure 1). To be
included in a cohort, patients were required to have at least one
record of the measure within 540 days prior to drug treatment inten-
sification and at least one follow-up recording of the variable of inter-
est. Participants in each cohort were followed until the first of: death,
leaving the practice, prescription of an alternative drug treatment for
type 2 diabetes, or end of study (July 1, 2017).
2.4 | Descriptive variables and covariates
Details of our cohort methodology have been published previously.23
Baseline covariates are those recorded prior to index drug prescrip-
tion. We only included measurements within 540 days prior to base-
line as older values might not reflect the values at the point of
treatment intensification. This time point was chosen pragmatically
based on the Quality Outcomes Framework recommendation that
patients with diabetes have full clinical review annually, with addi-
tional time for delays in arranging appointments and for data entry.30
Medical diagnoses such as cardiovascular disease and retinopathy
were defined as present if they were listed in the medical record on or
before the date of drug intensification. We defined use of
angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers or statins as any prescription for such a drug in the year
before the start of follow-up.
2.5 | Statistical analysis
2.5.1 | Propensity-score matching
Variables considered as potential confounders, based on previous
work defining factors associated with drug prescription,23 were: age;
gender; ethnicity; baseline values of HbA1c, eGFR, BMI and systolic
BP; baseline diagnosis of cardiovascular disease, retinopathy or cur-
rent smoking; quintile of IMD score; time taking metformin before
intensification; and the year that treatment was intensified.
Propensity-score matching between the three classes of drugs
was used to assemble a sample in which each patient receiving SGLT2
inhibitors was matched to up to four patients prescribed DPP-4 inhibi-
tors and up to five patients prescribed SUs. These matching goals
were chosen to reflect the relative number of users in each group.
F IGURE 1 Flow diagram of study
participants. BMI, body mass index;
BP, blood pressure; CPRD, Clinical
Practice Research Datalink; DPP-4,
dipeptidyl peptidase-4; eGFR,
estimated glomerular filtration rate;
HbA1c, glycated haemoglobin; SU,
sulphonylurea; SGLT2, sodium-
glucose co-transporter-2
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Each matched set had to include a minimum of one patient from each
of the three treatment groups being compared. Patients were mat-
ched without replacement on the propensity score within a calliper of
0.025, ~0.2 times the standard deviation of the propensity score. The
estimated propensity scores were obtained from logistic regression.
An iterative approach to the selection of confounders was taken,
including a potential confounder in the model if required to obtain
balance of the variable across treatment groups, as measured by the
standardized mean difference, accepting imbalances up to 0.2. We
matched cohorts on their baseline measures of BMI, systolic BP, eGFR
or HbA1c by including additional “exact” matching on each variable.
To account for the variability in the number of individuals in the mat-
ched sets, patients in incomplete sets were up-weighted to give each
matched set equal weight.31 Separate propensity-score models were
fitted to each sub-cohort (one for each outcome measure). Missing
data in confounders were handled using a missing category
approach.32
2.5.2 | Mixed effects linear regression
For each continuous outcome, we applied mixed effects linear
regression models to the matched samples, with a random effect
for patient, to estimate the mean of the measure over time, for
each treatment group. We fitted a cubic model for the outcome
over time. Follow-up time was split at 12, 24, 36, 60, 84 and
96 weeks, with cut-offs based on commonly reported time periods
in clinical trials. Treatment effects were estimated separately in
each time band. We used these models to estimate differences in
means at 12 and 60 weeks compared to week zero. Overall differ-
ences across the 96-week period were obtained by averaging the
period-specific treatment effect estimates and weighting by the
duration of the period. To explore differential drop out over
follow-up, we calculated mean baseline level of HbA1c, eGFR, sys-
tolic BP and BMI for all patients remaining in the analysis popula-
tion at each follow-up time point.
2.5.3 | Sensitivity analyses
To assess the robustness of results to the assumptions made in our
primary analysis we completed a series of sensitivity analyses. First,
we applied the mixed effects models to 1:1:1 matched samples (rather
than matched sets with varying numbers of matches). Second, we
removed the censoring when patients were prescribed an additional
or alternative diabetic medication, to obtain results analogous to an
intention-to-treat estimate. Third, we assessed the impact of con-
ducting a complete case analysis by imputing missing data using
chained equations. Fourth, we restricted the analysis to patients who
had at least one baseline and one follow-up measure for all four out-
come measures, to determine whether the primary results were
influenced by inclusion of patients without select measures into dif-
ferent cohorts. Fifth, we excluded individuals from the analysis if they
had high numbers of tests for each measure (eGFR, HbA1c, BMI or
systolic BP) during follow-up to assess whether frequent measure-
ments had an impact on the findings.
2.6 | Patient and public involvement statement
Patients were not involved in the design or conduct of the study. We
plan to disseminate the results through peer-reviewed publication.
2.7 | Ethics approval
The protocol for this research was approved by the Independent Sci-
entific Advisory Committee of the Medicines and Healthcare products
Regulatory Agency Database Research (number 16_267). This study
was also approved by the London School of Hygiene and Tropical
Medicine Ethics Committee, ref: 11923.
3 | RESULTS
Within the study population of individuals who intensified from met-
formin monotherapy with an SU, a DPP-4 inhibitor or a SGLT2 inhibi-
tor, 40% were women and the mean age, BMI, eGFR and systolic BP
were 60 years, 33 kg/m2, 89 mL/min/1.73m2 and 133 mmHg, respec-
tively (Table 1). The subcohorts for each physiological variable of
interest were as follows: eGFR, n = 5067; HbA1c, n = 5392; BMI,
n = 6587 and systolic BP, n = 7958. Details of the cohort selection are
provided in Figure 1.
3.1 | Propensity-score matched analysis
Initial imbalances in baseline characteristics across treatment groups
were minimized after propensity-score matching, for each cohort
(HbA1c, eGFR, BMI and systolic BP; Figure S1). The propensity scores
for SGLT2 inhibitors showed substantial overlap across the three
treatment groups (Figure S2).
Table S1 describes the unmatched SGLT2 inhibitor users and
Table S2 shows the number of matches identified for each cohort.
The proportion of SGLT2 inhibitor users not matched ranged from 3%
in the BMI cohort to 11% in the systolic BP cohort. The length of
follow-up (days) and number of repeated measures did not vary sub-
stantially between each clinical variable (Table S3).
Table 2 provides the baseline characteristics of the largest
propensity-score matched cohort, that for HbA1c. Baseline character-
istics for the eGFR, systolic BP and BMI matched cohorts are shown
in Tables S4 to S6. After propensity-score matching, cohorts were
well matched on baseline covariates, and closely matched on the
baseline physiological variables of interest. Figure S2 shows the per-
centage standardized mean difference in baseline covariates for
unmatched and matched cohorts, for each measure.
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Estimated mean values of each clinical measure for each treat-
ment group at the analysed time points, and changes from baseline,
from linear mixed models fitted within the propensity-score matched
cohorts are shown in Figure 2 and Table S7.
HbA1c fell substantially after intensification from a baseline of
76 to 77 mmol/mol for all drugs, but this fall was greatest for SGLT2
inhibitor users. The mean fall at week 12 was −15.2 mmol/mol (95%
CI –16.9, −13.5) for SGLT2 inhibitor users, −14.3 mmol/mol (95% CI
–15.5, −13.2) for SU users and − 11.9 mmol/mol (95% CI –13.1,
−10.6) for DPP-4 inhibitors users. This fall compared to baseline was
similar at 60 weeks of follow-up for all drug classes. The mean differ-
ence over 96 weeks of follow-up for SGLT2 inhibitor users was
TABLE 1 Description of the study population at baseline for individuals intensifying treatment from metformin monotherapy with
sulphonylureas, sodium-glucose co-transporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors between 2014 and 2017
SUs N = 5010 SGLT2 inhibitors N = 1187 DPP-4 inhibitors N = 4434
Age, years 61 (13) 55 (10) 61 (12)
Women, n (%) 1988 (39.7) 474 (39.9) 1745 (39.4)
BMI, kg/m2 32 (6) 37 (7) 33 (7)
Missing, n (%) 470 (9.4) 54 (4.5) 285 (6.4)
eGFR, mL/min/1.73m2 89 (18) 96 (13) 88 (18)
Missing, n (%) 1683 (33.6) 493 (41.5) 1568 (35.4)
Systolic BP, mmHg 133 (14) 134 (14) 133 (14)
Missing, n (%) 837 (16.7) 293 (24.7) 880 (19.8)
HbA1c, mmol/mol 80 (21) 77 (17) 73 (16)
Missing, n (%) 2180 (43.5) 629 (53) 2085 (47)
Metformin treatment, months 40 (37) 36 (33) 44 (37)
Cardiovascular disease, n (%) 707 (14.1) 119 (10) 601 (13.6)
Heart failure, n (%) 194 (3.9) 24 (2) 146 (3.3)
Retinopathy, n (%) 868 (17.3) 181 (15.2) 861 (19.4)
ACE inhibitor/ARB treatment, n (%) 2711 (54.1) 670 (56.4) 2490 (56.2)
Statin treatment, n (%) 3530 (70.5) 819 (69) 3387 (76.4)
IMD, n (%)
1 (least deprived) 467 (9.3) 93 (7.8) 398 (9.0)
2 485 (9.7) 99 (8.3) 378 (8.5)
3 567 (11.3) 117 (9.9) 449 (10.1)
4 643 (12.8) 99 (8.3) 427 (9.6)
5 (most deprived) 589 (11.8) 81 (6.8) 479 (10.8)
Missing 2259 (45.1) 698 (58.8) 2303 (51.9)
Smoking status, n (%)
Non-smoker 1883 (37.6) 462 (38.9) 1642 (37.0)
Current 818 (16.3) 193 (16.3) 688 (15.5)
Ex-smoker 2297 (45.8) 532 (44.8) 2102 (47.4)
Missing 12 (0.2) N < 5 N < 5
Ethnicity, n (%)
White 2052 (41.5) 500 (42.1) 1944 (43.8)
South Asian 229 (4.6) 31 (2.6) 146 (3.3)
Black 122 (2.4) 9 (0.8) 61 (1.4)
Other 59 (1.2) 5 (0.4) 26 (0.6)
Mixed heritage 14 (0.3) N < 5 16 (0.4)
Missing 2534 (50.6) 640 (53.9) 2241 (50.5)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin 2 receptor blocker; BMI, body mass index; BP, blood pressure; DPP-4, dipeptidyl
peptidase-4; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; IMD, index of multiple deprivation; SGLT2, sodium-glucose
co-transporter-2; SU, sulphonylurea.
Note: Values for continuous values are mean (SD) and categorical values are n (%), as indicated. % values are of entire cohort. Frequencies below five not
stated as per Medicines and Healthcare products Regulatory Agency database research policy.
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−5.4 mmol/mol (95% CI –7.4, −3.4) compared to DPP-4 inhibitor
users and −1.7 (95% CI –3.7, +0.2) compared to SU users.
Baseline systolic BP was 134 to 135 mmHg and fell for SGLT2
inhibitors users throughout follow-up, but not for DPP-4 inhibitor or
SU users. The mean fall at week 12 was −2.3 mmHg (95% CI –3.8,
−0.8) for SGLT2 inhibitor users, −0.8 mmHg (95% CI –1.9, +0.4) for
SU users and − 0.9 mmHg (95% CI –2.1, +0.2) for DPP-4 inhibitor
users. At 60 weeks, systolic BP remained lower than baseline for
SGLT2 inhibitor users but not for other drug classes. The mean differ-
ence over 96 weeks of follow-up for SGLT2 inhibitor users was
TABLE 2 Description of the propensity-score matched and weighted glycated haemoglobin cohort at baseline for individuals intensifying
treatment from metformin monotherapy with sulphonylureas, sodium-glucose co-transporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors
between 2014 and 2017
SUs SGLT2 inhibitors DPP-4 inhibitors
Number of individualsa 1691 481 1445
Counts after weighting 481 481 481
Age, years 56.4 (11.3) 56.3 (9.6) 56.6 (10.6)
Women, n (%) 191 (40) 191 (40) 190 (39)
BMI, kg/m2 34.4 (5.4) 34.8 (5.5) 34.3 (5.4)
eGFR, mL/min/1.73m2 93.5 (15.4) 93.3 (12.2) 93.3 (14.7)
Systolic BP, mmHg 133.9 (13.3) 133.7 (12.4) 133.7 (13.2)
HbA1c, mmol/mol 76.7 (18.2) 76.4 (16.8) 76.7 (16.6)
Metformin treatment, months 36.1 (34.4) 38.0 (32.9) 38.2 (35.2)
Cardiovascular disease, n (%) 57 (12) 45 (9) 51 (11)
Heart failure, n (%) 14 (3) 12 (2) 11 (2)
Retinopathy, n (%) 79 (16) 75 (16) 88 (18)
ACE inhibitor/ARB treatment, n (%) 252 (52) 278 (58) 252 (52)
Statin treatment 337 (70) 339 (70) 360 (75)
IMD
1 (least deprived) 50 (10) 51 (11) 50 (10)
2 51 (11) 54 (11) 51 (11)
3 59 (12) 60 (12) 61 (13)
4 41 (9) 40 (8) 37 (8)
5 (most deprived) 35 (7) 37 (8) 36 (7)
Missing 245 (51) 239 (50) 246 (51)
Smoking status, n (%)
Non-smoker 178 (37) 199 (41) 182 (38)
Current 87 (18) 75 (16) 73 (15)
Ex-smoker 213 (44) 207 (43) 225 (47)
Missing <5 <5 <5
Ethnicity, n (%)
White 202 (42) 194 (40) 192 (40)
South Asian 9 (2) 11 (2) 11 (2)
Black 6 (1) 7 (1) 6 (1)
Other <5 <5 <5
Mixed heritage <5 <5 <5
Missing 261 (54) 267 (56) 269 (56)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin 2 receptor blocker; BMI, body mass index; BP, blood pressure; DPP-4, dipeptidyl
peptidase-4; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; IMD, Index of multiple deprivation; SU, sulphonylurea; SGLT2,
sodium-glucose co-transporter-2.
aNumber of individuals contributing data to the HbA1c analysis, before weighting was applied. Values for categorical values are weighted mean (SD) and
categorical values are n (%), as indicated, of entire cohort. After iteration of the propensity-score model, the following covariates were included in the
model: age; HbA1c; eGFR; BMI; systolic BP; patient-level IMD score; and ethnicity. The groups were further matched on decile of baseline HbA1c.
Figures provided are weighted means or counts. Frequencies below five not stated as per MHRA Database Research policy.
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−1.82 mmHg (95% CI –3.18, −0.45) compared to DPP-4 inhibitor
users and −3.06 mmHg (95% CI –4.43, −1.68) compared to SU users.
Mean BMI at baseline was 36 to 37 kg/m2 and fell compared to
baseline over follow-up for SGLT2 inhibitor and DPP-4 inhibitor users.
The mean fall at week 12 was −0.7 kg/m2 (95% CI –0.9, −0.5) for
SGLT2 inhibitor users, 0.0 kg/m2 (95% CI –0.3, +0.2) for SU users
and −0.3 kg/m2 (95% CI –0.5, −0.1) for DPP-4 inhibitor users. At
60 weeks, BMI remained lower than baseline for SGLT2 inhibitor and
DPP-4 inhibitor users but not SU users. These falls in BMI are equiva-
lent to a weight loss of 2.3 kg for a DPP-4 inhibitor user and 5.0 kg
for an SGLT2 inhibitor user at 60 weeks of treatment for a person
1.7 m tall, the mean height of the cohort of patients who were pre-
scribed SGLT2 inhibitors. The mean difference over 96 weeks of
follow-up for SGLT2 inhibitor users was −0.92 kg/m2 (95% CI –1.17,
−0.66) compared to DPP-4 inhibitor users and −1.67 kg/m2 (95% CI
–1.95, −1.38) compared to SU users.
Baseline eGFR was 95 mL/min/1.73m2 and fell at 12 weeks for
SGLT2 inhibitor and DPP-4 inhibitor users. The mean fall at week
12 was −3.1 mL/min/1.73m2 (95% CI –4.1, −2.0) for SGLT2 inhibitor
users, the mean increase was +0.5 mL/min/1.73m2 (95% CI –0.4,
+1.3) for SU users and the mean fall was −1.0 mL/min/1.73m2 (95%
CI –1.9, −0.2) for DPP-4 inhibitor users. At 60 weeks, the fall in eGFR
from baseline was ~2 mL/min/1.73m2 for each drug class. The mean
difference over 96 weeks of follow-up for SGLT2 inhibitor users was
−0.03 mL/min/1.73m2 (95% CI –1.01, 0.94) versus DPP-4 inhibitor
users and −0.78 mL/min/1.73m2 (95% CI –1.82, −0.27) versus SU
users.
During and at the end of follow-up participants who remained in
the cohort were similar in their baseline characteristics to the entire
cohort at baseline, suggesting that differential loss to follow-up of
patients whose health status varied importantly from the entire
cohort had not occurred (Tables S8–S11).
Results of all sensitivity analyses were all similar to those of the
main analysis (Figures S3–S7 and Table S12). The distribution of base-
line covariates for individuals excluded because of missing baseline or
follow-up data was similar to that in the study population
(Tables S14–S17).
4 | DISCUSSION
In the present study, we robustly estimated and compared the effects
of the three drug options commonly used to intensify metformin mon-
otherapy – SUs, SGLT2 inhibitors and DPP-4 inhibitors – on HbA1c,
BMI, systolic BP and eGFR in UK primary care. In cohorts of people
with similar baseline characteristics and levels of each clinical measure
we show that all three drug options were associated with large falls in
HbA1c, with better overall glycaemic control for people prescribed
SGLT2 inhibitors. People prescribed DPP-4 inhibitors and SGLT2
inhibitors experienced falls in BMI that were sustained over the study
duration, with those prescribed SGLT2 inhibitors experiencing about
twice the weight loss observed for DPP-4 inhibitor users. Systolic BP
fell compared to baseline at 12 weeks for SGLT2 inhibitor users but
not for users of the other drug classes. Over the study duration, sys-
tolic BP was ~3 mmHg lower for those prescribed SGLT2 inhibitors
compared to those prescribed SUs; however, the CIs for the estimates
of systolic BP were large, and overlapped for the SGLT2 inhibitor and
DPP-4 inhibitor cohorts. Users of SGLT2 inhibitors demonstrated falls
in eGFR at 12 weeks of treatment but, over time, the fall in eGFR was
small and similar for each drug class.
F IGURE 2 Mean (95% confidence
intervals) of each clinical measure
during treatment for propensity-score
matched individuals after
intensification with a dipeptidyl
peptidase-4 (DPP-4) inhibitor, a
sodium-glucose co-transporter-2
(SGLT2) inhibitor or a sulphonylurea
(SU) following metformin
monotherapy. BMI, body mass index;
BP, blood pressure; eGFR, estimated
glomerular filtration rate; HbA1c,
glycated haemoglobin
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The major strength of the present study is that it reflects recent
clinical practice, where relative equipoise about choice of drug class
and wide national variation in choice create an opportunity for direct
comparison of drug effects. Selecting patients whose drug therapy is
being intensified at the same stage of treatment reduces time-related
bias. We have previously examined the differences in characteristics
of patients prescribed each drug class in detail and, based on this,
have used propensity-score matching to achieve cohorts of patients
very similar in baseline characteristics. Regular monitoring of people
with type 2 diabetes in UK primary care provided extensive data,
enabling us to use the vast majority of participants from our baseline
cohort for modelling each clinical variable.
The relatively short period over which SGLT2 inhibitors have
been used in UK primary care, however, means that the sample size
was smaller than that of many primary care database studies, with a
follow-up of 2 years, shorter than recent clinical trials. This means that
we can only examine class effects and the study would be underpow-
ered to detect drug-specific effects and endpoints such as cardiovas-
cular disease mortality. We classified the start date of treatment for
each intensification drug from the first record in primary care. For a
proportion of patients who initiated the drugs in secondary care, this
date would be misclassified. Our “baseline” values of physiological
variables may therefore have been measured after treatment had
started. However, this would have led to underestimation of early dif-
ferences and, given the short duration of prescriptions issued in sec-
ondary care, we would anticipate that this would affect only a very
small proportion of our results. Proteinuria data were insufficiently
complete to use as a variable in our analysis.
Our study design focused on providing matches of patients pre-
scribed DPP-4 inhibitors and SUs to patients prescribed SGLT2 inhibi-
tors. This means that the results are generalizable only to
contemporary SGLT2 inhibitor users in primary care who had, for
example, a high BMI and well preserved renal function compared to
users of other drug classes. Patients with a relative contraindication
for a drug, for example, those with poor renal function (and therefore
prescribed DPP-4 inhibitors or SUs), would not have been matched.
Nonetheless, this study design does provide a robust comparison of
the drug effects in routine care for patients for whom there was the
possibility of being prescribed one of the three drug classes.
Finally, we sought to study the biological effects of the drug clas-
ses, therefore, we censored follow-up when patients commenced
treatment with an alternative drug class, analogous to an “as-treated”
analysis in a clinical trial. If a greater proportion of patients stopped
treatment with one of the drug classes this would limit the validity of
between-drug comparisons, particularly if the decision to stop treat-
ment was associated with an outcome variable (such as failure for
glycaemic control to improve). However, we saw similar results in our
simulated “intention-to-treat” analysis, where we did not censor
patients when they changed treatment, suggesting that this has not
substantially impacted our results. As a small proportion of the cohort
(4%) stop the initial drug and do not restart a different diabetic treat-
ment (which would lead to censoring), clinical measures early on in
the study period are likely to most closely represent the “as-treated”
drug effects.
As we have shown previously, SGLT2 inhibitors are prescribed to
a different population in UK primary care compared to patients
enrolled in recent major outcome trials (Table S13).23 Participants in
our study were younger, with better renal function, and included a
lower proportion of people with cardiovascular disease, heart failure
and retinopathy. Our study population had poorer glycaemic control
and was heavier at baseline compared to participants in recent cardio-
vascular outcome studies. Perhaps related to this, our study partici-
pants also showed greater improvement after initiating SGLT2
inhibitors compared to trial participants. We found a fall in HbA1c
equivalent to 1.4% after 12 weeks of treatment, while clinical trial
HbA1c fall estimates range from −0.25% (95% CI –0.31, −0.20) in
CREDENCE to −0.58% (95% CI 0.61, −0.56) in CANVAS.
For patients commencing SGLT2 inhibitors, the present study
estimated falls in BMI compared to baseline equivalent to weight loss
of 2 kg at 12 weeks for an individual 1.7 m tall. Outcome studies
show weight loss ranging from 1 kg at 12 weeks in CREDENCE to
2 kg at 6 months in DECLARE-TIMI. At the end of the present study,
mean weight loss compared to baseline was 5 kg for SGLT2 inhibitor
users compared to 2 kg in CREDENCE and 4 kg in DECLARE-TIMI.
Falls in BP and eGFR on initiating treatment with SGLT2 inhibi-
tors are widely recognized and, in the present study, we found striking
similarities between the effects seen in clinical trials and in our routine
care population, although there is substantial uncertainty around our
estimates. We found a mean fall in systolic BP of 2.3 mmHg (95% CI
–3.8, −0.8) compared to baseline at 12 weeks for SGLT2 inhibitor
users, but no fall for those prescribed other drug classes. Trial falls in
systolic BP compared to baseline range from 2.8 mmHg at 12 weeks
in the CREDENCE study to 5.5 mmHg in EMPA-REG (10-mg dose
arm). Over the duration of the study, our results showed a mean dif-
ference in systolic BP of −3.06 mmHg (95% CI –4.43, −1.68) com-
pared to SU-treated patients. Estimates compared to placebo in
clinical trials were very similar, ranging from −2.7 mmHg (95% CI –
3.0, −2.4) in the DECLARE-TIMI study to −3.93 mmHg (95% CI –
4.30, −3.56) in CANVAS.
For renal function we found a fall in eGFR of −3.1 mL/
min/1.73 m2 (95% CI –4.1, −2.0) at 12 weeks, similar to that observed
at 3 weeks (−3.72 ± 0.25 mL/min/1.73 m2) in CREDENCE and the
same as that observed in CANVAS at 12 weeks (−3.1 ± 0.1 mL/
min/1.73 m2). At 60 weeks we saw a fall of −2.2 mL/min/1.73 m2
(95% CI –3.6, −0.7), again, very similar to estimates reported in clinical
trials, for example, a slope of 2.74 mL/min/1.73 m2 per year (95% CI
2.37, 3.11) in CREDENCE. However, unlike the clinical trials, falls in
eGFR in our comparison group were not different from those in
SGLT2 inhibitor-treated patients, ~2 mL/min/1.73 m2 at 60 weeks for
patients treated with SUs and DPP-4 inhibitors. By contrast placebo-
treated patients in CREDENCE had a slope of decline of renal function
of −4.59 mL/min/1.73 m2 per year, while in CANVAS they had a dif-
ference from baseline of −3.9 ± 0.2 mL/min/1.73 m2 at a mean
follow-up of 188 weeks.
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These results demonstrate the huge value of primary care data
for conducting observational research. Estimates for both improve-
ment in glycaemic control and HbA1c were very similar to those
found in previous research on intensification of treatment for type
2 diabetes using the CPRD,19 which provides validation of our
methods. This is the first study to examine how changes in BP and
renal function relate to changes observed in clinical trials using CPRD
data. Given the consistency of the results, we are reassured that the
benefits of SGLT2 inhibitors seen in clinical trials will be maintained in
routine care, although given the lower risk profile of SGLT2 inhibitor-
treated patients, evidence of hard outcome benefits may take longer
to accrue. This is particularly the case for outcomes related to renal
function, where our results suggest that the rate of renal decline is
slower in non-SGLT2-inhibitor-treated patients than that observed in
clinical trials, which may reflect the overall lower risk profile (younger
with higher baseline eGFR) or the tighter glycaemic control seen in
patients treated with other active agents in routine care.
In conclusion, routine primary care data can be used to study the
effect of the new classes of treatments for type 2 diabetes on a range
of biological variables, and provide estimates that are directly compa-
rable to those seen in controlled clinical trials. Although SGLT2 inhibi-
tor use was associated with the largest reductions in glycaemic
control, weight and blood pressure, SUs and DPP-4 inhibitors were
also associated with beneficial changes, reinforcing the need for active
comparator outcome trials of these drugs.
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6.4 Plots of measures for random sample 
To visualise the amount of follow-up available for each individual. I selected a 10% 
random sample of the individuals selected after propensity score matching. Figures 
6.1-6.4 present the values over time for BMI, systolic blood pressure, eGFR and 
HbA1c. These plots demonstrate the value of linear mixed models to summarise the 
mean changes in measures between the drugs of interest. They also show the shorter 
follow-up for the individuals prescribed SGLT2is, as discussed in the limitations of 
Paper 4.  
 
Figure 6.1 BMI during treatment, for 10% random selection of propensity score 
matched cohorts, following intensification with DPP4i, SGLT2i and SU after 
metformin monotherapy 
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Figure 6.2 Systolic Blood Pressure during treatment, for 10% random selection 
of propensity score matched cohorts, following intensification with DPP4i, 
SGLT2i and SU after metformin monotherapy 
 
Figure 6.3 HbA1c during treatment, for 10% random selection of propensity 
score matched cohorts, following intensification with DPP4i, SGLT2i and SU 
after metformin monotherapy 
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Figure 6.4 eGFR during treatment, for 10% random selection of propensity 
score matched cohorts, following intensification with DPP4i, SGLT2i and SU 
after metformin monotherapy 
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6.5 Investigation of clinical outcomes 
As part of my PhD, I also examined clinically relevant endpoints for cardiovascular 
disease, kidney disease, and urinary tract infections (UTI). 
Prior to completing the work, I estimated likely minimal effect sizes detectable for a 
renal outcome. I used estimated sample sizes for each cohort, assuming an outcome 
rate of 3% for renal decline with 80% power, full details in Appendix 6. For the 
smallest SGLT2i cohort, the smallest estimated difference compared to the SU group 
that the study could detect would be 30%. 
However, this calculation was completed at the early planning stages and after 
development of the inclusion and exclusion criteria, the sample size was further 
reduced. More limited numbers in each cohort meant that the minimal effect size 
would need to be greater than 30%. The following section provides a summary of an 
exploratory analysis including crude event rates and adjusted Cox regression 
analyses for a range of clinical outcomes related to type 2 diabetes.  
Population: Individuals that started treatment with metformin monotherapy between 
2000 and 2017, and intensified treatment between January 2014 and July 2017. 
Statistical analyses: Intention-to-treat analysis. Crude event rates and Cox 
regression models to provide adjusted hazard ratios, using the largest cohort, the 
sulfonylureas as the referent drug. I applied multiple imputation to impute missing 
baseline covariates.  
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Results: 
Outcome  Crude outcome rates, without MI 
Events, rates (95% CI) 
Result of Cox 
regression with MI 
HR (95% CI) 
30% fall in eGFR SU 73, 10.02 (7.97, 12.60) Referent 
 SGLT2i 6, 5.88 (2.64, 13.09) 0.97 (0.41, 2.28) 
 DPP4i 46, 8.57 (6.42, 11.45)  0.92 (0.62, 1.37)  
Fall in eGFR to  SU 49, 5.86 (4.43, 7.75) Not applicable 
below  SGLT2i <5     
30 ml/min/1.73m2 DPP4i 29, 4.69 (3.26, 6.75)  
New diagnosis for  SU 79, 7.34 (5.90, 9.15) Referent 
cardiovascular  SGLT2i 8, 4.24 (2.12, 8.47) 0.75 (0.35, 1.59) 
disease DPP4i 45, 5.49 (4.10, 7.34) 0.78 (0.52, 1.17) 
New diagnosis for  SU 46, 3.8 (2.85, 5.08) Referent 
heart failure SGLT2i <5    0.17 (0.02, 1.24) 
 DPP4i 38, 4.12 (3.00, 5.66) 1.05, (0.67, 1.66) 
UTI diagnosis SU 83 6.64 (5.3, 8.24) Referent 
 SGLT2i 17, 8.14 (5.06, 13.09) 1.30 (0.75, 2.25) 
 DPP4i 65, 6.86 (5.38, 8.75) 1.06 (.74, 1.52) 
Table 6.2 Crude outcome rates prior to multiple imputation and results of Cox 
regression analysis with multiple imputation for type 2 diabetes related 
outcomes, comparing SGLT2i and DPP4i users to SU user cohort. 
Adjusted at baseline for age, gender, HbA1c, eGFR, BMI, time taking metformin 
before change, smoking status at baseline and ethnicity. Multiple imputation to 
account for missing data **also adjusted for cardiovascular disease diagnosis 
excluding heart failure at baseline. MI: Multiple imputation 
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Conclusions: Given the small number of SGLT2i users, this analysis cannot rule out 
clinically relevant differences between the drugs prescribed at the first stage of 
treatment intensification. Point estimates indicate possible lower rates of heart failure 
in the SGLT2i group, and higher rates of UTI compared to the SU cohort. A study of 
the long-term rates for clinical outcomes related to type 2 diabetes will require 
longer follow-up and a greater number of users of SGLT2i. Given the growing trend 
for SGLT2i prescribing at this stage of treatment these data should be available soon.  
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7 Chapter 7: Discussion 
 
 
Chapter summary 
• The research presented in this thesis investigates the changing use of 
antidiabetic drugs and applies methods to compare these drugs at the first 
stage of treatment intensification, using observational health data for 
clinically important outcomes.  
•  The outputs from this research include a systematic review of the 
evidence for kidney function outcomes comparing oral antidiabetic drugs 
(Chapter 2) and three observational studies. The first paper describes 
prescribing trends for antidiabetic therapies in the UK (Chapter 4), the 
second identifies associations between patient-level factors and the drugs 
chosen by GPs at the first stage of intensification (Chapter 5). The final 
study is a cohort study that compares changes in eGFR, BMI, BP and 
HbA1c between commonly prescribed drug options (Chapter 6). 
• The work has demonstrated that EHRs can provide insights into drug 
prescribing practices and closely reflect findings from RCTs for 
comparative assessment of new drugs. 
• In this closing chapter, I summarise the strengths and limitations of each 
study, and discuss possible extensions of this work. 
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7.1  Summary of findings 
Completion of this work has relied upon the use of routinely collected electronic 
health records from UK primary care, specifically UK CPRD GOLD. This thesis 
demonstrates the benefits of using electronic health records for comparative drug 
research, and addresses sources of potential bias when using such data. The 
following sections provides a brief overview of the main findings for each study, and 
consideration of the implications for clinical practice. Followed by a section 
discussing the strengths and limitations of the approaches taken as part of this 
research.  
7.1.1 Changing use of antidiabetic drugs in the UK: trends in prescribing 
2000–2017 
Previously known  
NHS England publishes raw prescribing numbers for all drugs prescribed by GPs on 
a monthly basis, and has been doing so since 2010. The data is available in an online 
dataset open to interrogation by the public called Open Prescribing.(125) This data 
shows prescribing patterns at the national level and indicated increased prescribing 
rates of DPP4i and SGLT2i drug classes, across the UK. However, what this data did 
not provide is at what stage GPs were prescribing these new drugs. A study by 
Sharma et al. investigated the use of first line and first stage intensification drugs in 
the UK between 2000 and 2013.(19) This work provides a more specific description 
of the prescribing trends for different stages of treatment, but did not provide 
contemporaneous data, and crucially does not cover the period in which SGLT2is 
became available, 2013 onwards.  
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What the study adds 
Given the striking trends apparent in the Open Prescribing data that showed large 
increases in the use of SGLT2is in England from 2013 onwards, the study presented 
in Chapter 4 shows changes in prescribing in a cohort of individuals at both 
treatment initiation and first stage of therapy intensification. I showed that GP 
prescribing has largely followed NICE prescribing guidance with increasing 
concordance over time. There was a large increase in prescriptions for new drug 
agents at the first stage of intensification. By mid-2017, DPP4is were the most 
prescribed first line intensification treatment (42%, 95% CI: 38, 47), overtaking 
prescriptions of SUs (30%, 95% CI: 25, 35). In 2017, GPs prescribed SGLT2is in 
22% (95% CI: 17, 27) of treatment intensifications. 
Kidney function is a key consideration for treatment choice. The DPP4i linagliptin is 
the only oral drug intended for first stage treatment intensification regardless of 
reduced kidney function without dose adjustments.(137) By contrast, 
recommendations regarding the use of metformin according to kidney function have 
changed. We showed changing prescribing practice for individuals with low renal 
function. However, some people with reduced kidney function are still prescribed 
metformin. For these people, sulfonylureas were the most commonly used first line 
drug, although prescribing of DPP4is for this subgroup has increased. 
In this work, we also identified distinct differences in prescribing practice across the 
countries of the UK. GPs in Northern Ireland prescribed SGLT2is in 18% (95% CI: 
11, 24) of first stage intensifications, whereas those in England used them in 9% 
(95% CI: 7, 11). 
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7.1.2 Factors associated with choice of intensification treatment for type 2 
diabetes after metformin monotherapy: a cohort study in UK primary 
care 
Previously known  
In the analysis of Paper 2 (Study of prescribing trends), a number of observations 
influenced the next stage of work.  
1. GP prescribing practice changed with the availability of new drug options 
2. People with reduced renal function received different drug options 
3. Prescribing varied across regions of the UK 
Evidence from wider literature indicated that GP prescribing can be influenced by 
drug marketing and that local practice guidelines such as those produced by clinical 
commissioning groups (CCGs) may limit availability of more expensive drug 
options without clear evidence of benefit. At the patient level, some drugs may be 
favoured, or contraindicated according to patient characteristics. During the period of 
this study it was thought that SGLT2is would not be effective for people with 
CKD.(138) SGLT2is also promote weight loss.(139)  
Previously published research in other drug areas suggested that GPs might favour 
certain patients when first prescribing new drugs, a phenomenon known as 
channelling. Understanding which factors influence prescribing was important 
before completing an outcome study. 
What the study adds 
The study provides a comprehensive description of the patient characteristics 
associated with prescribing of SUs, DPP4i and SGLT2is between 2014 and 2017, at 
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the first stage of treatment intensification. The study showed evidence of expected 
associations between patient factors and prescribing, based on the characteristics of 
the drug, and others that were unexpected.  
Notably, the analysis showed preferential prescribing of new drugs according to non-
clinical characteristics, with younger, more wealthy and white people being more 
likely to receive newer drug options. This suggested inequality of prescribing. Both 
DPP4is and SGLT2is were favoured for individuals with better glycaemic control: in 
people with HbA1c greater than 75, the odds ratios for prescription of newer drugs 
compared to SUs was 0.70 (95% CI 0.56 to 0.88) and 0.76 (95% CI 0.52 to 1.12) for 
DPP4i and SGLT2is intensification respectively. Furthermore, people that were 
overweight or obese were more likely to received SGLT2is and DPP4is. These 
underlying clinical differences could also be associated with future outcomes.  
This paper therefore influenced the design of the final analysis. The study 
demonstrated that despite people being at the same stage of treatment, there were 
still systematic differences in the patient populations receiving each drug. 
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7.1.3 Comparative effects of sulfonylureas, DPP4is and SGLT2 inhibitors 
added to metformin monotherapy: a propensity-score matched cohort 
study in UK primary care 
Previously known  
Evidence from clinical trials including EMPA-REG, CANVAS, DECLARE-TIMI 
and CREDENCE indicated that SGLT2is may benefit patients, not just by reducing 
blood glucose, but also by reducing long-term cardiovascular and kidney disease 
risk. However, these studies were limited to people with increased risk for 
cardiovascular disease, above the presence of type 2 diabetes.(55-57, 140) People 
that received SGLT2is in practice do not mirror the increased cardiovascular risk 
profiles of the individuals included in these trials. This means that the 
generalisability of the findings from RCTs to the population receiving SGLT2i in 
routine clinical practice is still unknown. Differences between the study populations 
of the RCTs and the population included in our studies are large and potentially 
important to disease progression and outcomes, Figure 7.1, and Table 7.1 
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Figure 7.1 Comparison of people intensifying metformin monotherapy in the 
UK (Paper 3) to people included in SGLT2i RCTs.(51, 63, 126, 143) Where 
studies have not provided overall means or percentages, I used the placebo 
group statistics. 
Abbreviations: SGLT2i: Sodium-glucose co-transporter-2 inhibitor, HbA1c: 
Haemoglobin A1c, eGFR: estimated glomerular filtration rate, BMI: Body mass 
index, BP: Blood pressure, ACEI: Angiotensin converting enzyme inhibitor, ARB: 
Angiotensin 2 receptor blockers. †Renin-angiotensin-aldosterone system inhibitors 
(CANVAS and CREDENCE) where ACEi/ARB statistics not available, aStatins or 
ezetimibe (DECLARE-TIMI), bbiguanides (CREDENCE). 
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 EMPA-
REG 
(2) 
CANVAS 
(3) 
DECLARE-
TIMI (4) 
CREDENCE 
(5) 
Current 
study** 
Mean age (years) 63 63 64 63 56 
Female (%) 28 36 37 34 40 
Mean HbA1c 
(mmol/mol)# 65 66 67 67 76 
Mean Systolic BP 
(mmHg)  135 136 135 140 134 
Mean BMI 
(kg/m2)  31 32 32 31 34 
Mean eGFR 
(mls/min/1.73m2)  74 77 86 56 92 
Cardiovascular 
disease (%) 
98.9c 65.6 40.8 50.4 11 
Retinopathy (%)  21  43 16 
Heart failure (%) 10.1 14.4 10.0 14.8 2 
Concomitant 
medications      
         Prevalent 
metformin users  74 77 82 58
a 100 
         ACE 
Inhibitor users  80 80
† 81$ 100† 54$ 
         Statin users  76 75 75b 69 73 
 
Table 7.1 Comparison of individuals included in our HbA1c matched 
analysis to individuals included in main SGLT2 inhibitor cardiovascular 
outcome trials.(55-57, 140)  
Where studies have not provided overall means or percentage, we have provided the placebo 
group statistics. #converted from % if data not given, **For HbA1c matched cohort, a 
biguanides, †Renin-angiotensin-aldosterone system inhibitors, $ACE Inhibitors or 
Angiotensin receptor blockers, b Statin or ezetimibe, c Cardiovascular risk factors (includes 
coronary artery disease, history of myocardial infarction, coronary artery bypass graft, 
history of stroke, peripheral artery disease, coronary artery disease and cardiac failure ) 
Abbreviations: SU: Sulfonylurea, DPP4i: dipeptidyl peptidase 4 inhibitors, SGLT2i: 
Sodium-glucose co-transporter-2 inhibitors, HbA1c: Haemoglobin A1c, eGFR: estimated 
glomerular filtration rate, BMI: Body mass index, BP: Blood pressure, ACEI: Angiotensin 
converting enzyme inhibitor, ARB: Angiotensin 2 receptor blockers. 
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According to the findings from Paper 3, and summarised in Table 7.1 and Figure 
7.1, people that initiated SGLT2is in routine practice after metformin monotherapy, 
were generally younger (by approximately 8 years) than individuals included in the 
RCTs, with higher BMIs and higher HbA1c. The RCTs also included lower 
proportions of women compared to those treated with SGLT2is in UK primary care. 
Background therapies were also different. In selection of our cohort, we required that 
all individuals were prescribed background metformin therapy, in line with 
recommendations of NICE. In the RCTs, background use of metformin was between 
56.2% (CREDENCE) and 86.1% (DECLARE-TIMI).(56, 57)  
In addition to providing evidence for different patient populations to those treated in 
primary care, the RCTs were also limited in that they were placebo-controlled and so 
did not provide insights into the comparative benefits of the commonly prescribed 
first stage intensification drugs.  
What the study adds 
This study measures the effects of the three most commonly prescribed treatments 
used at the first stage of intensification in routine primary care settings. The study 
compared the drugs in three-way comparisons, from the point of starting new first 
stage intensification medication. By selecting people to be at the same stage of 
intensification and then using propensity score matching, all individuals had similar 
values at baseline for important clinical factors. The results show differences 
between SGLT2is, SUs and DPP4is, in the changes of eGFR, systolic blood 
pressure, BMI and HbA1c over 96 weeks post drug-initiation. SGLT2is were 
associated with greater falls in HbA1c and BMI compared to SUs and DPP4is. In the 
SGLT2i group, HbA1c fell by 16 mmol/mol (95% CI: 14, 19) at 60 weeks, 
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compared to 10 mmol/mol (95% CI: 8, 12) and 14 mmol/mol (95% CI 12, 15) in the 
DPP4i and SU treated cohorts. Considering BMI, the SGLT2i group fell by 1.7 
kg/m2 (95% CI: 1.4, 2.1) and the DPP4i group fell by 0.8 kg/m2 (0.6, 1.0) whereas 
the BMI in the SU group did not appear to change (0.2 kg/m2, 95% CI: 0.0, 0.4). 
Systolic BP fell for SGLT2i users over follow-up but not for those prescribed DPP4i 
or SUs. Mean eGFR decreased over time for each drug class, and was similar across 
classes at 96 weeks.  
The study presented has closely replicated the findings from clinical trials. As 
CRENDENCE and EMPA-REG have shown improved cardio-renal outcomes for 
people using SGLT2is, the results suggest that these benefits could be realised in 
routine settings, and in a broader patient population. Though recently updated ADA-
EASD treatment guidelines now encourage prescribing of SGLT2is to people with 
increased cardiovascular risk.(41)This work suggests that SGLT2is should also be 
considered for lower risk populations. However, further studies are warranted once 
more data has accrued to investigate whether the improved outcomes are realised in 
lower risk populations. 
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7.2 Strengths and limitations  
The research included in this thesis uses routinely collected data from UK primary 
care (CPRD GOLD). The following section outlines the strengths and weaknesses of 
using UK primary care data to complete these studies.  
7.2.1 Strengths 
Representative sample 
CPRD GOLD is a representative sample of the UK population.(88) Most of the 
clinical trials of type 2 diabetes drugs and long-term outcomes are restricted to 
people with cardiovascular risk factors. By using data from a large sample of UK 
GPs, the results from these studies should be generalisable to the UK type 2 diabetes 
population, as treated in routine care. The work presented in this thesis therefore 
adds to results from clinical trials.  
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People with type 2 diabetes are well monitored in UK primary care 
In the UK, treatment for people with type 2 is delivered predominantly in primary 
care, and QOF incentivisation has ensured good monitoring of this group, outlined in 
Chapter 3. There is high level of recording of the variables of interest including 
blood pressure, HbA1c, eGFR and BMI and this minimises information bias.(93)  
Prescribing data to identify stage of treatment intensification 
This thesis predominantly focusses on the drugs prescribed by GPs at the first stage 
of treatment intensification. I developed methods to ensure that all individuals 
included in the studies have first received a prescription for metformin, and then 
received a new drug to intensify treatment. This treatment pattern reflects the 
prescribing recommendations issued by NICE for the intensification of treatments 
for type 2 diabetes. Prescribing data is also well recorded in the CPRD GOLD 
dataset, as discussed in Chapter 3. Prescriptions issued by GPs are automatically 
recorded by the VISION system and so accurately reflect the drugs prescribed by 
GPs. The research presented, therefore, shows prescribing at a well-defined point in 
treatment. As prescribing data is automatically recorded in the database, the potential 
for misclassification of disease and treatment stage is minimised.(88, 141)  
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7.2.2 Limitations  
Generalisability 
CPRD GOLD only contains records of prescriptions from primary care. However, 
secondary care prescribers may be more prone to start people on newer drug options, 
compared to their colleagues in primary care. People intensified in secondary care 
settings would not be apparent in the record until the GP provides further 
prescriptions, and to be included would need to survive until they see their GP. I 
would therefore miss very sick people that do not survive long enough to receive the 
prescription. If diabetic specialists prefer one drug class for people who are sicker, 
this could result in a biased estimation of effect. However, in Paper 3 (Patient level 
factors associated with prescribing), when evaluating baseline characteristics of 
the three cohorts, individuals receiving SGLT2is appeared to be healthier, younger 
and with higher kidney function than the SU and DPP4i cohorts. Therefore, there is 
no indication that the people receiving SGLT2i initiators received these drugs 
because they were systematically referred to secondary care settings for more 
specialist treatment of their diabetes.  
Selection bias 
Inclusion in my studies relies primarily on prescription data.  
For Paper 4 (Comparative study of drugs on continuous variables), eligibility 
relies upon both prescription data and availability of repeated measures for HbA1c, 
eGFR, BMI and systolic BP.  
Given care recommendations and QOF incentivisation, people with diabetes receive 
regular reviews of their diabetes care.(112) There are various factors that might 
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influence the frequency with which tests were completed. These might include: i) 
low renal function, ii) access to blood testing facilities, iii) patient tendency for, or 
lack of self-care, or v) development of possible drug side-effects. Each of these 
factors may also be associated with outcomes. If, for example, a GP was concerned 
with a falling eGFR, the GP may ask a patient to attend more regularly for closer 
monitoring. This individual would therefore have a higher chance of entering the 
cohort and then contribute more data to the analysis than those for whom the GP was 
not as concerned. Hence, the findings from the study may be reflective of those 
sicker individuals receiving frequent tests.(141)  
In clinical trials, differential loss to follow-up is an important factor for 
consideration. Similarly, in Paper 4 (Comparative study of drugs on continuous 
variables) some individuals might drop out, or be selected out of the study, by being 
treated in other settings, where data is not captured by CPRD. Therefore, those who 
become very sick would be lost from the follow-up. To assess whether this might 
have occurred I examined the baseline characteristics for individuals contributing 
data at each time point in the analysis, to assess if imbalance in the baseline measure 
occurred over time. For each of HbA1c, eGFR, BMI and systolic BP, balance in the 
baseline measures were maintained despite fewer people contributing data over time. 
This indicates that differential attrition was limited, though without the information 
of reasons for loss to follow-up further assertions are not possible. 
Time-related bias 
Time-related bias can be induced when time is misclassified as unexposed or 
exposed between treatment groups, and is particularly prevalent when comparing a 
treated to a non-treated group. In 2018, Suissa published a comment on the quality of 
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observational studies of SGLT2is. In the report, he noted two major sources of time-
related bias: immortal time bias and ‘time-lag’ bias.(77) Immortal-time bias stems 
from differences in the allocation of time between entering the study and first 
exposure. In Paper 3 and Paper 4, people were excluded if they did not survive long 
enough to receive additional metformin or two prescriptions of the index drugs. The 
sickest people could be hospitalised or die in the period between the two required 
drug prescriptions. However, the reasons for using this criterion was to avoid 
misclassification of treatment (switching rather than intensification). As detailed in 
Section 1.1 and 5.4 a sensitivity analysis demonstrated negligible impacts on the 
effects estimates. On balance, this seems to be the most appropriate option.  
Bias can be induced where comparisons are made between people at different stages 
of disease. This work used treatment patterns to identify people at the same stage of 
treatment. All individuals included in Papers 3 and 4 had first received treatment 
with metformin monotherapy, followed by one of SU, SGLT2i and DPP4i. In Paper 
3 (Patient level factors associated with prescribing) the length of time between the 
first metformin prescription and the time of SU, DPP4i or SGLT2i prescription was 
1,182 days (SD: 1,103), 1,320 days (SD: 1,105) and 1,137 days (SD: 1,023) 
respectively. This indicates that the cohorts were similar in terms of disease duration 
and suggests that the risk of comparing different stages of disease was low.  
However, this could be an imperfect proxy for disease severity. In Paper 3 (Patient 
level factors associated with prescribing), the finding that non-clinical 
characteristics, such as being older or of South Asian ethnicity, were associated with 
less frequent prescribing of newer agents, was unexpected. The assumption made 
was that in using prescribing data, the population was limited only to individuals at 
the same stage of disease. Thus, the prescribing pattern was a proxy for disease 
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severity. The likelihood of being at a later stage of disease may be associated with 
both the prescribing choice and one of the outcomes. Though we adjusted for other 
proxies of disease intensity such as time from metformin initiation, and baseline 
HbA1c, these may not have fully accounted for disease severity perceived by the 
prescriber. Thus, disease severity may still be acting as a confounder of the 
associations. For example, GPs may have selected people of South Asian ethnicity 
for intensification at a later stage of disease, compared to white people. In this 
instance, SUs may be favoured due to their long-established evidence for HbA1c 
reduction. Disease severity could still be confounding associations between 
prescribing and patient characteristics.  
Adherence 
CPRD GOLD data does not include adherence to medications or whether the patient 
collects the prescription from the pharmacy. People with type 2 diabetes are exempt 
from prescribing charges, and so the cost of prescriptions should not affect 
adherence. Other factors may limit an individual’s likelihood of collecting and taking 
prescribed medications and may also affect future outcomes. Traits such as health-
seeking behaviour, adherence to concurrent prescribing and comorbidities, may 
induce bias into the estimates of effect, as outlined in Section 3.2. This is a potential 
source of bias for Paper 4 (Comparative study of drugs on continuous variables) 
as misclassification of true medication exposure may bias estimates. For example, 
someone exhibiting health-seeking behaviours may request newer drug options such 
as the SGLT2is more than the older SUs. These individuals may be more likely to 
exercise and achieve weight loss over time. This would induce a bias in favour of the 
SGLT2i cohort for BMI reduction compared to the SU cohort.  
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In requiring two prescriptions for the drug of interest, the cohorts are limited to 
people not experiencing early adverse events who stop taking the medication. The 
outcomes observed will be limited to only those people that were initially tolerant of 
treatment. This may introduce a bias, with drugs appearing to be more beneficial 
than in the population.(142) As comparisons are made between drugs, with the same 
set of inclusion criteria, differences observed between groups would be biased if one 
drug had a higher rate for early side effects than another.  
Paper 2 (Study of prescribing trends) and Paper 3 (Patient level factors 
associated with prescribing) are focussed on the GP prescribing trends, without 
looking at outcomes, so will not be effected by bias induced by differential 
adherence to prescribing. 
Time-varying exposures  
For Paper 4 (Comparative study of drugs on continuous variables), we censored 
individuals when they changed treatment. The reason for doing this is that the 
outcomes of interest may lead to changes in prescribing and the aim was to compare 
the biological effects of the drug. In the context of hard outcomes such as kidney 
failure, if a GP changes treatment because of changes in eGFR, an as-treated 
approach would miss the kidney failure outcome, but the drug may have induced it. 
For continuous measures of covariates, the bias induced would be less severe as we 
observe all changes in kidney function over time. However, even after the drug is no 
longer prescribed, there may be a lag in terms of effect on outcomes.(142) For this 
reason, an ‘intention-to-treat’ analysis was also included for comparison, where only 
the prescriptions at baseline were accounted for, and changes in treatment did not 
induce censoring. Some evidence of the expected overlap of drug effects are 
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apparent towards the end of follow-up in the intention-to-treat that is not seen in the 
as-treated analysis. For example, in the intention-to-treat HbA1c analysis, at 60 
weeks the three drug cohorts appear to converge SU: 64.2 mmol/mol (95% CI: 62.9, 
65.6 mmol/mol), SGLT2i: 61.6 mmol/mol (95% CI: 59.1, 64.1 mmol/mol) and 
DPP4i: 67.1 mmol/mol (95% CI: 65.5, 68.8 mmol/mol), which is not as seen in the 
as-treated cohort (SU: 62.9 mmol/mol (95% CI: 61.4, 64.4 mmol/mol), SGLT2i: 
60.3 mmol/mol (95% CI: 57.9, 62.8 mmol/mol) and DPP4i: 66.9 mmol/mol (95% 
CI: 65.0, 68.8 mmol/mol)). This suggests that the as-treated analysis is more 
informative of the biological action of the drugs compared to the intention to treat 
analysis. 
Confounding by indication 
Confounders are variables that are both associated with the outcome and exposure, 
and not on the causal pathway between exposure and outcome. Confounding by 
indication, where a covariate is both an indication for treatment, and is associated 
with the outcome, was addressed in this work. A primary aim of Paper 3 (Patient 
level factors associated with prescribing) was to investigate the prescribing 
practice according to clinical baseline factors to establish if they differed 
systematically between groups. It showed that they did differ, and the clinical factors 
associated with prescribing are likely to be associated with future outcomes. The 
study found that people prescribed SGLT2is, on average, had higher eGFR at 
baseline. As eGFR was an outcome of interest for Paper 4, in the cohort study 
analysis I matched on baseline factors that might act as confounders. Though we 
achieved good balance on the measured variables, there is still potential that there 
were unmeasured confounders, which induced bias. 
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Unmeasured and residual confounding 
Despite taking steps to deal with confounding in Paper 3 (Patient level factors 
associated with prescribing) and Paper 4 (Comparative study of drugs on 
continuous variables) there are still likely to be sources of unmeasured and residual 
confounding. Aspects of an individual that are apparent to a GP may not be recorded 
in the health record.  
For Paper 3 (Patient level factors associated with prescribing) there may have 
been unmeasured clinical reasons for favouring SUs for people of South Asian or 
Black heritage. Ethnicity is associated with different pathophysiology of diabetes 
and treatment risks and so could explain divergence of prescribing practice from 
people of white ethnicity.(143)Another important example for my work is frailty. 
Frailty is a complex presentation that is not be completely represented by the health 
record, but may influence both prescribing practice and future outcomes, as in in 
Paper 4. Probability of prescribing for each drug could differ. GPs may use SUs 
with more caution in individuals that have increased risks associated with 
hypoglycaemic attacks, as SUs are associated with higher rates of 
hypoglycaemia.(144) For a frail individual, a hypoglycaemic attack can be 
potentially catastrophic, leading to falls and periods of hospitalisation.(2) Frail 
people are also at higher risks for adverse health outcomes.(145) 
Another piece of information not considered are prescriptions for structured 
nutritional education or exercise programmes. At treatment intensification, GPs may 
increase lifestyle interventions.(40) If individuals made changes to improve their 
health at the same time as treatment escalation, the estimates will include the effects 
of these interventions. This work may therefore overestimate the effect of each of 
these drugs on measures such as BMI and HbA1c. If GPs favoured prescribing of 
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SGLT2is to people more prone to embrace lifestyle changes, then the findings that 
SGLT2is lead to larger reductions in BMI compared to DPP4is or SUs may be 
biased.    
In Paper 4 (Comparative study of drugs on continuous variables), I used 
propensity scores to balance the baseline covariates in each group, as a result, all 
people with the same propensity score will have the same distribution of known 
confounders.(146) After matching on propensity scores, I showed that individuals in 
the matched cohorts were similar on both continuous and categorical covariates. For 
example, prior to matching the proportion of individuals with the most deprivation, 
according to IMD, in the SU group was 21%, compared to 17% in the SGLT2i 
cohort. After matching this was more similar between at the cohorts, 15% and 16% 
in the SU and SGLT2i cohorts respectively. However, the IMD only serves as a 
proxy for individual-level deprivation. IMD is an area-level proxy for socioeconomic 
status based on an individual’s post-code so will not fully adjust for individual-level 
differences such as income, which may be associated with both prescribing practice 
and future outcomes, thus leading to residual confounding.(147) The effect of the 
bias on effect estimates could be in any direction. If high socioeconomic status were 
associated with SGLT2i prescribing and closer control of BMI, the effect of 
SGLT2is leading to reduction in BMI would be overestimated due to the residual 
confounding by socioeconomic status.  
Missing data 
Though the population of interest are a monitored group of individuals, this does not 
remove the potential for missing covariate data to bias effect estimates. Paper 3 
(Patient level factors associated with prescribing) shows that kidney function was 
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associated with drug prescribing choice, but there was a high proportion of missing 
data. GPs may test kidney function more for those with a history of eGFR decline. 
Equally, as the SGLT2i class requires good renal function to reduce blood glucose, 
GPs can only prescribe SGLT2is to those people that have had recent eGFR tests and 
with good patterns of kidney function in recent years.  
In both Paper 3 (Patient level factors associated with prescribing) and Paper 4 
(Comparative study of drugs on continuous variables), I used a range of 
approaches for dealing with missing data at baseline.  
For both studies I used complete case analyses. For results from the complete case 
analysis to be unbiased for the general population the method relies upon the 
assumption that data is missing completely at random (MCAR), or at least 
missingness is not related to the outcome, given the observed predictors.(127)  
In Paper 3 (Patient level factors associated with prescribing), I then applied 
multiple imputation in the primary analysis to handle missing data in covariates, and 
presented the results of a complete case analysis as supplementary information 
(Appendix 5, Supplementary Table 3). The results from both analyses are very 
similar. Results from the complete case analysis have wider confidence intervals for 
the estimates, which is expected given the loss of data for those excluded. 
For Paper 4 (Comparative study of drugs on continuous variables) the primary 
analysis dealt with missing baseline covariate information using a missing indicator 
approach. Missing values of continuous covariates were replaced by the mean for the 
sample, and a missing indicator was included in the propensity score model.(148) 
This method was selected as multiple imputation with propensity scores require the 
full analysis to be completed across multiple imputed datasets. In the case of this 
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study, we modelled the change in the outcomes over time after treatment change, and 
applications of propensity scores in this setting have not been commonly used. The 
missing indicator method was a simpler approach that enabled more data to be 
included in the models. I contrasted results from the primary analysis to an approach 
that used multiple imputation to estimate baseline covariates. The propensity score 
was an average propensity from multiple imputed datasets, and used this to match 
cohorts at baseline. The results of these two approaches are very similar, Paper 4 
Figure 2, and Appendix 6, Supplementary figure 5 however it is not possible to 
test the underlying assumptions for these methods, as I do not have the missing data. 
Though not applied here, other methods to account for missing not at random 
(MNAR) missingness patterns are available in the literature. Such sensitivity 
analyses could investigate how robust findings are to different missingness 
patterns.(149) These approaches include selection model and pattern-mixture 
models.(150) 
Generalisability of methods 
The methods applied in this context benefitted from the relative equipoise in the 
prescribing decision at treatment intensification. Given that guidelines had not made 
strong recommendations for one drug, this stage of treatment prescribing was well 
suited for comparisons. Now that clinical trial evidence has grown indicating the 
benefits of SGLT2is, this relative equipoise is likely to diminish.(41) After changes 
in guidelines, clinicians will likely favour SGLT2is for people with higher 
cardiovascular disease risk. In other disease settings, where treatments are intensified 
over time, assumptions regarding relative equipoise may not hold.(151) The methods 
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and findings have therefore been applied to a specific prescribing practice, that 
occurred for a short period in time. 
7.3 Future directions 
The results from Paper 4 (Comparative study of drugs on continuous variables) 
indicate that this primary care data and the cohort identified can mirror the changes 
in eGFR, BMI, blood pressure and HbA1c identified in the recent cardiovascular 
outcome trials. What this work has not been able to investigate is whether these 
changes will translate to the reductions in patient outcomes that have been reported 
by clinical trials for SGLT2is in recent months. Given that the cohort identified in 
this thesis is a healthier population than those included in the RCTs, with lower risks 
for renal and cardiovascular outcomes, completion of a properly powered study of 
diabetes related outcomes will require more data, as shown in Section Error! 
Reference source not found.. There are two clear ways to increase numbers: (i) wait 
for the accrual of prescriptions and outcomes in CPRD GOLD, (ii) use the CPRD 
Aurum dataset to augment the numbers. These options should allow for a fully 
powered comparative study of outcomes for SUs, SGLT2is and DPP4is in 
combination with metformin. 
Another possible avenue for exploration would be the heterogeneity in the type 2 
diabetes population. There is a growing body of evidence showing that, within the 
type 2 diabetes population, there are different subtypes that respond to interventions 
differently. Machine learning algorithms have been applied to RCT data in post hoc 
analyses, revealing different outcome rates according to diabetes management and 
overall health that were not identified in the primary RCT analysis. In these post-hoc 
analyses, subgroups within the RCT populations benefitted more from weight-loss 
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intervention than others (Look AHEAD)(152) or intensive blood glucose lowering 
(ACCORD-BP or SPRINT trials).(153) Other studies have shown that electronic 
health records can be used to identify subgroups within the type 2 diabetes 
populations. Using analytical techniques such as topological data analysis and 
machine learning algorithms, type 2 diabetes populations appear to contain three or 
four subtypes with different comorbidity risk profiles. Some subtypes had higher 
rates of diabetic kidney disease, and others showed lower rates of comorbidities (3, 
154-156) Better understanding of these subtypes could help to personalise treatments 
and improve patient outcomes. Repeating comparative effectiveness work, using 
disease subtypes as subgroups could highlight people that respond better to each of 
the drugs and help guide clinicians.  
Such work could benefit from additional clinical information, such as genetic data 
from the UK Biobank. However, classification of type 2 diabetes subtypes using the 
data currently collected in primary care settings, without the need for additional data 
would allow for bigger studies and have faster impact on clinical practice.  
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7.4 Conclusion 
With the rapid uptake of new drugs to treat type 2 diabetes in primary care practice 
in the UK, this thesis has demonstrated the ability for electronic health records to 
assess how GPs prescribe these drugs and how they compare with each other in 
terms of clinical variables. The studies presented indicate that prescribing practice in 
the UK has changed quickly over time. GPs prescribing new drugs may be 
influenced by both clinical and non-clinical factors. By following individuals that 
received these drugs in routine practice, I have been able to show similar changes in 
clinical variables to those reported in clinical trials. Finally, the SGLT2i cohort 
appear to experience greater falls in BMI and HbA1c over follow-up compared to 
both DPP4i and SU cohorts. This work therefore further demonstrates the potential 
for observational health data, with careful study design, to enrich the findings from 
clinical trials in real-time and in routine clinical settings.  
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9 Appendix 
 
9.1 Appendix 2: Supplementary material for Paper 1 
This section provides the supplementary material for the systematic review article in 
chapter 2.First the PRISMA checklist ; then table S2.1 and table S2.2 detail the 
searches used to identify studies from Medline and Web of Science; followed by 
further comparisons presented in an included study that were not included in the 
systematic review article (table S2.3); table S2.4 contains detailed definitions of 
composite renal outcomes reported by the observational studies included in the 
systematic review; and table S2.5 and S2.6 contain checklists for used to assess 
study quality.
185
  
 
 
PRISMA 2009 Checklist 
Section/topic  # Checklist item  
Reported in 
section, 
paragraph 
(p)  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic 
review registration number.  
Abstract 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already 
known.  
Intro, p2 
Objectives  4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, and 
study design (PICOS).  
Intro, p2 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed 
(e.g., Web address), and, if available, provide registration information 
including registration number.  
Methods, p1 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and 
report characteristics (e.g., years considered, language, publication 
status) used as criteria for eligibility, giving rationale.  
Methods p2 
Information sources  7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional studies) in 
the search and date last searched.  
Methods, p2, 
fig1 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
Sup tables 1 
and 2 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in the 
meta-analysis).  
Methods, p3 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
Methods, p6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, 
funding sources) and any assumptions and simplifications made.  
Methods, p6 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data 
synthesis.  
Methods, p6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in 
means).  
Methods, p5 
Synthesis of results  14 Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (e.g., I2) for each 
meta-analysis.  
NA 
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org. 
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Table S2.1: First Ovid Medline search 
1 (kidney or renal or Albumin or ACR or albuminuria or CKD or creatinine or 
dialysis or eGFR or esrd or glomerular or GFR* or cystatinC or haematuria or 
microvascular or protein:creatinine or proteinurea or proteinuria).af. 
1152518 Advanced 
2 Renal Insufficiency/ or Cystatin C/ or Kidney/ or Kidney Diseases/ or 
Glomerular Filtration Rate/ or Creatinine/ or Diabetic Nephropathies/ or 
Proteinuria/ 
389625 Advanced 
3 1 or 2 1161071 Advanced 
4 (antidiabetic or Acarbose or Acetohexamide or Actos or Actraphane or 
Alogliptin or glucosidase or Amaryl or Aspart or Avandia or Avandamet or 
insulin or Biguanide* or Bolamyn or Bydureon or Byetta or Calabren or 
Canagliflozin or Chloropropamide or Competact or Dacadis or Daonil or 
Dapagliflozin or Degludec or Determir or Diabetamide or Diabinese or 
Diagemet or Diaglyk or Diamicron or Dimelor or Dipeptidyl or DPP-4 or 
DPP-4i or Duclazide or Duformin or Edicil or Empagliflozin or Enyglid or 
Eucreas or Euglucon or Exenatide or Forxiga or Galvus or Glargine or 
Glibenclamide or Glibenese or Glibornuride or Gliclazide or Gliflozin or 
Glimepiride or Glinides or Glipizide or Gliquidone or Glitpins or GLP-1 or 
Glucagon-like or Glucamet or Glucient or Glucobay or Glucophage or Glutril 
or Glyconon or Glymese or Glymidine or Guar or Guarem or Guarina or 
Glurenorm or Humaject or Humalog or Humulin or Hypurin or Hypurin or 
incretin or Innolet or Insulatard or Insulin or Invokana or aspart or degludec or 
detemir or glargine or Isophane or Lispro or Insuman or Invokana or Isophane 
or Janumet or Januvia or Jentadueto or Komboglyze or Laaglyda or Lantus or 
Levemir or Libanil or Linagliptin or Liraglutide or Lisophane or Lispro or 
Lixisenatide or Lyxumia or Malix or Meglinitides or Metabet or Metformin or 
Minodiab or Dapagliflozin or Pioglitazone or Saxagliptin or Vildagliptin or 
Metsol or Mixtard or Nateglinide or Nateglinide or Nazdol or Neuphane or 
Niddaryl or Novomix or NovoNorm or Onglyza or Orabet or Penmix or 
Pioglitazone or Prandin or Protamine or Pur-in or Rastinon or Repaglinide or 
Romozin or Rosiglitazone or Maleate or Saxagliptin or Semi-Daonil or 
Sitagliptin or Starlix or SU or Sukkarto or Sulfonylurea or Sulphonylurea or 
Tempulin or Tolanase or Tolazamide or Tolbutamide or Trajenta or Tresiba or 
Troglitazone or TZD or thiazolidinedione or Victoza or Vildagliptin or 
Vildagliptin or Vipdomet or Vipidia or Xigduo or Zicron).ab,ti. 
332666 Advanced 
5 Hypoglycemic Agents/ 48689 Advanced 
6 4 or 5 346663 Advanced 
7 (Case-control* or Cohort* or Comparative effectiveness* or Cross-sectional 
or Meta-analysis or Nonexperimental or Pharmacoepid* or Prospectiv* or 
RCT* or Trial*).ab,ti. 
1487119 Advanced 
8 Clinical Trial/ or Comparative Effectiveness Research/ or Cohort Studies/ or 
Cross-Sectional Studies/ or Case-Control Studies/ 
1063484 Advanced 
9 7 or 8 2064294 Advanced 
10 3 and 6 and 9 6491 Advanced 
11 limit 10 to (male and female and humans and yr="1980 -Current") 4083 Advanced 
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Table S2.2 First search Web of science 
Se
t Results Criteria  
# 4 532 #3 AND #2 AND #1 
Timespan=1980-2016 
Search language=Auto  
# 3 Approx.  
559,338 
TI=(antidiabetic or Acarbose or Acetohexamide or Actos or Actraphane or 
Alogliptin or glucosidase or Amaryl or Aspart or Avandia or Avandamet or 
insulin or Biguanide* or Bolamyn or Bydureon or Byetta or Calabren or 
Canagliflozin or Chloropropamide or Competact or Dacadis or Daonil or 
Dapagliflozin or Degludec or Determir or Diabetamide or Diabinese or 
Diagemet or Diaglyk or Diamicron or Dimelor or Dipeptidyl or "DPP-4" or 
"DPP-4i" or Duclazide or Duformin or Edicil or Empagliflozin or Enyglid or 
Eucreas or Euglucon or Exenatide or Forxiga or Galvus or Glargine or 
Glibenclamide or Glibenese or Glibornuride or Gliclazide or Gliflozin or 
Glimepiride or Glinides or Glipizide or Gliquidone or Glitpins or "GLP-1" or 
Glucagon-like or Glucamet or Glucient or Glucobay or Glucophage or Glutril or 
Glyconon or Glymese or Glymidine or Guar or Guarem or Guarina or 
Glurenorm or Humaject or Humalog or Humulin or Hypurin or Hypurin or 
incretin or Innolet or Insulatard or Insulin or Invokana or aspart or degludec or 
detemir or glargine or Isophane or Lispro or Insuman or Invokana or Isophane 
or Janumet or Januvia or Jentadueto or Komboglyze or Laaglyda or Lantus or 
Levemir or Libanil or Linagliptin or Liraglutide or Lisophane or Lispro or 
Lixisenatide or Lyxumia or Malix or Meglinitides or Metabet or Metformin or 
Minodiab or Dapagliflozin or Pioglitazone or Saxagliptin or Vildagliptin or 
Metsol or Mixtard or Nateglinide or Nateglinide or Nazdol or Neuphane or 
Niddaryl or Novomix or NovoNorm or Onglyza or Orabet or Penmix or 
Pioglitazone or Prandin or Protamine or Pur or Rastinon or Repaglinide or 
Romozin or Rosiglitazone or Maleate or Saxagliptin or Daonil or Sitagliptin or 
Starlix or SU or Sukkarto or Sulfonylurea or Sulphonylurea or Tempulin or 
Tolanase or Tolazamide or Tolbutamide or Trajenta or Tresiba or Troglitazone 
or TZD or thiazolidinedione or Victoza or Vildagliptin or Vildagliptin or 
Vipdomet or Vipidia or Xigduo or Zicron or Hypoglycaemic or Hypoglycemic) 
Timespan=1980-2016 
Search language=Auto  
# 2  Approx. 
1,428,406 
TI=(Cohort* or Comparative or Nonexperimental or Pharmacoepid* or 
Prospectiv* or RCT* or Trial*) 
Timespan=1980-2016 
Search language=Auto  
# 1  Approx. 
2,999,026 
TS=(kidney or renal or Albumin or ACR or albuminuria or CKD or creatinine or 
dialysis or eGFR or esrd or glomerular or GFR* or cystatinC or haematuria or 
microvascular or proteinurea) 
Timespan=1980-2016 
Search language=Auto  
Table S2.1 First search Web of science, across Web of ScienceTM Core 
Collection, BIOSIS Citation Index, KCI-Korean Journal Database, MEDLINE, 
SciELO Citation Index 
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Table S2.3 Report of further comparisons from Hippisley-Cox and Coupland 
(2016) paper 
Author  
(Year) Kidney outcomes 
Kidney outcomes recorded 
HR (95% CI) 
Hippisley-Cox and 
Coupland (2016) (157) 
1 Incident severe kidney failure (Read 
code defined as kidney dialysis, 
transplantation, or CKD stage 5 based 
on serum creatinine values 
Incident kidney failure 
 
MTF referent 
 
TZD: 2.55 (1.13, 5.74) 
DPP4I: 3.52 (2.04, 6.07) 
SU: 2.63 (2.25, 3.06) 
 
MTF+TZD: 0.71 (0.33, 1.50) 
MTF+SU: 0.76 (0.62, 0.92) 
MTF+DPP4I: 0.59 (0.28, 1.25) 
 
SU+TZD: 2.14 (1.27, 3.61) 
SU+DPP4I: 3.21 (2.08, 4.93) 
 
SU+TZD+MTF: 1.21 (0.75, 1.96) 
SU+DPP4I+MTF: 0.68 (0.39, 1.20) 
Abbreviations: MTF: metformin, SU: sulfonylurea, TZD: thiazolidinedione, DPP4I: Dipeptidyl peptidase-
4, CKD: Chronic Kidney Disease 
Table S2.2 Report of further comparisons from Hippisley-Cox and Coupland 
(2016) paper 
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Table S2.4 Detailed definitions of composite renal outcomes for observational 
studies 
Author (Year) Definition of Renal outcomes 
Hung et al (2012) (158) 
1: eGFR event  
>=25% decline, confirmed 3-12 months following 
 
2: ESRD 
Defined as eGFR<15 (confirmed in 3-12 months following), ICD-
9 codes for dialysis (confirmed in 3-12 months following), renal 
transplant  
 
3: Mortality 
Pendergrass et al (2012) (159) 1st ARF (ICD-9 code 584*) 
Currie et al. (2013) (160) 
Renal failure (Read code defined, covering disease areas: CKD, 
dialysis, transplantation, renal failure, nephritis, nephropathy, 
necrosis) 
Hung et al (2013) (161) 
1: eGFR event  
>=25% decline, confirmed 3-12 months following 
 
2: ESRD  
Defined as eGFR<15 (confirmed in 3-12 months following), ICD-
9 codes for dialysis (confirmed in 3-12 months following), renal 
transplant 
 
3: Mortality 
Masica et al. (2013) (162) 
1: New proteinuria (based on 24-hour albumin/protein, spot 
protein, spot ACR, or dipstick)  
 
2: New eGFR to <60  
Hippisley-Cox and Coupland (2016) (157) 
1: Incident severe kidney failure (Read code defined as kidney 
dialysis, transplantation, or CKD stage 5 based on serum 
creatinine values) 
Kolaczynski et al (2016) (163) Incident nephropathy (ICD-10 codes: E11.2 or E14.2) 
Goldshtein et al. (2016) (164) Improvements in urinary ACR (at least 20% improvement in ACR and change in KDIGO category) 
Abbreviations: ESRD: End stage renal disease, ARF: Acute Renal Failure, ACR: Albumin: Creatinine Ratio, CKD: 
Chronic Kidney Disease, KDIGO: Kidney Disease: Improving Global Outcomes, ICD: International Classification of 
Diseases 
Table S2.3 Detailed definitions of composite renal outcomes for observational 
studies
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Table S2.6 Cochrane items for quality of RCT studies 
 Authors, year 
Scoring as Fit for Purpose: Sufficient (+), Insufficient (-) 
Item 
B
ak
ri
s, 
20
03
 
H
an
ef
el
d,
 2
00
4 
Sc
he
rn
th
an
er
 e
t a
l. 
(2
00
4)
 
M
at
th
ew
s, 
20
05
 
L
ac
hi
n,
 2
01
1 
H
ee
rs
pi
nk
 e
t a
l. 
20
17
 
Pa
n 
et
 a
l. 
20
16
 
Random sequence generation (selection bias) ? ? + ? ? + - 
Allocation concealment (selection bias) - ? + ? ? + - 
Blinding of participants and researchers (performance bias) - + + + + + - 
Blinding of outcome assessment (detection bias) ? + ? + + + - 
Incomplete outcome data (attrition bias) ? + ? ? - + ? 
Selective reporting (reporting bias) + + + + + + + 
Table S2.5 Cochrane items for quality of RCT studies 
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9.2 Appendix 3: Methods 
9.2.1 Creation of diabetic drug list 
 
Based on the literature, I used the following terms to search the CPRD Codebrowser 
for diabetic drugs.  
Initial search terms 
BNF header terms: *ctos* *maryl* *olamyn* *ydureon* *yetta* *ompetact* 
*iamicron* *ucreas* *orxiga* *alvus* *libenclamide * *liclazide* *limepiride* 
*lipizide* *lucient* *lucophage* *nvokana* *anumet* *anuvia* *ardiance* 
*entadueto* *omboglyze* *yxumia* *etabet* *etformin* *inodiab* *ovonorm* 
*nglyza* *ioglitazone* *randin* *epaglinide* *tarlix* *olbutamide* *rajenta* *ictoza* 
*ipdomet* *okanamet* *igduo* *ultophy* *logliptin* *anagliflozin* *apagliflozin* 
*mpagliflozin* *xenatide * *libenclamide* *inagliptin* *iraglutide* *ixisenatide* 
*ateglinide* *axagliptin* *itagliptin* *ildagliptin* *iguanide* *PP-4i* *LP-1* 
*lucagon-like peptide-1* *eglitinides * *GLT-2* *ulfonylurea* *ulphonylurea* 
*hiazolinedione* *tzd* *ntidiabetic* *sulin*: *iguanide* *antidiabetic* *ulphonylurea* 
*hypodermic* *insulin*" 
BNF codes: 0601020* 060102* *06010201* *06010202* *06010203* *06010200* 
*71190600* 
Product names: *ctos* *maryl* *olamyn* *ydureon* *yetta* *ompetact* *iamicron* 
*ucreas* *orxiga* *alvus* *libenclamide * *liclazide* *limepiride* *lipizide* *lucient* 
*lucophage* *nvokana* *anumet* *anuvia* *ardiance* *entadueto* *omboglyze* 
*yxumia* *etabet* *etformin* *inodiab* *ovonorm* *nglyza* *ioglitazone* *randin* 
*epaglinide* *tarlix* *olbutamide* *rajenta* *ictoza* *ipdomet* *okanamet* *igduo* 
*ultophy* *logliptin* *anagliflozin* *apagliflozin* *mpagliflozin* *xenatide * 
*libenclamide* *inagliptin* *iraglutide* *ixisenatide* *ateglinide* *axagliptin* 
*itagliptin* *ildagliptin* *iguanide* *PP-4i* *LP-1* *lucagon-like peptide-1* 
*eglitinides * *GLT-2* *ulfonylurea* *ulphonylurea* *hiazolinedione* *tzd* 
*sulin**glinide* *gliptin* *glymidine* *bornuride* *glutide* *guar* *nsulin* 
*carbose* *gliptin* *gliflozin* *xenatide* *benclamide* *liclazide* *mepiride* 
*lipizide* *glutide* *etformin* *glitazone* *glinide* 
Drug substance name: *ctos* *maryl* *olamyn* *ydureon* *yetta* *ompetact* 
*iamicron* *ucreas* *orxiga* *alvus* *libenclamide * *liclazide* *limepiride* 
*lipizide* *lucient* *lucophage* *nvokana* *anumet* *anuvia* *ardiance* 
*entadueto* *omboglyze* *yxumia* *etabet* *etformin* *inodiab* *ovonorm* 
*nglyza* *ioglitazone* *randin* *epaglinide* *tarlix* *olbutamide* *rajenta* *ictoza* 
*ipdomet* *okanamet* *igduo* *ultophy* *logliptin* *anagliflozin* *apagliflozin* 
*mpagliflozin* *xenatide * *libenclamide* *inagliptin* *iraglutide* *ixisenatide* 
*ateglinide* *axagliptin* *itagliptin* *ildagliptin* *iguanide* *PP-4i* *LP-1* 
*lucagon-like peptide-1* *eglitinides * *GLT-2* *ulfonylurea* *ulphonylurea* 
*hiazolinedione* *tzd* *sulin* *vandamet* *vandia* *hlorpropamid* *ompetact* 
*oanil* *liquidone* *lurenorm* *uar**acarbose* *acetohexa* *actos* *aloglipti* 
*amaryl* *avandamet* *avandia* *bolamyn* *bydureon* *byetta* *calabren* 
*canaglifl* *chlorprop* *competact* *dapaglifl* *diabetami* *diagemet* *diaglyk* 
*diamicron* *dimelor* *enyglid* *eucreas* *euglucon* *exenatide* *forxiga* 
193
    
*galvus* *glibencla* *gliclazid* *glimepiri* *glipizide* *glucamet* *glucient* 
*glucophag* *glutril* *glyconon* *glymese* *guar* *guarem* *guarina* *invokana* 
*janumet* *januvia* *jentaduet* *komboglyz* *laaglyda* *libanil* *linaglipt* 
*liragluti* *lixisenat* *lyxumia* *metabet* *metformin* *metsol* *nazdol* *niddaryl* 
*novonorm* *onglyza* *pioglitaz* *prandin* *rastinon* *romozin* *rosiglita* 
*saxaglipt* *starlix* *sukkarto* *tolbutami* *trajenta* *victoza* *vildaglip* 
*vipdomet* *xiapex* *xultophy* *xigduo* *zemplar* *zicron* *daonil* *dacadis* 
*diabinese* *duclazide* *duformin* *edicil* *empaglifl* *glibenese* *glibornur* 
*gliquidon* *glucobay* *glurenorm* *glymidine* *malix* *minodiab* *nateglini* 
*orabet* *repaglini* *semi-daon* *sitaglipt* *tolanase* *tolazamid* *troglitaz* 
*vipidia* 
Exclusion terms 
Product names: *xiapex* *collagenase* *dressin* *supple* *lubricants* *hypodermic* 
*soft-tissue* *needle* *flextouch* *cap* *needle* *sterile* *lancet* *unilet* 
*zemplar* *probioguard* *guarina* *hypoguard* *lactose* *container* *guardi* 
*cream* *bag* *cough* *eye* *film* *sharpsguard* *spray* *folguard* 
BNF header: *enzymes* *dressin* *supple* *lubricants* *hypodermic* *soft-tissue* 
*needle* *lancet* *unilet* *zemplar* *probioguard* *guarina* *hypoguard* *lactose* 
*container* *guardi* *cream* *bag* *cough* *eye* *film* *sharpsguard* *spray* 
*folguard* 
BNF code: *09040251* *72214300* *71190600* *11080100* 
Appendix table 6: Terms used to create type 2 diabetes drug list
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9.3 Appendix 4: Supplementary material for chapter 4 
This appendix provides the supplementary material for the trends in prescribing 
paper (Paper 2) presented in Chapter 4.  
9.3.1 4.1 Drug codes to group drugs classes into drug  
productname agent class 
gliclazide 80mg tablets gliclazide su 
sitagliptin 100mg tablets sitagliptin dpp4i 
gliclazide 40mg tablets gliclazide su 
linagliptin 5mg tablets linagliptin dpp4i 
dapagliflozin 10mg tablets dapagliflozin sglt2i 
saxagliptin 5mg tablets saxagliptin dpp4i 
alogliptin 25mg tablets alogliptin dpp4i 
gliclazide 30mg modified-release tabl.. gliclazide su 
sitagliptin 50mg tablets sitagliptin dpp4i 
glimepiride 1mg tablets glimepiride su 
empagliflozin 10mg tablets empagliflozin sglt2i 
canagliflozin 100mg tablets canagliflozin sglt2i 
sitagliptin 25mg tablets sitagliptin dpp4i 
forxiga 10mg tablets (astrazeneca uk .. dapagliflozin sglt2i 
dapagliflozin 5mg tablets dapagliflozin sglt2i 
metformin 1g / sitagliptin 50mg tablets sitagliptin dpp4i 
saxagliptin 2.5mg tablets saxagliptin dpp4i 
glimepiride 2mg tablets glimepiride su 
glipizide 5mg tablets glipizide su 
janumet 50mg/1000mg tablets (merck sh.. sitagliptin dpp4i 
alogliptin 12.5mg tablets alogliptin dpp4i 
linagliptin 2.5mg / metformin 1g tabl.. linagliptin dpp4i 
empagliflozin 25mg tablets empagliflozin sglt2i 
forxiga 5mg tablets (astrazeneca uk l.. dapagliflozin sglt2i 
trajenta 5mg tablets (boehringer inge.. linagliptin dpp4i 
gliclazide 60mg modified-release tabl.. gliclazide su 
januvia 100mg tablets (merck sharp & .. sitagliptin dpp4i 
vildagliptin 50mg tablets vildagliptin dpp4i 
vipdomet 12.5mg/1000mg tablets (taked.. alogliptin dpp4i 
alogliptin 6.25mg tablets alogliptin dpp4i 
glimepiride 3mg tablets glimepiride su 
alogliptin 12.5mg / metformin 1g tabl.. alogliptin dpp4i 
invokana 100mg tablets (janssen-cilag.. canagliflozin sglt2i 
glimepiride 4mg tablets glimepiride su 
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productname agent class 
jardiance 10mg tablets (boehringer in.. empagliflozin sglt2i 
saxagliptin 2.5mg / metformin 1g tabl.. saxagliptin dpp4i 
glibenclamide 5mg tablets glibenclamide su 
vildagliptin 50mg / metformin 850mg t.. vildagliptin dpp4i 
linagliptin 2.5mg / metformin 850mg t.. linagliptin dpp4i 
vipidia 25mg tablets (takeda uk ltd) alogliptin dpp4i 
canagliflozin 300mg tablets canagliflozin sglt2i 
dapagliflozin 5mg / metformin 1g tabl.. dapagliflozin sglt2i 
dapagliflozin 5mg / metformin 850mg t.. dapagliflozin sglt2i 
vildagliptin 50mg / metformin 1g tabl.. vildagliptin dpp4i 
empagliflozin 5mg / metformin 1g tabl.. empagliflozin sglt2i 
xigduo 5mg/1000mg tablets (astrazenec.. dapagliflozin sglt2i 
diamicron 30mg mr tablets (servier la.. gliclazide su 
januvia 50mg tablets (merck sharp & d.. sitagliptin dpp4i 
komboglyze 2.5mg/1000mg tablets (astr.. saxagliptin dpp4i 
canagliflozin 50mg / metformin 850mg .. canagliflozin sglt2i 
januvia 25mg tablets (merck sharp & d.. sitagliptin dpp4i 
saxagliptin 2.5mg / metformin 850mg t.. saxagliptin dpp4i 
empagliflozin 5mg / metformin 850mg t.. empagliflozin sglt2i 
jentadueto 2.5mg/1000mg tablets (boeh.. linagliptin dpp4i 
onglyza 5mg tablets (astrazeneca uk l.. saxagliptin dpp4i 
vipidia 12.5mg tablets (takeda uk ltd) alogliptin dpp4i 
eucreas 50mg/850mg tablets (novartis .. vildagliptin dpp4i 
jentadueto 2.5mg/850mg tablets (boehr.. linagliptin dpp4i 
vipidia 6.25mg tablets (takeda uk ltd) alogliptin dpp4i 
canagliflozin 50mg / metformin 1g tab.. canagliflozin sglt2i 
invokana 300mg tablets (janssen-cilag.. canagliflozin sglt2i 
xigduo 5mg/850mg tablets (astrazeneca.. dapagliflozin sglt2i 
diamicron 80mg tablets (servier labor.. gliclazide su 
tolbutamide 500mg tablets tolbutamide su 
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9.4 Appendix 5: Supplementary material for chapter 5 
 
This appendix provides the supplementary material for factors affecting prescribing 
paper (paper 3) presented in chapter 5 and the diagnostic code list used in the 
investigation of diagnostic codes. 
 
9.4.1 5.1 Supporting Information for paper 3 
Drug N %  
Insulin 368 34.0 
TZDs 290 26.8 
GLP-1 286 26.45 
SUs and DPP4is 55 5.1 
Glinides 14 1.3 
SU and insulin 14 1.3 
DPP4i and insulin 11 1.0 
Drug classes n<10 44 4.1 
Total 1,082 
 
Supplementary Table 1: Drugs prescribed, other than the drug classes of interest. 
Abbreviations: SU: Sulfonylurea, DPP4i: dipeptidyl peptidase 4inhibitors, TZD: 
Thiazolidinediones, GLP1: Glucagon-like peptide-1
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Insulin 
N=368 
Other 
combinations 
n=714 
Age at baseline 
(years) < 30 
17 (4.6) 9 (1.3) 
 30 to 39 43 (11.7) 45 (6.3) 
 40 to 49 53 (14.4) 139 (19.5) 
 50 to 59 74 (20.1) 224 (31.4) 
 60 to 69 78 (21.2) 185 (25.9) 
 70 to 79 63 (17.1) 88 (12.3) 
 ≥80 40 (10.9) 24 (3.4) 
Gender Female  175 (47.6) 321 (45) 
BMI at baseline Underweight/normal 59 (17.2) 47 (6.7) 
 Overweight 102 (29.7) 132 (18.7) 
 Obese 182 (53.1) 526 (74.6) 
 Missing  25 (6.8) 9 (1.3) 
Ethnicity  White 160 (82.1) 394 (90.6) 
 South Asian 16 (8.2) 19 (4.4) 
 Black 12 (6.2) 12 (2.8) 
 Other 6 (3.1) 9 (2.1) 
 Mixed n <5 n<5 
 Missing  173 (47) 279 (39.1) 
Patient-level index of  1 LEAST deprived 40 (20.6) 62 (17.2) 
multiple deprivation 2 36 (18.6) 64 (17.7) 
 3 42 (21.6) 69 (19.1) 
 4 37 (19.1) 86 (23.8) 
 5 MOST deprived 39 (20.1) 80 (22.2) 
 Missing  174 (47.3) 353 (49.4) 
Alcohol status Non-drinker 84 (25.7) 90 (13.1) 
 Ex-drinker 42 (12.8) 92 (13.4) 
 Current drinker 201 (61.4) 507 (73.6) 
 Missing  41 (11.1) 25 (3.5) 
Smoking status Non-smoker 145 (40.1) 259 (36.3) 
 Current 72 (19.9) 138 (19.4) 
 Ex-smoker 145 (40.1) 316 (44.3) 
 Missing  6 (1.6) n<5 
Time taking 
metformin  Mean (SD) 561 (907) 1124 (1069) 
HbA1c at baseline 
(mmol/mol) Mean (SD) 85 (30) 77 (21) 
 < 53 (7%) 29 (15.8) 45 (10.6) 
 53 to 74 54 (29.5) 184 (43.2) 
 >75 (9%) 100 (54.6) 197 (46.2) 
 Missing  185 (50.3) 288 (40.3) 
eGFR at baseline 
(ml/min/1.73m2)  Mean (SD) 91 (24) 94 (19) 
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Insulin 
N=368 
Other 
combinations 
n=714 
eGFR category 
(ml/min/1.73m2) < 60 
27 (14.1) 40 (9.3) 
 60 to 89 73 (38) 136 (31.7) 
 ≥ 90 92 (47.9) 253 (59) 
 Missing  176 (47.8) 285 (39.9) 
Diagnosis for 
proteinuric renal 
disease  
 7 (1.9) 14 (2) 
Raised ACR at 
baseline 
 35 (35.4) 71 (23.5) 
 Missing  269 (73.1) 412 (57.7) 
Diagnosis for 
Neuropathy 
 33 (9) 42 (5.9) 
Amputation record  5 (1.4) 11 (1.5) 
Diagnosis for 
Retinopathy  
 66 (17.9) 119 (16.7) 
Diagnosis for 
Blindness  
 n<5 8 (1.1) 
>1 sign of 
microvascular disease 
 116 (31.5) 211 (29.6) 
Systolic BP at 
baseline (mmHg) Mean (SD) 130 (17) 134 (15) 
 Missing  15 (4.1) 12 (1.7) 
Diagnosis for CVD   69 (18.8) 77 (10.8) 
Diagnosis for Heart 
failure  
 9 (2.4) 6 (0.8) 
Prescription for ACEI 
or ARB 
 183 (49.7) 378 (52.9) 
Prescription for statin  212 (57.6) 502 (70.3) 
Supplementary Table 2: Patient demographic and lifestyle factors for people 
prescribed insulin or other drug options at the first stage of intensification. 
Numbers are N (%) unless otherwise stated. Abbreviations: SU: Sulfonylurea, 
DPP4i: dipeptidyl peptidase 4inhibitors, SGLT2i: Sodium-glucose co-transporter-2 
inhibitors, HbA1c: Heamoglobin A1c, eGFR: estimated Glomerular Filtration Rate, 
BMI: Body mass index, BP: Blood pressure, ACEi: Angiotensin-converting-enzyme 
inhibitor, ARB: Angiotensin II receptor blockers, SD: Standard Deviation, ACR: 
Albumin creatinine ratio
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Variable SU, Ref DPP4i, OR (95% 
CI) 
SGLT2i, OR 
(95% CI) 
Age at baseline, years    
 < 30 1 1.94 (0.86, 4.35) 4.07 (1.42, 11.67) 
 30-<40 1 0.85 (0.59, 1.22) 1.48 (0.85, 2.56) 
 40-<50 1 0.94 (0.77, 1.16) 1.81 (1.31, 2.51) 
 50-<60 1 0.86 (0.72, 1.02) 1.53 (1.16, 2.03) 
 60-<70 1 1 1 
 70-<80 1 0.93 (0.77, 1.12) 0.56 (0.36, 0.87) 
 80 + 1 0.87 (0.67, 1.14) 0.14 (0.03, 0.60) 
Gender    
 Male 1 1 1 
 Female 1 0.94 (0.83, 1.07) 1.04 (0.84, 1.29) 
HbA1c at baseline 
(mmol/mol) 
   
 <= 53 (7%) 1 1 1 
 53-75 1 1.35 (1.02, 1.79) 1.11 (0.66, 1.89) 
 75+ (9%) 1 0.70 (0.53, 0.94) 0.78 (0.46, 1.32) 
eGFRat baseline 
(ml/min/1.73m2) 
   
 < 60 1 1 1 
 60-89 1 
1.12 (0.91, 1.39) 
15.45 (3.76, 
63.37) 
 90 + 1 
1.18 (0.93, 1.50) 
16.52 (3.99, 
68.29) 
Time taking metformin 
prior to intensification 
(years) 
   
 < 1 1 1 1 
 1 to <3 1 1.20 (1.01, 1.42) 1.48 (1.12, 1.95) 
 > 3 1 1.20 (1.02, 1.40) 1.24 (0.94, 1.64) 
Diagnosis of CVD    
 No CVD 1 1 1 
 CVD diagnosis 1 0.98 (0.83, 1.17) 0.76 (0.53, 1.09) 
Diagnosis of retinopathy    
 No retinopathy 1 1 1 
 Retinopathy diagnosis 1 0.97 (0.83, 1.14) 0.87 (0.64, 1.17) 
BMI at baseline kg/m2    
 Normal/underweight 1 1 1 
 Overweight 1 1.10 (0.88, 1.37) 2.48 (1.21, 5.07) 
 Obese 1 1.62 (1.31, 2.00) 6.01 (3.02, 11.99) 
Smoking status    
 None 1 1 1 
 Ex 1 0.96 (0.84, 1.10) 0.90 (0.71, 1.14) 
 Current 1 0.91 (0.76, 1.10) 0.76 (0.56, 1.03) 
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Variable SU, Ref DPP4i, OR (95% 
CI) 
SGLT2i, OR 
(95% CI) 
Ethnicity    
 White 1 1 1 
 South Asian 1 0.72 (0.57, 0.92) 0.50 (0.31, 0.81) 
 Black 1 0.59 (0.41, 0.85) 0.45 (0.23, 0.91) 
 Other 1 0.92 (0.59, 1.43) 0.48 (0.18, 1.25) 
 Mixed 1 1.29 (0.53, 3.14) 0.36 (0.04, 3.00) 
Calendar time    
 Early 2014 1 1 1 
 Late 2014 1 1.19 (0.98, 1.45) 1.73 (1.07, 2.80) 
 Early 2015 1 1.37 (1.14, 1.65) 3.02 (1.97, 4.64 
 Late 2015 1 1.72 (1.40, 2.11) 6.17 (4.02, 9.48) 
 Early 2016 1 2.31 (1.88, 2.86) 7.82 (5.09, 12.02) 
 Late 2016 1 2.35 (1.84, 2.99) 8.55 (5.41 13.50) 
 Early 2017 1 
2.90 (2.20, 3.82) 
15.10 (9.41, 
24.61) 
Supplementary Table 3 Complete case analysis. Fully adjusted odds ratios (95% 
CIs) for prescription of DPP4i or SGLT2i compared to SUs. Multinomial logistic 
regression without multiple imputation. Abbreviations: SU: Sulfonylurea, DPP4i: 
dipeptidyl peptidase 4inhibitors, SGLT2i: Sodium-glucose co-transporter-2 inhibitors, 
HbA1c: Heamoglobin A1c, eGFR: estimated Glomerular Filtration Rate, BMI: Body 
mass index 
.
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Variable SU, Ref DPP4i, OR (95% CI) 
SGLT2i, OR (95% 
CI) 
Age at baseline, years    
 < 30 1 1.78 (1.03, 3.10) 3.55 (1.68, 7.51) 
 30-<40 1 1.07 (0.81, 1.41) 1.26 (0.80, 1.99) 
 40-<50 1 0.98 (0.83, 1.15) 1.42 (1.10, 1.83) 
 50-<60 1 1.01 (0.88, 1.15) 1.42 (1.15, 1.76) 
 60-<70 1 1 1 
 70-<80 1 1.00 (0.86, 1.16) 0.50 (0.36, 0.70) 
 80 + 1 0.83 (0.67, 1.03) 0.12 (0.04, 0.33) 
Gender    
 Male 1 1 1 
 Female 1 0.98 (0.88, 1.09) 1.03 (0.87, 1.22) 
HbA1c at baseline 
(mmol/mol) 
   
 <= 53 (7%) 1 1 1 
 53-75 1 1.27 (0.99, 1.64) 1.32 (0.80, 2.17) 
 75+ (9%) 1 0.75 (0.5*, 0.98) 0.82 (0.50, 1.34) 
eGFRat baseline 
(ml/min/1.73m2) 
   
 < 60 1 1 1 
 60-89 1 1.10 (0.91, 1.32) 2.85 (1.53, 5.30) 
 90 + 1 1.12 (0.92, 1.37) 3.35 (1.80, 6.23) 
Time taking metformin prior to 
intensification (years) 
  
 < 1 1 1 1 
 1 to <3 1 1.22 (1.07, 1.39) 1.54 (1.23, 1.93) 
 > 3 1 1.25 (1.10, 1.42) 1.30 (1.04, 1.63) 
Diagnosis of CVD    
 No CVD 1 1 1 
 CVD diagnosis 1 1.00 (0.87, 1.16) 0.95 (0.72, 1.27) 
Diagnosis of 
retinopathy 
   
 No retinopathy 1 1 1 
 Retinopathy 
diagnosis 
1 1.12 (0.99, 1.28) 0.78 (0.60, 1.01) 
BMI at baseline kg/m2    
 Normal/underweight 1 1 1 
 Overweight 1 1.28 (1.08, 1.52) 1.95 (1.21, 3.14) 
 Obese 1 1.68 (1.43, 1.99) 4.98 (3.16, 7.83) 
Smoking status    
 None 1 1 1 
 Ex 1 1.01 (0.90, 1.12) 0.92 (0.76, 1.11) 
 Current 1 0.99 (0.85, 1.15) 0.78 (0.60, 1.01) 
Ethnicity    
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Variable SU, Ref DPP4i, OR (95% CI) 
SGLT2i, OR (95% 
CI) 
 White 1 1 1 
 South Asian 1 0.73 (0.59, 0.89) 0.59 (0.40, 0.86) 
 Black 1 0.64 (0.48, 0.85) 0.45 (0.24, 0.82) 
 Other 1 0.66 (0.45, 0.97) 0.52 (0.25, 1.07) 
 Mixed 1 1.01 (0.48, 2.12) 0.73 (0.15, 3.60) 
Patient-level IMD    
1 LEAST deprived 1 1 1 
2 1 0.95 (0.80, 1.12) 0.98 (0.73, 1.30) 
3 1 0.95 (0.80, 1.12) 1.02 (0.76, 1.33) 
4 1 0.79 (0.67, 0.93) 0.61 (0.46, 0.81) 
5 MOST 1 0.99 (0.84, 1.18) 0.59 (0.44, 0.80) 
Calendar time    
 Early 2014 1 1 1 
 Late 2014 1 1.18 (1.00, 1.38) 1.80 (1.24, 2.62) 
 Early 2015 1 1.38 (1.19, 1.60) 2.70 (1.92, 3.80) 
 Late 2015 1 1.66 (1.41, 1.95) 4.43 (3.14, 6.24) 
 Early 2016 1 2.17 (1.84, 2.57) 6.99 (4.99, 9.79) 
 Late 2016 1 2.56 (2.11, 3.10) 10.42 (7.33, 14.83) 
 Early 2017 1 2.85 (2.29, 3.54) 14.73 (10.23, 21.21) 
Supplementary Table 4: Results of first sensitivity analysis: Multinomial logistic 
regression. Model also included adjustment for patient-level IMD, England only. 
Multiple imputation used to account for missing data. N= 8,217. Abbreviations: SU: 
Sulfonylurea, DPP4i: dipeptidyl peptidase 4inhibitors, SGLT2i: Sodium-glucose co-
transporter-2 inhibitors, HbA1c: Heamoglobin A1c, eGFR: estimated Glomerular 
Filtration Rate, BMI: Body mass index
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Variable 
SU, Ref DPP4i, OR (95% 
CI) 
SGLT2i, OR 
(95% CI) 
Age at baseline, years    
 < 30 1 1.36 (0.85, 2.17) 2.48 (1.39, 4.40) 
 30-<40 1 1.01 (0.81, 1.26) 1.32 (0.97, 1.81) 
 40-<50 1 0.98 (0.86, 1.11) 1.27 (1.04, 1.52) 
 50-<60 1 0.98 (0.88, 1.08) 1.21 (1.04, 1.42) 
 60-<70 1 1 1 
 70-<80 1 0.96 (0.85, 1.08) 0.47 (0.37, 0.60) 
 80 + 1 0.88 (0.74, 1.04) 0.14 (0.07, 0.28) 
Gender    
 Male 1 1 1 
 Female 1 0.92 (0.85, 1) 0.99 (0.87, 1.12) 
HbA1c at baseline 
(mmol/mol) 
   
 <= 53 (7%) 1 1 1 
 53-75 1 1.41 (1.14, 1.73) 1.17 (0.79, 1.71) 
 75+ (9%) 1 0.73 (0.59, 0.90) 0.79 (0.54, 1.16) 
eGFRat baseline 
(ml/min/1.73m2) 
   
 < 60 1 1 1 
 60-89 1 1.05 (0.90, 1.23) 5.88 (3.29, 10.50) 
 90 + 1 1.02 (0.86, 1.21) 6.77 (3.75, 12.23) 
Time taking metformin prior to 
intensification (years) 
  
 < 1 1 1 1 
 1 to <3 1 1.26 (1.13, 1.40) 1.40 (1.19, 1.64) 
 > 3 1 1.30 (1.17, 1.43) 1.23 (1.05, 1.44) 
Diagnosis of CVD    
 No CVD 1 1 1 
 CVD diagnosis 1 0.94 (0.84, 1.06) 0.95 (0.78, 1.16) 
Diagnosis of 
retinopathy 
   
 No retinopathy 1 1 1 
 Retinopathy 
diagnosis 
1 1.09 (0.99, 1.21) 1.02 (0.86, 1.21) 
BMI at baseline kg/m2    
 Normal/underweight 1 1 1 
 Overweight 1 1.31 (1.14, 1.51) 2.22 (1.52, 3.26) 
 Obese 1 1.72 (1.50, 1.98) 5.66 (3.93, 8.17) 
Smoking status    
 None 1 1 1 
 Ex 1 0.98 (0.90, 1.07) 1.00 (0.87, 1.15) 
 Current 1 0.93 (0.83, 1.05) 0.80 (0.67, 0.96) 
Ethnicity    
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Variable 
SU, Ref DPP4i, OR (95% 
CI) 
SGLT2i, OR 
(95% CI) 
 White 1 1 1 
 South Asian 1 0.70 (0.57, 0.86) 0.60 (0.42, 0.89) 
 Black 1 0.66 (0.49, 0.90) 0.55 (0.29, 1.06) 
 Other 1 0.78 (0.50, 1.24) 0.87 (0.40, 1.67) 
 Mixed 1 1.17 (0.55, 2.49) 2.05 (0.61, 6.91) 
Calendar time    
 Early 2014 1 1 1 
 Late 2014 1 1.13 (1.00, 1.29) 1.80 (1.37, 2.35) 
 Early 2015 1 1.35 (1.20, 1.53) 2.62 (2.04, 3.36) 
 Late 2015 1 1.58 (1.38, 1.80) 3.87 (3.01, 4.98) 
 Early 2016 1 2.00 (1.75, 2.29) 5.68 (4.43, 7.28) 
 Late 2016 1 2.17 (1.87, 2.52) 7.90 (6.12, 10.20) 
 Early 2017 1 2.44 (2.07, 2.88) 11.11 (8.53, 14.47) 
Supplementary Table 5: Results of second sensitivity analysis: Model included 
individuals included individuals that were censored, or died in the 60 day after 
prescribing of the first intensification treatment. With multiple imputation to 
account for missing data. Abbreviations: SU: Sulfonylurea, DPP4i: dipeptidyl 
peptidase 4inhibitors, SGLT2i: Sodium-glucose co-transporter-2 inhibitors, HbA1c: 
Heamoglobin A1c, eGFR: estimated Glomerular Filtration Rate, BMI: Body mass index
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Variable 
SU, Ref DPP4i, OR (95% 
CI) 
SGLT2i, OR 
(95% CI) 
Age at baseline, years    
 < 30 1 1.35 (0.85, 2.17) 2.44 (1.37, 4.34) 
 30-<40 1 1.02 (0.81, 1.27) 1.32 (0.97, 1.80) 
 40-<50 1 0.97 (0.86, 1.11) 1.26 (1.05, 1.52) 
 50-<60 1 0.97 (0.88, 1.08) 1.21 (1.04, 1.41) 
 60-<70 1 1 1 
 70-<80 1 0.97 (0.86, 1.09) 0.48 (0.38, 0.61) 
 80 + 1 0.90 (0.76, 1.07) 0.15 (0.07, 0.29) 
Gender    
 Male 1 1 1 
 Female 1 0.92 (0.85, 0.99) 0.98 (0.87, 1.11) 
HbA1c at baseline 
(mmol/mol) 
   
 < 54 1 1 1 
 54-75 1 1.34 (1.07, 1.67) 1.12 (0.77, 1.63) 
 75+ 1 0.70 (0.56, 0.88) 0.77 (0.52, 1.12) 
eGFR at baseline (ml/min/1.73m2)   
 < 60 1 1 1 
 60-89 1 1.05 (0.90, 1.22) 5.81 (3.22, 10.50) 
 90 + 1 1.00 (0.85, 1.17) 6.67 (3.68, 12.10) 
Time taking metformin prior to 
intensification (years) 
  
 < 1 1 1 1 
 1 to <3 1 1.28 (1.15, 1.42) 1.41 (1.20, 1.65) 
 > 3 1 1.34 (1.21, 1.48) 1.25 (1.07, 1.47) 
Diagnosis of CVD    
 No CVD 1 1 1 
 CVD diagnosis 1 0.95 (0.85, 1.06) 0.95 (0.78, 1.17) 
Microvascular disease    
 No markers 1 1 1 
 One marker  0.94 (0.86, 1.02) 0.94 (0.81, 1.08) 
 Two or more markers 1 0.96 (0.81, 1.14) 0.80 (0.58, 1.10) 
BMI at baseline kg/m2    
 Normal/underweight 1 1 1 
 Overweight 1 1.30 (1.12, 1.50) 2.22 (1.51, 3.25) 
 Obese 1 1.70 (1.48, 1.95) 5.61 (3.89, 8.12) 
Smoking status    
 None 1 1 1 
 Ex 1 0.99 (0.91, 1.08) 1.00 (0.87, 1.15) 
 Current 1 0.94 (0.84, 1.06) 0.81 (0.68, 0.97) 
Ethnicity    
 White 1 1 1 
 South Asian 1 0.71 (0.58, 0.87) 0.60 (0.42, 0.85) 
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Variable 
SU, Ref DPP4i, OR (95% 
CI) 
SGLT2i, OR 
(95% CI) 
 Black 1 0.69 (0.50, 0.94) 0.54 (0.30, 0.96) 
 Other 1 0.78 (0.53, 1.14) 0.86 (0.39, 1.90) 
 Mixed 1 1.15 (0.48, 2.73) 2.11 (0.60, 7.47) 
Calendar time    
 Early 2014 1 1 1 
 Late 2014 1 1.13 (1.00, 1.29) 1.80 (1.37, 2.35) 
 Early 2015 1 1.36 (1.20, 1.53) 2.61 (2.04, 3.36) 
 Late 2015 1 1.58 (1.39, 1.80) 3.86 (3.00, 4.98) 
 Early 2016 1 1.99 (1.74, 2.28) 5.64 (4.40, 7.23) 
 Late 2016 1 2.16 (1.86, 2.50) 7.88 (6.11, 10.17) 
 Early 2017 1 2.42 (2.05, 2.85) 10.95 (8.41, 14.27) 
Supplementary table 6: Results of third sensitivity analysis: Replaced retinopathy 
with a count of microvascular disease markers. With multiple imputation to 
account for missing data. Abbreviations: SU: Sulfonylurea, DPP4i: dipeptidyl 
peptidase 4inhibitors, SGLT2i: Sodium-glucose co-transporter-2 inhibitors, HbA1c: 
Heamoglobin A1c, eGFR: estimated Glomerular Filtration Rate, BMI: Body mass index
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Supplementary Fig 1 Repeated the primary analysis for each individual year 
2014-2016 (excluding time as a covariate), and compared ORs for different 
ethnicity (South Asian and Black) 
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9.5 Appendix 6: Supplementary material for chapter 6 
9.5.1 Supplementary files for paper 6 
 
 
 
Supplementary Figure 1: Standardised mean % differences in baseline characteristics for 
each cohort, unadjusted and compared to the final selected weighted matched sample 
Where hba1c_baseline_miss, egfr_baseline_miss, bmi_baseline_miss and bp_baseline_miss are the baseline 
measures, after accounting for missingness in the variables. egfr_traj: eGFR trajectory, time_on_first: time 
taking metformin prior to changing drug, cardiovascular_diag_before and retinopathy_diag_before are 
indicators of cardiovascular disease and retinopathy respectively. any_arb and any_sta are indicators of 
prescriptions for ARB or statins prior to baseline. imd_pt: patient-level index of multiple deprivation
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Supplementary Figure 2: Propensity score for SGLT2i for each measure of 
interest, in final selected PS model. 
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Measure 
Number of 
SGLT2is 
available 
Number of 
unmatched 
SGLT2is 
Mean of 
measure in 
unmatched 
DPP4i contrast SU contrast 
PS for SGLT2i 
Mean (SD) 
PS for SGLT2i 
Mean (SD) 
eGFR 483 21 94.0 0.52 (0.12) 0.45 (0.13) 
HbA1c 516 35 75.2 0.54 (0.11) 0.49 (0.11) 
BMI 764 26 43.9 0.47 (0.15) 0.45 (0.17) 
Sys BP 824 88 136.1 0.54 (0.11) 0.49 (0.14) 
Supplementary Table 1: Description of unmatched SGLT2is 
Measure 
 
Mean number of 
SU matches 
Mean number of 
DPP4i matches 
eGFR 
 3.53 2.97 
HbA1c 
 3.52 3.00 
BMI 
 2.92 2.66 
Sys BP 
 3.47 2.97 
Supplementary Table 2: Number of matches found for each treatment group 
(Aim was for 5:1:4 SU:SGLT2i:DPP4i) 
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Length of follow-up Mean number of measures for analysis 
cohort 
Days, mean (median) DPP4i SGLT2i SU 
eGFR 
616 (582) 5.5 5.4 6.1 
HbA1c 
605 (572) 5.5 5.1 5.8 
BMI 
624 (590) 5.4 5.6 5.5 
Systolic BP 
617 (582) 7.1 6.5 7.5 
Supplementary Table 3: Length of follow-up (days) and number of repeated 
measures available for each analysis cohort 
212
  
 
 
 Category SU SGLT2i DPP4i 
Counts  1630 462 1374 
Age at baseline Years 55.8 (10.9) 56 (10.3) 56.4 (10.8) 
BMI baseline kg/m2 34.9 (5.9) 35 (5.7) 34.9 (5.7) 
eGFR baseline ml/min/1.73m2 95 (13.8) 94.8 (13.2) 94.7 (13.6) 
Systolic BP at baseline mmHg 133.8 (13.3) 134.1 (12.6) 133.8 (13.3) 
HbA1c at baseline mmol/mol 76.1 (17.6) 75.9 (16.1) 76 (16.2) 
Time taking metformin 
prior to intensification Month 36.1 (34.8) 37.7 (32.6) 38.1 (34.4) 
Gender Female, n (%) 179 (39) 189 (41) 179 (39) 
Diagnosis of CVD n (%) 51 (11) 45 (10) 45 (10) 
Diagnosis of HF n (%) 15 (3) 14 (3) 10 (2) 
Diagnosis of 
retinopathy n (%) 75 (16) 75 (16) 88 (19) 
Prescription for ARB or 
ACE inhibitor n (%) 243 (53) 273 (59) 246 (53) 
Prescription for statin n (%) 319 (69) 324 (70) 343 (74) 
Patient-level index of 
multiple deprivation 
1 LEAST 
deprived 47 (10) 48 (10) 47 (10) 
 2 45 (10) 47 (10) 43 (9) 
 3 60 (13) 58 (13) 59 (13) 
 4 43 (9) 41 (9) 40 (9) 
 5 MOST deprived 40 (9) 32 (7) 37 (8) 
 Missing category 228 (49) 236 (51) 237 (51) 
Smoking status Non-smoker 180 (39) 178 (39) 178 (39) 
 Current 80 (17) 72 (16) 69 (15) 
 Ex-smoker 200 (43) 212 (46) 215 (47) 
 Missing category <5 <5 <5 
Ethnicity White 191 (41) 193 (42) 189 (41) 
n (%) South Asian 12 (3) 10 (2) 9 (2) 
 Black 8 (2) 7 (2) 7 (2) 
 Other 1 (0) 1 (0) 0 (0) 
 Mixed 1 (0) 2 (0) 1 (0) 
 
Missing 
category 249 (54) 249 (54) 255 (55) 
Supplementary Table 4: Baseline characteristics for final weighted matched 
sample for eGFR  
After iteration of the propensity score model, the following covariates were included in the model: 
age, HbA1c, eGFR, eGFR2, BMI, systolic BP, patient-level IMD, ethnicity. The group was further 
matched on quintiles of baseline eGFR % is of entire cohort.
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 Category SU SGLT2i DPP4i 
Count  2158 738 1960 
Age at baseline Years 55.6 (11.5) 55.2 (10.1) 56.1 (10.6) 
BMI baseline kg/m2 36.6 (6.2) 36.4 (6.5) 36.4 (6.2) 
eGFR baseline ml/min/1.73m2 92.8 (12.8) 92.6 (9.9) 92.1 (11.2) 
Systolic BP at baseline mmHg 134.1 (13.5) 134 (13.4) 134 (13.1) 
HbA1c at baseline mmol/mol 76.8 (14.1) 76.5 (12.4) 75.9 (11.8) 
Time taking metformin 
prior to intensification Month 
36.2 (35.1) 36.4 (33.2) 37.1 (34.2) 
Gender Female,  n (%) 
325 (44) 303 (41) 316 (43) 
Diagnosis of CVD n (%) 85 (11) 73 (10) 77 (10) 
Diagnosis of HF n (%) 20 (3) 15 (2) 17 (2) 
Diagnosis of retinopathy n (%) 127 (17) 111 (15) 123 (17) 
Prescription for ARB or 
ACE inhibitor n (%) 
412 (56) 419 (57) 408 (55) 
Prescription for statin n (%) 505 (68) 516 (70) 559 (76) 
Patient-level index of 
multiple deprivation 
1 LEAST 
deprived 57 (8) 60 (8) 58 (8) 
 2 60 (8) 57 (8) 58 (8) 
 3 76 (10) 72 (10) 70 (10) 
 4 69 (9) 58 (8) 65 (9) 
 5 MOST deprived 54 (7) 48 (7) 45 (6) 
 Missing category 421 (57) 443 (60) 442 (60) 
Smoking status Non-smoker 285 (39) 284 (38) 279 (38) 
 Current 129 (18) 113 (15) 124 (17) 
 Ex-smoker 322 (44) 341 (46) 334 (45) 
 Missing category <5 <5 <5 
Ethnicity White 313 (42) 306 (41) 310 (42) 
n (%) South Asian 21 (3) 19 (3) 14 (2) 
 Black 8 (1) 6 (1) 7 (1) 
 Other 2 (0) 2 (0) 2 (0) 
 Mixed 2 (0) 2 (0) 2 (0) 
 Missing category 392 (53) 403 (55) 403 (55) 
Supplementary Table 5: Baseline characteristics for final weighted matched 
sample for BMI 
After iteration of the propensity score model, the following covariates were included in the model: 
age, HbA1c, eGFR, BMI, BMI2, systolic BP, patient-level IMD, ethnicity. The groups were further 
matched on centiles of baseline BMI. % is of entire cohort.
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 Category SU SGLT2i DPP4i 
Counts  2554 736 2186 
Age at baseline Years 56.6 (11.5) 56.5 (9.8) 56.5 (10.6) 
BMI baseline kg/m2 34.7 (5.5) 35.1 (5.5) 34.7 (5.4) 
eGFR baseline ml/min/1.73m2 91.6 (12.7) 91.5 (9.6) 91.2 (11) 
Systolic BP at baseline mmHg 134.5 (14.4) 134.4 (14) 134.4 (14.1) 
HbA1c at baseline mmol/mol 76 (13) 75.8 (12.1) 75.5 (11.4) 
Time taking metformin 
prior to intensification Month 37.2 (35.3) 36.5 (32.4) 38.1 (34.3) 
Gender Female, n (%) 305 (41) 295 (40) 283 (38) 
Diagnosis of CVD n (%) 92 (13) 80 (11) 82 (11) 
Diagnosis of HF n (%) 21 (3) 17 (2) 17 (2) 
Diagnosis of 
retinopathy n (%) 119 (16) 107 (15) 128 (17) 
Prescription for ARB or 
ACE inhibitor n (%) 414 (56) 438 (60) 407 (55) 
Prescription for statin n (%) 514 (70) 517 (70) 555 (75) 
Patient-level index of 
multiple deprivation 
1 LEAST 
deprived 65 (9) 64 (9) 59 (8) 
 2 59 (8) 56 (8) 55 (7) 
 3 75 (10) 76 (10) 76 (10) 
 4 60 (8) 60 (8) 59 (8) 
 5 MOST deprived 53 (7) 55 (7) 54 (7) 
 Missing category 425 (58) 425 (58) 433 (59) 
Smoking status Non-smoker 282 (38) 293 (40) 276 (37) 
 Current 125 (17) 113 (15) 118 (16) 
 Ex-smoker 327 (44) 330 (45) 342 (47) 
 Missing category <5 <5 <5 
Ethnicity White 298 (41) 291 (40) 295 (40) 
n (%) South Asian 16 (2) 19 (3) 17 (2) 
 Black 9 (1) 9 (1) 9 (1) 
 Other <5 <5 <5 
 Mixed <5 <5 <5 
 Missing category 410 (56) 412 (56) 410 (56) 
Supplementary Table 6: Baseline characteristics for final weighted matched 
sample for Systolic BP 
After iteration of the propensity score model, the following covariates were included in the model: 
age, HbA1c, eGFR, BMI, systolic BP, patient-level IMD, ethnicity. The groups were further matched 
on 20 groups of baseline systolic BP. % is of entire cohort.
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HbA1c (mmol/mol) eGFR (ml/min/1.73m2) 
 Week: 0 12 60 0 12 60 
SU 
Absolute 
value 
76.7 
(75.8-77.5) 
62.3 
(61.2-63.5) 
62.9 
(61.4-64.4) 
95.0 
(94.3-95.8) 
95.5 
(94.4-96.5) 
93.0 
(91.8-94.2) 
 
Change 
from 
baseline 
 -14.3 (-15.5, -13.2) 
-13.8 
(-15.4, -12.2)  
0.5 
(-0.4, 1.3) 
-2.0 
(-2.9, -1.1) 
SGLT2i 
Absolute 
value 
76.4 
(74.9-77.9) 
61.2 
(59.7-62.8) 
60.3 
(57.9-62.8) 
94.8 
(93.6-96.0) 
91.8 
(90.2-93.3) 
92.7 
(90.9-94.5) 
 
Change 
from 
baseline 
 -15.2 (-16.9, -13.5) 
-16.1 
(-18.7, -13.5)  
-3.1 
(-4.1, -2.0) 
-2.2 
(-3.6, -0.7) 
DPP4i 
Absolute 
value 
76.7 
(75.7-77.6) 
64.8 
(63.5-66.1) 
66.9 
(65.0-68.8) 
94.7 
(93.9-95.4) 
93.6 
(92.6-94.7) 
92.8 
(91.6-93.9) 
 
Change 
from 
baseline 
 -11.9 (-13.1, -10.6) 
-9.8 
(-11.6, -7.9)  
-1.0 
(-1.9, -0.2) 
-1.9 
(-2.9, -1.0) 
 
  BMI (kg/m2) Systolic BP (mmHg) 
 Week: 0 12 60 0 12 60 
SU 
Absolute 
value 
36.6 
(36.2-37.0) 
36.6 
(36.1-37.0) 
36.8 
(36.4-37.2) 
134.5 
(133.9-135.2) 
133.8 
(132.7-134.9) 
134.8 
(133.6-
135.9) 
 
Change 
from 
baseline 
 0.0 (-0.3, 0.2) 
0.2 
(0.0, 0.4)  
-0.8 (-1.9, -
0.4) 
0.2 
(-1.0, 1.4) 
SGLT2i 
Absolute 
value 
36.4 
(35.9-36.8) 
35.7 
(35.2-36.2) 
34.6 
(34.1-35.2) 
134.4 
(133.4-135.4) 
132.1 
(130.7-133.5) 
131.8 
(130.2-
133.5) 
 
Change 
from 
baseline 
 -0.7 (-0.9, -0.5) 
-1.7 
(-2.1, -1.4)  
-2.3 
(-3.8, -0.8) 
-2.6 
(-4.4, -0.8) 
DPP4i 
Absolute 
value 
36.4 
(36.1-36.8) 
36.1 
(35.8-36.5) 
35.7 
(35.3-36.1) 
134.4 
(133.7-135.0) 
133.4 
(132.3-134.6) 
133.4 
(132.2-
134.6) 
 
Change 
from 
baseline 
 -0.3 (-0.5, -0.1) 
-0.8 
(-1.0, -0.6)  
-0.9 
(-2.1, 0.2) 
-0.9 
(-2.1, 0.3) 
 
Supplementary Table 7. Mean (95% confidence intervals) absolute values and change 
from baseline for clinical variables at baseline, 12, and 60 weeks, for propensity score 
matched cohorts of individuals following intensification with DPP4i, SGLT2i and SU 
after metformin monotherapy. Abbreviations: SU: Sulfonylurea, DPP4i: dipeptidyl peptidase 4 inhibitors, SGLT2i: 
Sodium-glucose co-transporter-2 inhibitors, HbA1c: Haemoglobin A1c, eGFR: estimated glomerular filtration rate, BMI: Body mass index, 
BP: Blood pressure. 
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Supplementary Figure 3: Mean (95% confidence intervals) of each clinical 
measure during treatment for 1:1:1 matched propensity score matched cohorts 
of individuals following intensification with DPP4i, SGLT2i and SU after 
metformin monotherapy 
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Supplementary Figure 4: Mean (95% confidence intervals) of each clinical 
measure during treatment, for propensity score matched cohorts of individuals 
(intention to treat model), following intensification with DPP4i, SGLT2i and SU 
after metformin monotherapy  
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Supplementary Figure 5: Mean (95% confidence intervals) of each clinical 
measure during treatment, for propensity score matched cohorts of individuals 
with missing data handled using multiple imputation, following intensification 
with DPP4i, SGLT2i and SU 
221
  
 
 
 
Supplementary Figure 6: Mean (95% confidence intervals) of each clinical 
measure during treatment, for a propensity score matched cohort of individuals 
(using only individuals with baseline and follow-up measures for all of eGFR, 
HbA1c, BMI and BP), following intensification with DPP4i, SGLT2i and SU 
after metformin monotherapy 
222
  
 
 
Supplementary Figure 7: Mean (95% confidence intervals) of each clinical 
measure during treatment, primary analysis repeated excluding individuals in 
the top 25th percentile for the number of tests available during follow-up 
(eGFR, HbA1c, BMI and BP), following intensification with DPP4i, SGLT2i 
and SU after metformin monotherapy 
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 Category SU 
SU 
Original 
cohort 
SGLT2i 
SGLT2i 
original 
cohort 
DPP4i 
DPP4i 
original 
cohort 
Counts  2,521 5,010 704 1,187 2,339 4,434 
Age at baseline Years 60.2 (12.6) 61 (13) 55 (10.3) 55 (10) 60.4 (12.3) 61 (12) 
BMI baseline kg/m2 31.9 (6.2) 32 (6) 36.9 (7.0) 37 (7) 33.2 (6.4) 33 (7) 
eGFR baseline ml/min/1.73m2 89.6 (10.3) 89 (18) 96.4 (7.0) 96 (13) 88.8 (9.8) 88 (18) 
Systolic BP at baseline mmHg 132.9 (12.0) 133 (14) 134.2 (12.1) 134 (14) 133.7 (11.8) 133 (14) 
HbA1c at baseline mmol/mol 80.2 (12.0) 80 (21) 77.1 (10.2) 77 (17) 73 (9.0) 73 (16) 
Time taking metformin 
prior to intensification Month 
39.9 (36.3) 40 (37) 35.9 (33.7) 36 (33) 43.9 (36.7) 44 (37) 
Gender Female, n (%) 993 (39) 1988 (39.7) 271 (38) 474 (39.9) 904 (39) 1745 (39.4) 
Diagnosis of CVD n (%) 351 (14) 707 (14.1) 74 (11) 119 (10) 298 (13) 601 (13.6) 
Diagnosis of HF n (%) 89 (4) 194 (3.9) 9 (1) 24 (2) 68 (3) 146 (3.3) 
Diagnosis of retinopathy n (%) 411 (16.0) 868 (17.3) 101 (14) 181 (15.2) 442 (19) 861 (19.4) 
Prescription for ARB or 
ACE inhibitor n (%) 
1361 (54.0) 2711 (54.1) 386 (55) 670 (56.4) 1301 (56) 2490 (56.2) 
Prescription for statin n (%) 1752 (69.0) 3530 (70.5) 483 (69) 819 (69) 1768 (76) 3387 (76.4) 
Patient-level index of 
multiple deprivation 
1 LEAST 
deprived 
208 (8) 467 (9.3) 44 (6) 93 (7.8) 163 (7) 398 (9.0) 
2 230 (9) 485 (9.7) 50 (7) 99 (8.3) 156 (7) 378 (8.5) 
3 267 (11) 567 (11.3) 54 (8) 117 (9.9) 197 (8) 449 (10.1) 
4 338 (13) 643 (12.8) 57 (8) 99 (8.3) 215 (9) 427 (9.6) 
 5 MOST deprived 
280 (11) 589 (11.8) 49 (7) 81 (6.8) 224 (10) 479 (10.8) 
 Missing category 1198 (48) 2259 (45.1) 450 (64) 698 (58.8) 1384 (59) 2303 (51.9) 
Smoking status Non-smoker 923 (37) 1883 (37.6) 274 (39) 462 (38.9) 866 (37) 1642 (37.0) 
 Current 426 (17) 818 (16.3) 116 (16) 193 (16.3) 394 (17) 688 (15.5) 
 Ex-smoker 1165 (46) 2297 (45.8) 314 (45) 532 (44.8) 1078 (46) 2102 (47.4) 
 Missing category 7 (0) 12 (0.2) <5 N<5 <5 N<5 
Ethnicity White 1040 (41) 2052 (41.5) 297 (42) 500 (42.1) 1053 (45) 1944 (43.8) 
n (%) South Asian 114 (5) 229 (4.6) 21 (3) 31 (2.6) 73 (3) 146 (3.3) 
 Black 63 (2) 122 (2.4) <5 9 (0.8) 32 (1) 61 (1.4) 
 Other 35 (1) 59 (1.2) <5 5 (0.4) 10 (0) 26 (0.6) 
 Mixed 9 (0) 14 (0.3) <5 N<5 7 (0) 16 (0.4) 
 Missing category 1260 (50) 2534 (50.6) 380 (54) 640 (53.9) 1164 (50) 2241 (50.5) 
Year started  2014 957 (38) 2090 (41.7) 125 (18) 217 (18.3) 670 (29) 1390 (31.3) 
follow-up 2015 828 (33) 1668 (33.3) 195 (28) 355 (29.9) 689 (29) 1453 (32.8) 
n (%) 2016 536 (21) 989 (19.7) 245 (35) 444 (37.4) 664 (28) 1207 (27.2) 
 2017 200 (8) 263 (5.2) 139 (20) 171 (14.4) 316 (14) 384 (8.7) 
Supplementary Table 14: Characteristics for people dropped from the eGFR 
sample due to missing baseline values and/or follow-up values. Compared to the 
study population at baseline for individuals intensifying treatment from 
metformin monotherapy with SU, SGLT2i or DPP4i between 2014-2017 (Table 
1)
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 Category SU 
SU 
Original 
cohort 
SGLT2i 
SGLT2i 
original 
cohort 
DPP4i 
DPP4i 
original 
cohort 
Counts  2358 5,010 671 1,187 2210 4,434 
Age at baseline Years 60.5 (12.8) 61 (13) 55.1 (10.5) 55 (10) 60.6 (12.4) 61 (12) 
BMI baseline kg/m2 31.9 (6.2) 32 (6) 37 (7.2) 37 (7) 33.1 (6.3) 33 (7) 
eGFR baseline ml/min/1.73m2 89.1 (10.2) 89 (18) 96.1 (6.9) 96 (13) 88.1 (10.3) 88 (18) 
Systolic BP at baseline mmHg 132.9 (12.2) 133 (14) 134.3 (12.1) 134 (14) 133.7 (11.8) 133 (14) 
HbA1c at baseline mmol/mol 79.8 (10.3) 80 (21) 76.6 (9.3) 77 (17) 72.9 (8.5) 73 (16) 
Time taking metformin 
prior to intensification Month 
40.1 (36.7) 40 (37) 35.6 (32.9) 36 (33) 44.6 (37.4) 44 (37) 
Gender Female, n (%) 932 (40) 1988 (39.7) 259 (39) 474 (39.9) 847 (38) 1745 (39.4) 
Diagnosis of CVD n (%) 341 (14) 707 (14.1) 74 (11) 119 (10) 291 (13) 601 (13.6) 
Diagnosis of HF n (%) 91 (4) 194 (3.9) 12 (2) 24 (2) 73 (3) 146 (3.3) 
Diagnosis of retinopathy n (%) 382 (16) 868 (17.3) 101 (15) 181 (15.2) 412 (19) 861 (19.4) 
Prescription for ARB or 
ACE inhibitor n (%) 
1306 (55) 2711 (54.1) 369 (55) 670 (56.4) 1235 (56) 2490 (56.2) 
Prescription for statin n (%) 1652 (70) 3530 (70.5) 458 (68) 819 (69) 1677 (76) 3387 (76.4) 
Patient-level index of 
multiple  
1 LEAST 
deprived 
174 (7) 467 (9.3) 39 (6) 93 (7.8) 141 (6) 398 (9.0) 
deprivation 2 219 (9) 485 (9.7) 44 (7) 99 (8.3) 139 (6) 378 (8.5) 
 3 243 (10) 567 (11.3) 52 (8) 117 (9.9) 174 (8) 449 (10.1) 
 4 316 (13) 643 (12.8) 58 (9) 99 (8.3) 198 (9) 427 (9.6) 
 5 MOST deprived 
261 (11) 589 (11.8) 43 (6) 81 (6.8) 206 (9) 479 (10.8) 
 Missing category 1145 (49) 2259 (45.1) 435 (65) 698 (58.8) 1352 (61) 2303 (51.9) 
Smoking status Non-smoker 885 (38) 1883 (37.6) 247 (37) 462 (38.9) 820 (37) 1642 (37.0) 
 Current 395 (17) 818 (16.3) 115 (17) 193 (16.3) 378 (17) 688 (15.5) 
 Ex-smoker 1074 (46) 2297 (45.8) 309 (46) 532 (44.8) 1012 (46) 2102 (47.4) 
 Missing category <5 12 (0.2) <5 N<5 <5 N<5 
Ethnicity White 977 (41) 2052 (41.5) 286 (43) 500 (42.1) 983 (44) 1944 (43.8) 
n (%) South Asian 120 (5) 229 (4.6) 20 (3) 31 (2.6) 66 (3) 146 (3.3) 
 Black 62 (3) 122 (2.4) <5 9 (0.8) 31 (1) 61 (1.4) 
 Other 35 (1) 59 (1.2) <5 5 (0.4) 10 (0) 26 (0.6) 
 Mixed 9 (0) 14 (0.3) <5 N<5 6 (0) 16 (0.4) 
 Missing category 1155 (49) 2534 (50.6) 358 (53) 640 (53.9) 1114 (50) 2241 (50.5) 
Year starting  2014 897 (38) 2090 (41.7) 122 (18) 217 (18.3) 617 (28) 1390 (31.3) 
follow-up 2015 761 (32) 1668 (33.3) 183 (27) 355 (29.9) 658 (30) 1453 (32.8) 
n (%) 2016 501 (21) 989 (19.7) 231 (34) 444 (37.4) 609 (28) 1207 (27.2) 
 2017 199 (8) 263 (5.2) 135 (20) 171 (14.4) 326 (15) 384 (8.7) 
Supplementary Table 15: Characteristics for people dropped from the HbA1c 
sample due to missing baseline values and/or follow-up values. Compared to the 
study population at baseline for individuals intensifying treatment from 
metformin monotherapy with SU, SGLT2i or DPP4i between 2014-2017 (Table 
1)
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 Category SU 
SU 
Original 
cohort 
SGLT2i 
SGLT2i 
original 
cohort 
DPP4i 
DPP4i 
original 
cohort 
Counts  1870 5,010 423 1,187 1751 4,434 
Age at baseline Years 61.2 (13.2) 61 (13) 56.3 (10.1) 55 (10) 61.6 (12.8) 61 (12) 
BMI baseline kg/m2 31.6 (5.6) 32 (6) 36.4 (7.3) 37 (7) 32.8 (6.0) 33 (7) 
eGFR baseline ml/min/1.73m2 88.4 (15.1) 89 (18) 95.2 (10.2) 96 (13) 87.6 (15.2) 88 (18) 
Systolic BP at baseline mmHg 133.7 (11.8) 133 (14) 134.5 (10.2) 134 (14) 134 (11.5) 133 (14) 
HbA1c at baseline mmol/mol 80.1 (16.6) 80 (21) 76.3 (13.2) 77 (17) 73.2 (13.5) 73 (16) 
Time taking metformin 
prior to intensification Month 
39.3 (36.4) 40 (37) 37 (32.2) 36 (33) 46.3 (38.4) 44 (37) 
Gender Female, n (%) 746 (40) 1988 (39.7) 160 (38) 474 (39.9) 660 (38) 1745 (39.4) 
Diagnosis of CVD n (%) 267 (14) 707 (14.1) 46 (11) 119 (10) 231 (13) 601 (13.6) 
Diagnosis of HF n (%) 94 (5) 194 (3.9) 8 (2) 24 (2) 71 (4) 146 (3.3) 
Diagnosis of retinopathy n (%) 289 (15) 868 (17.3) 70 (17) 181 (15.2) 342 (20) 861 (19.4) 
Prescription for ARB or 
ACE inhibitor n (%) 
1007 (54) 2711 (54.1) 244 (58) 670 (56.4) 983 (56) 2490 (56.2) 
Prescription for statin n (%) 1275 (68) 3530 (70.5) 292 (69) 819 (69) 1293 (74) 3387 (76.4) 
Patient-level index of 
multiple  
1 LEAST 
deprived 
179 (10) 467 (9.3) 31 (7) 93 (7.8) 156 (9) 398 (9.0) 
deprivation 2 215 (11) 485 (9.7) 38 (9) 99 (8.3) 159 (9) 378 (8.5) 
 3 216 (12) 567 (11.3) 43 (10) 117 (9.9) 178 (10) 449 (10.1) 
 4 252 (13) 643 (12.8) 39 (9) 99 (8.3) 178 (10) 427 (9.6) 
 5 MOST deprived 
238 (13) 589 (11.8) 33 (8) 81 (6.8) 206 (12) 479 (10.8) 
 Missing category 770 (41) 2259 (45.1) 239 (57) 698 (58.8) 874 (50) 2303 (51.9) 
Smoking status Non-smoker 698 (37) 1883 (37.6) 168 (40) 462 (38.9) 639 (36) 1642 (37.0) 
 Current 309 (17) 818 (16.3) 76 (18) 193 (16.3) 280 (16) 688 (15.5) 
 Ex-smoker 855 (46) 2297 (45.8) 179 (42) 532 (44.8) 832 (48) 2102 (47.4) 
 Missing category 8 (0) 12 (0.2) <5 N<5 <5 N<5 
Ethnicity White 714 (38) 2052 (41.5) 179 (42) 500 (42.1) 774 (44) 1944 (43.8) 
n (%) South Asian 95 (5) 229 (4.6) 12 (3) 31 (2.6) 64 (4) 146 (3.3) 
 Black 56 (3) 122 (2.4) <5 9 (0.8) 32 (2) 61 (1.4) 
 Other 31 (2) 59 (1.2) <5 5 (0.4) 16 (1) 26 (0.6) 
 Mixed <5 14 (0.3) <5 N<5 9 (1) 16 (0.4) 
 Missing category 969 (52) 2534 (50.6) 226 (53) 640 (53.9) 856 (49) 2241 (50.5) 
Year starting  2014 668 (36) 2090 (41.7) 49 (12) 217 (18.3) 400 (23) 1390 (31.3) 
follow-up 2015 563 (30) 1668 (33.3) 92 (22) 355 (29.9) 491 (28) 1453 (32.8) 
n (%) 2016 440 (24) 989 (19.7) 152 (36) 444 (37.4) 538 (31) 1207 (27.2) 
 2017 199 (11) 263 (5.2) 130 (31) 171 (14.4) 322 (18) 384 (8.7) 
Supplementary Table 16: Characteristics for people dropped from the BMI 
sample due to missing baseline values and/or follow-up values. Compared to the 
study population at baseline for individuals intensifying treatment from 
metformin monotherapy with SU, SGLT2i or DPP4i between 2014-2017 (Table 
1)
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 Category SU SU Original cohort SGLT2i 
SGLT2i 
original cohort DPP4i 
DPP4i original 
cohort 
Counts  1128 5,010 363 1,187 1182 4,434 
Age at baseline Years 59.4 (13.0) 61 (13) 55.1 (10.0) 55 (10) 60.3 (12.6) 61 (12) 
BMI baseline kg/m2 31.8 (6.1) 32 (6) 36.5 (7.7) 37 (7) 33 (6.4) 33 (7) 
eGFR baseline ml/min/1.73m2 90 (14.5) 89 (18) 96 (10.3) 96 (13) 88.6 (14.8) 88 (18) 
Systolic BP at baseline mmHg 132.2 (6.5) 133 (14) 133.5 (5.4) 134 (14) 132.3 (6.6) 133 (14) 
HbA1c at baseline mmol/mol 80.9 (17.1) 80 (21) 77.6 (13.5) 77 (17) 73.9 (14.1) 73 (16) 
Time taking metformin 
prior to intensification Month 
39.1 (35.9) 40 (37) 38.7 (34.7) 36 (33) 45.5 (39.0) 44 (37) 
Gender Female, n (%) 422 (37) 1988 (39.7) 142 (39) 474 (39.9) 473 (40) 1745 (39.4) 
Diagnosis of CVD n (%) 146 (13) 707 (14.1) 36 (10) 119 (10) 147 (12) 601 (13.6) 
Diagnosis of HF n (%) 46 (4) 194 (3.9) <5 24 (2) 39 (3) 146 (3.3) 
Diagnosis of retinopathy n (%) 159 (14) 868 (17.3) 60 (17) 181 (15.2) 213 (18) 861 (19.4) 
Prescription for ARB or 
ACE inhibitor n (%) 
549 (49) 2711 (54.1) 191 (53) 670 (56.4) 615 (52) 2490 (56.2) 
Prescription for statin n (%) 759 (67) 3530 (70.5) 251 (69) 819 (69) 855 (72) 3387 (76.4) 
Patient-level index of 
multiple  
1 LEAST 
deprived 
106 (9) 467 (9.3) 25 (7) 93 (7.8) 103 (9) 398 (9.0) 
deprivation 2 137 (12) 485 (9.7) 39 (11) 99 (8.3) 108 (9) 378 (8.5) 
 3 127 (11) 567 (11.3) 31 (9) 117 (9.9) 132 (11) 449 (10.1) 
 4 154 (14) 643 (12.8) 37 (10) 99 (8.3) 120 (10) 427 (9.6) 
 5 MOST deprived 
133 (12) 589 (11.8) 26 (7) 81 (6.8) 147 (12) 479 (10.8) 
 Missing category 471 (42) 2259 (45.1) 205 (56) 698 (58.8) 572 (48) 2303 (51.9) 
Smoking status Non-smoker 408 (36) 1883 (37.6) 136 (37) 462 (38.9) 452 (38) 1642 (37.0) 
 Current 214 (19) 818 (16.3) 67 (18) 193 (16.3) 193 (16) 688 (15.5) 
 Ex-smoker 498 (44) 2297 (45.8) 160 (44) 532 (44.8) 536 (45) 2102 (47.4) 
 Missing category 8 (1) 12 (0.2) <5 N<5 <5 N<5 
Ethnicity White 443 (39) 2052 (41.5) 171 (47) 500 (42.1) 531 (45) 1944 (43.8) 
n (%) South Asian 53 (5) 229 (4.6) 12 (3) 31 (2.6) 33 (3) 146 (3.3) 
 Black 32 (3) 122 (2.4) <5 9 (0.8) 23 (2) 61 (1.4) 
 Other 18 (2) 59 (1.2) <5 5 (0.4) 12 (1) 26 (0.6) 
 Mixed <5 14 (0.3) <5 N<5 <5 16 (0.4) 
 Missing category 578 (51) 2534 (50.6) 178 (49) 640 (53.9) 578 (49) 2241 (50.5) 
Year starting  2014 386 (34) 2090 (41.7) 43 (12) 217 (18.3) 238 (20) 1390 (31.3) 
follow-up 2015 321 (28) 1668 (33.3) 78 (21) 355 (29.9) 318 (27) 1453 (32.8) 
n (%) 2016 267 (24) 989 (19.7) 126 (35) 444 (37.4) 355 (30) 1207 (27.2) 
 2017 154 (14) 263 (5.2) 116 (32) 171 (14.4) 271 (23) 384 (8.7) 
Supplementary Table 17: Characteristics for people dropped from the systolic 
blood pressure sample due to missing baseline values and/or follow-up values. 
Compared to the study population at baseline for individuals intensifying 
treatment from metformin monotherapy with SU, SGLT2i or DPP4i between 
2014-2017 (Table 1) 
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9.5.2 Excerpt from ISAC application 
PROTOCOL NUMBER: 16_267 
 
I. Sample size considerations 
A recent study using CPRD data comparing people on antidiabetic therapies for 
T2DM reported a mean follow-up time of 2.8years, after initiating treatment with 
metformin and sulfonylurea dual therapy.(160) We will assume that the follow-up 
time will be similar in this study, which is a cautious estimate as the study censored 
participants at the point of further switching. A study by Hung et al, 2012 that 
described persistent (confirmed 3-12 months after) falls in eGFR of 25%, or ESRD 
as the composite end point, in a cohort of people with T2DM selected from veterans’ 
health records, this is a similar outcome to our primary outcome of interest.(158) 
They reported annual rates of the composite end point to be between 3.2% and 
5%.(158). This study has a tighter outcome definition than we plan for our primary 
analysis, as we do not require persistent falls in eGFR. However, assuming a similar 
3% outcome rate, the results displayed in Table 9.1 shows the minimal effect size for 
each exposure group that we could detect with an 80% power.(166) Our study would 
be adequately powered to detect clinically relevant differences in effect. 
 
Exposure group vs. MTF+SU 
(n=54,288) 
Estimated smallest HR 
detected with 80% power 
MTF + DPP4i (n=16386) 0.88 or 1.12 
MTF + TZD (n= 10115) 0.86 or 1.14 
MTF + SGLT2i (n=1314) 0.68 or 1.36 
Assuming 3% outcome rate in baseline group over a 3 year follow-up period. Two-sided 
significance level of 95% 
Table 9.1 Power considerations for composite endpoint (first occurrence of a 
decrease of 50% or more in eGFR, or end-stage renal disease or renal 
replacement therapy) in dual users: using Cox regression command in Stata 
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